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Thrombolytic therapy (TT) significantly reduces mortality and morbidity
following acute myocardial infarction (AMI). This is presumed to be secondary to
reperfusion of the infarct related artery. Increased use of TT has produced a
requirement for early, accurate diagnosis of AMI. Not all patients show equivalent
benefit to TT; consequently, the management of patients post-AMI is likely to
become increasingly varied. There is a need for non-invasive assessment of arterial
patency to identify patients in whom myocardium remains at risk.
To compare 4 recognised biochemical markers, creatine kinase-MB
(CK-MB), mass and activity, myoglobin and troponin-T to serum and urinary
creatine concentrations in the diagnosis and differentiation of AMI, and the non¬
invasive assessment of arterial patency following thrombolysis, 191 patients admitted
to a coronary care unit with a differential diagnosis of AMI were studied. On the
basis of the admission electrocardiogram (ECG), they were divided into the
following groups:
Group A: Admission ECG diagnostic of AMI, (n=56)
Group B: Admission ECG non-diagnostic of AMI but AMI proven at day 3, (n=48)
Group C: Admission ECG non-diagnostic of AMI, AMI excluded at day 3, (n= 87)
Type 1: Q-waves on day 3 ECG (n=58).
Type 2: No Q-waves on day 3 ECG (n=46).
Patients in group A were considered to have achieved successful reperfusion if they
had >50% resolution of ST segment elevation within 2 hours of TT.
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RESULTS
Serum and urine creatine concentrations were not discriminatory in the diagnosis of
AMI. The other 4 markers were able to differentiate all subgroups from non-AMI
with a high degree of sensitivity and specificity (range 80-98% and 94-99%
respectively); troponin-T having the greatest diagnostic power for all AMI (groups
A and B) and group A, p<0.05.
CK-MB mass was best at detecting group B and type 2 infarction, p<0.05.
Myoglobin was able to identify AMI faster than CK-MB activity in all patient
groups, p<0.01 and detect all infarcts, group A and type 1 infarction faster than
troponin-T, p<0.04. CK-MB mass was more rapid than CK-MB activity for all
AMI diagnosis, p<0.05.
Patients in group A who reperfused were diagnosed most accurately by myoglobin
at 2 hours after TT, p<0.05, and by CK-MB mass at 4 hours after TT, p<0.05.
Myoglobin concentrations peaked significantly earlier than all other markers in
reperfusers, p< 0.001. All 4 markers showed significantly earlier peaks in
reperfusers than non-reperfusers, p< 0.001.
CONCLUSIONS
Serum or urine creatine concentrations are not useful diagnostic markers for AMI
CK-MB mass and activity, myoglobin and troponin-T are all highly sensitive and
specific in AMI diagnosis, troponin-T having an advantage over CK-MB activity and
myoglobin.
Myoglobin provides the earliest diagnosis of AMI, and the most rapid biochemical
indication of reperfusion following thrombolytic therapy.
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Acute myocardial infarction (AMI) is a common cause of mortality and
morbidity (Kannel,1990). In England and Wales, 89,336 deaths were reported in
1990 (HMS0,1990).
In the past 10-20 years there has been a considerable amount of research into
this subject. As the pathophysiology of acute infarction has become more clearly
understood, so the associated clinical, electrocardiographic and enzymological
features of AMI have been re-evaluated.
In essence, AMI is part of a heterogeneous spectrum of a presumed common
pathology, namely acute occlusion of a coronary artery. This manifests itself as the
acute coronary syndromes, that is, unstable angina through AMI to sudden cardiac
death (Willerson,1986).
The diagnosis of AMI is traditionally made from the triad of chest pain,
electrocardiogram (ECG) changes and a rise in certain, so-called, cardiac enzymes.
The presence of any two of these criteria being regarded as sufficient to confirm the
diagnosis (World Health Organisation criteria (WHO, 1962)).
There are a number of problems inherent within this approach. Firstly, the
pain associated with AMI is not always typical and in some instances may be absent,
so-called silent infarction (Kannel,1984). Secondly, ECG changes diagnostic ofAMI
may not be present; in up to 60% of cases in some series (Lee, 1989). Thirdly, the
rise in serum concentration of certain enzymes has an in-built temporal delay which
implies that for some markers at least 10 to 16 hours must pass from the time of
onset of AMI before this rise can be detected (Hutler,1981; Sharkey, 1988).
Recent large scale clinical trials of thrombolytic therapy administered soon
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after the onset of AMI have shown significant reductions in both mortality and
morbidity (GISSI, 1987; ASSET, 1988; ISIS-2,1988; AIMS, 1988). These trials also
showed that the earlier that thrombolytic therapy was given, the greater the benefit.
As new technologies such as percutaneous transluminal coronary angioplasty
(PTCA) have been developed, and the number and use of pharmacological agents
expanded, the potential to intervene positively in the process of AMI has become
apparent (O'Neill, 1987; Meyer, 1982; Hartzler, 1983). Consequently the management
and prognosis of AMI has changed significantly.
Any information pertaining to the patency of the infarct related artery is
clearly very useful when such a potential to intervene exists. Primarily, the
diagnosis of AMI is required, but in addition to this, an indication as to whether
reperfusion or re-occlusion of the artery has taken place will further influence
management.
These matters will be considered in greater detail below.
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1.2 PATHOLOGY OF ACUTE MYOCARDIAL INFARCTION
The atherosclerotic lesion common to all acute coronary syndromes is the
raised fibro-lipid plaque present in large and medium-sized arteries (Singh, 1984).
The nature of the plaque can vary considerably from being fibrous-rich (consisting
mostly of collagen and smooth muscle cells), to being lipid-rich (consisting mostly
of lipid-filled foam cells). A spectrum of plaque types between these two extremes
exists (Hangartner, 1986; Ambrose, 1988).
The presence of a plaque within the vessel wall results in a reduction in
luminal diameter. A slow progression in reduction of diameter is thought to be
responsible for the symptoms of chronic stable angina which occur at a relatively
fixed degree of exertion for any one patient. When a plaque has caused a reduction
in lumen diameter of at least 70%, it is termed a high grade stenosis
(Willerson,1984). If the plaque occupies the complete circumference of the vessel
wall it is termed a concentric lesion; if it occupies only part it is described as
eccentric (Hangartner, 1986; Ambrose, 1985). Since part of the intima in eccentric
lesions is unaffected by the plaque it is subject to vasospastic influences and the
potential for an acute alteration in luminal diameter exists. The morphology of
individual plaques is also seen to vary, thus, a type I stenosis is smooth in outline,
whereas a type II stenosis has an uneven contour. As will become apparent, these
qualitative assessments of coronary artery anatomy do appear to be related to events
taking place at the time of infarction.
Coronary angiography following AMI demonstrates that thrombus formation
resulting in total (no forward flow) or sub-total (95% obstruction) vessel occlusion
is the principal cause of AMI (DeWood,1980). The majority of occlusions are
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secondary to a deep focal endothelial injury, namely ulceration or rupture of the
plaque with resultant intimal haemorrhage and exposure of collagen and lipid
(Ridolfi,1977; Davies,1985; Fuster,1988; Davies,1989; Onodera,1989). This
provides a profound thrombogenic stimulus (Fuster,1988), and thrombus formation
results in subsequent expansion of the plaque (Davies,1985). The actual mechanism
of initiation of thrombus formation is not entirely understood, but the majority of
thrombi occur at predominately lipid-filled plaques (Hangartner, 1986), and are more
likely to form at a type II rather than a type I lesion (Roberts, 1972; Ambrose, 1985).
Although serial angiographic studies (pre- and post-AMI) up to 7 years apart
have shown that arterial occlusion does not always take place at previously identified
high grade stenoses (Singh, 1984; Ambrose, 1988; Haft, 1988), the risk of vessel
occlusion is related:
a) to the complexity of the underlying lesion after rupture, that is, if it occupies an
irregular profile within the lumen and therefore a large surface area on which
thrombus may form, and b) to the presence of local spasm (as may occur in
eccentrically sited plaques) (Oliva, 1977; Maseri, 1978,1986; Gibson, 1986a).
The effect of vessel spasm is increasingly recognised as having a significant
role in the pathogenesis of acute coronary syndromes (Willerson,1986;
Maseri, 1978). Endothelial injury results in loss of production of naturally occurring
vasodilators such as prostaglandin I2 (PGI2). The local release of thromboxane A2
(TXA2) and serotonin by platelets further promotes vasoconstriction and platelet
aggregation (Willerson,1984; Haft, 1988).
There is often a stuttering process to the development of complete coronary
artery occlusion which may be manifest clinically, usually by variation in severity
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of pain (Braunwald,1988). This often places in doubt the exact moment of
infarction. This has important clinical consequences because of recent developments
in the management of AMI. This will be described more fully below.
In a comparison of patients presenting less than (early), and greater than
(late), 6 hours from the onset of chest pain, Beek found a considerable overlap with
regard to ECG and enzyme characteristics (Beek, 1991). He concluded that some
patients supposedly presenting "late" after infarction in fact have evidence of recent
arterial obstruction and so would benefit from reperfusion therapy. This is further
verified by the observation that the development of histological changes of infarction
seen in post-mortem studies occur over a greater number of hours than those seen
in animal studies when ligation of a coronary artery has been used as the model of
infarction (Wassermann,1989; Maseri,1986). The development of the pathological
changes of AMI appears to be in 2 phases, an evolving phase and a convalescent
phase (Pepine,1989). Restoration of blood flow to the myocardium during the
evolving phase may prevent, either partially or completely, some of the changes of
infarction.
The success of myocardial salvage is dependent upon a number of factors
including the presence of a good collateral circulation (Fujita,1991), low heart rate
and low blood pressure (rate product). It follows that if the process of coronary
artery occlusion is intermittent, and a number of variables further affect the time
taken for myocardium to become non-viable, then the time window for success of
thrombolytic therapy is potentially greater than that predicted from animal studies
(Wassermann, 1989).
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It is also now recognised that the effects of infarction are not simply necrosis
of the tissue supplied by the affected vessel. Thinning of the infarct zone and its
subsequent enlargement (infarct expansion) result in changes in structure and
function in myocardium distant from the site of infarction (Golia,1994). This
process is termed ventricular remodelling and is first seen to occur during the
convalescent phase. It has been proposed that although late administration of
thrombolytic therapy will not be able to restore blood flow to the infarcted area to
prevent those changes seen in the evolving phase, it may have beneficial effects with
respect to preventing infarct expansion and the subsequent complications associated
with extensive ventricular remodelling; namely impaired left ventricular function and
arrhythmogenesis (Podrid,1992; Golia,1994).
In summary, the intermittent nature of vessel occlusion and the benefit of
restoring myocardial flow provide strong reasons for being able to rapidly and
accurately diagnose AMI, and the degree of patency of the infarct related artery; the
latter preferably by non-invasive methods.
1.2.1 O-WAVE AND NON O-WAVE MYOCARDIAL INFARCTION
Acute myocardial infarction has traditionally been categorised as transmural
or subendocardial by pathologists (Marmor,1982). This pathological classification
does not bear close correlation to ECG changes and currently the clinical
classification of patients with AMI into Q-wave AMI (QAMI) and non Q-wave AMI
(NQAMI) is preferred (Boden, 1989a,b; Spodick, 1988); that is, whether AMI results
in the development of Q-waves on the 12-lead ECG.
One distinct advantage of this change in nomenclature is that by using a
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classification which is readily apparent from a non-invasive test, namely, the
electrocardiograph, clinical trials and patient management can be developed with a
significant degree of conformity between investigators. The difficulty of using a
pathological classification is that the true diagnosis can only be made at post-mortem
studies with the accuracy and/or validity of data verified in only a small proportion
of patients. Phibbs argues that this differentiation of AMI into QAMI and NQAMI
has no pathological basis and urges that it be refrained from (Phibbs, 1983).
However, he makes no suggestion as to what, if anything, should be used in its
place. As will become apparent, considerable differences between these two groups
of patients do exist. Since the majority of workers currently accept this
differentiation of patients, this classification will be used for the remainder of the
discussion.
1.2.1.1 PATHOPHYSIOLOGICAL DIFFERENCES BETWEEN O-WAVE AND
NON O-WAVE MYOCARDIAL INFARCTION
QAMI is thought to occur when there is a complete and persistent obstruction
to flow and the whole of the myocardium in any given zone is seen to infarct. New
Q-waves are then identified on the ECG, typically during the first 3 days after the
onset of symptoms (Coll, 1988).
NQAMI results when some degree of myocardial perfusion is maintained by
either anterograde (Davies,1985; Goldberg, 1987) or collateral flow (Fuster,1979;
Ferlinz,1990; Dwyer,1990). Anterograde flow may be maintained by a reduction
in the degree of vasospasm or by spontaneous recanalisation resulting in early
reflow (Boden,1991). Angiographic studies have shown that the restoration of flow
must be complete (Thrombolysis in Myocardial Infarction (TIMI) grade 3) as
opposed to partial (TIMI grade 2) in order to detect any variation in infarct size or
ECG classification with respect to QAMI (Karagounis,1992). NQAMI constitute 20-
40% of all AMI (Abbott, 1973; Gibson, 1986a; Goldberg, 1987; Huey,1987).
Although some degree of vessel perfusion persists in NQAMI this is not
sufficient to completely prevent myocardial necrosis. Experimentally complete
obstruction to flow must be of less than 2 hours duration for NQAMI to result and
greater than 2 hours for QAMI to result (Ferlinz,1990). Thus, NQAMI has been
described as an incomplete or aborted QAMI (Boden, 1989b, 1991) resulting in some
degree of salvage of epicardial myocardium. It appears also to be a predictor of
greater clinical instability due to the presence of viable but threatened myocardium
within the perfusion zone of the infarct related artery (Gibson, 1986b). This is
supported by the observation that coronary angiography at 1 and 7 days after
NQAMI showed that the number of vessels occluded actually increased, whereas
angiographically at similar intervals following QAMI a decrease in the number of
vessels occluded was noted (DeWood,1986; Marmor,1982). Peak creatine kinase
(Krone, 1983) and total CK release (Stone, 1988) are lower in the NQAMI group,
indicating smaller infarct size (Chouhan,1991).
Interestingly, coronary angiography reveals no significant differences in
coronary artery anatomy between QAMI and NQAMI (Krone, 1983; Schulze,1978).
This supports the evidence outlined above that a number of characteristics of the
plaque other than size have a significant influence on the degree of obstruction of
the lumen during the acute event, and hence the extent and duration of vessel
occlusion (Schweitzer, 1990a).
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1.2.1.2 CLINICAL DIFFERENCES BETWEEN O-WAVE AND NON O-WAVE
MYOCARDIAL INFARCTION
Although the classification of QAMI and NQAMI is based upon a simple
non-invasive test, namely the 12-lead ECG, a large number of clinical differences
between these 2 groups of patients have been identified, supporting the observations
that pathological differences exist and raising the possibility of differing therapeutic
approaches in their management (Boden, 1989b).
The first AMI experienced by any given patient is unlikely to be a NQAMI
(Benhorin,1990). Prodromal symptoms such as sweating, nausea and vomiting are
more likely with NQAMI (Ingram, 1980; Scheldt, 1976). In-hospital mortality is
significantly lower for NQAMI versus QAMI (4-12% v 9-25%) (Marmor,1982;
Goldberg, 1987; Stone, 1988). Most studies show that late mortality increases
dramatically in the NQAMI group to 12% by year 3, and continues at 12% for each
subsequent year (Krone, 1983). Although Goldberg showed no significant difference
between NQAMI and QAMI patients he did confirm a trend to increased late
mortality in the NQAMI group (Goldberg, 1987).
Late cardiac events are more common in the NQAMI group. For example,
reinfarction has been reported to be as high as 57% by year 5 in the NQAMI group,
compared to 15% in the QAMI group (Spodick,1983; Stone, 1988). Twice as many
patients with NQAMI require PTCA or coronary artery bypass grafting surgery
(CABG) than those with QAMI (Gibson, 1986b).
In-hospital morbidity also differs significantly between the 2 groups. Infarct
expansion is more frequently observed in the QAMI group. Congestive cardiac
failure (CCF) and serious atrial and ventricular arrhythmias are observed more
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frequently in the QAMI group due to the larger amount of myocardium infarcted
during the acute event (Taylor, 1980). This is also manifest by increased wall motion
abnormalities in patients with QAMI (Hutter,1981; Horowitz, 1982), and overall
impaired left ventricular function (Chouhan,1991).
Within each of the 2 groups, patient subsets are identified. Thus, patients
with anterior QAMI have an increased incidence of CCF compared to those with
inferior QAMI (Benhorin,1990). Those patients with a peak aspartate
aminotransferase (AST) level <240 Units/Litre (U/L) had an in-hospital mortality
of 3%, whereas patients with peak AST >240 U/L had a much higher in-hospital
mortality of 11% (Krone, 1983).
Within the NQAMI group, patients less than 60 years of age have an
excellent prognosis, whereas patients greater than 60 years of age have a 12%
mortality by 3 years, and an 11% yearly mortality thereafter (Goldberg, 1989).
Patients with ECG changes affecting 2 or more leads, or with a magnitude of at
least 2mm ST segment shift have a greater incidence of recurrent ischaemia,
infarction and death compared to those with more subtle ECG abnormalities
(Cohen, 1991).
Patients identified as having sustained a NQAMI at day 3 with ST segment
depression on their admission ECG have a significantly worse prognosis than
patients presenting with ST segment elevation or no significant ECG changes
(Willich, 1987; Dewhurst,1991; Boden,1991; Abbott, 1973). Ogawa demonstrated
that those with ST segment depression have a higher incidence of three vessel
disease, cardiogenic shock and death (Ogawa, 1985). Patients with ST segment
depression compared to ST segment elevation were older, had an increased
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incidence of diabetes mellitus, hypertension, previous MI or angina and congestive
cardiac failure (Willich,1987).
Overall, there seems little doubt that patients with QAMI and NQAMI do
differ significantly, and also that within each of these categories of AMI different
subsets exist. The development or lack of development of Q-waves following AMI
has a marked effect on the predicted in-hospital and post-discharge mortality and
morbidity. As the management of patients following AMI is increasingly likely to
exploit these differences, the ability to classify these patients early in their clinical
course may be of clinical benefit.
1.2.2 THROMBOLYTIC THERAPY AND ACUTE MYOCARDIAL
INFARCTION
Only relatively recently has it become accepted generally that opening
coronary arteries at the time of AMI could benefit prognosis (Rentrop, 1979).
Several large multi-centre, multi-national, double-blind, placebo-controlled trials of
intravenous thrombolytic therapy in acute myocardial infarction have demonstrated
significant reductions in mortality and morbidity if given within hours from the
onset of chest pain (GISSI,1987; ASSET, 1988; ISIS-2,1988; AIMS, 1988).
Comparison of the three currently available preparations, streptokinase (SK), tissue
plasminogen activator (tPA) and anisoylated plasminogen streptokinase activator
complex (APSAC) showed no overall advantage with respect to 30 day mortality for
any individual agent (ISIS-3,1992), similarly there was no advantage demonstrated
between tPA and SK at 6 months (GISSI-2,1990). These findings have been
questioned more recently by the Global Utilisation of Streptokinase and Tissue
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Plasminogen Activator for Occluded Coronary Arteries (GUSTO) study, in which
a reduction in 30 day mortality was seen for an accelerated tPA with intravenous
heparin regime, compared to SK with either subcutaneous or intravenous heparin
(GUSTO-1,1993). However, all patients in GUSTO had ST segment elevation on the
admission ECG, all received thrombolytic therapy within 6 hours of symptom onset,
and perhaps most importantly, the trial was not double-blind in design, unlike ISIS-3
and GISSI-2. These differences in study design may explain this disparity in
observed mortality reduction.
What is apparent from all trials of thrombolytic therapy in AMI, is that
benefit is greatest the earlier that thrombolytic therapy is administered after the
onset of symptoms (0'Rourke,1988). Recent studies of out of hospital thrombolysis,
or even percutaneous transluminal coronary angioplasty suggest that the first 100
minutes following the onset of symptoms are of paramount importance to initiate
therapy aimed at restoring arterial patency (Weaver, 1990; GREAT, 1992;
Ziljstra, 1993).
The side effects of thrombolytic therapy are relatively low in number but can
be serious, especially if given in clinical situations that can mimic AMI, for
example, dissection of the aorta (Satler,1984; Blankenship,1989) and bacterial
endocarditis (Herzog,1991). The need for not only rapid, but also accurate diagnosis
of AMI, is of marked clinical importance.
1.2.2,1 CORONARY ARTERY PATENCY FOLLOWING THROMBOLYSIS
All thrombolytic agents increase the conversion of plasminogen to plasmin,
although tPA and APSAC are more fibrin-specific than SK (Verstraete,1987).
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Intravenous thrombolytic therapy reverses some of the processes of thrombus
formation. In general, thrombolysis is more successful when plaque disruption is
superficial (Onodera,1989). This is explained by the observation that dissolution of
the fibrin network and fibrin-rich material (which lies distally) is relatively easy,
whereas removal of the intra-plaque platelet-rich component is more difficult
(Hugenholtz,1993).
The immediate end-point of successful administration of thrombolytic therapy
is patency of the infarct related artery. An important series of studies investigating
this area is the Thrombolysis in Myocardial Infarction (TIMI) studies. They defined
the degree of reperfusion into 4 grades, (0, absent anterograde flow; 1, penetration
of the thrombus by contrast material but incomplete filling of the distal vessel; 2,
complete opacification of the distal vessel with delayed filling or washout; and 3,
normal vessel flow) (TIMI, 1985).
Patency rates differ between different thrombolytic agents. The GUSTO-1
trial demonstrated that the greatest vessel patency at 90 minutes after initiation of
thrombolytic therapy was seen for an accelerated tPA regime; 54 % had TIMI grade
3 flow and 27% TIMI grade 2 flow. Whereas following SK, 30% had TIMI grade
3, and 25% TIMI grade 2 flow (GUSTO-1,1993). Accelerated tPA resulted in 13%
more patients with TIMI grade 3 flow than if tPA was given at a fixed rate
(Simes,1995). Earlier studies had shown patency rates to be of the order of 60-80%
if thrombolytic therapy was given within 4-6 hours of the onset of chest pain
(Davies,1984; TIMI, 1985; Maseri,1986; O'Neill, 1987), with overall early coronary
patency following tPA exceeding that of SK by a ratio of 1.4 (Granger, 1992). It has
also been demonstrated consistently that patency is greater following intra-coronary
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(72-96%) (Weinstein,1982), compared to intra-venous (45-65%) (Spann,1982)
injection. Interestingly, patency is higher when treating occlusions of the left
anterior descending artery (LAD) compared to the right coronary artery (RCA)
(TIMI,1985; Schroder, 1987; Bates, 1988).
Coronary angiography following AMI has revealed that vessel patency
increases with time even if a thrombolytic agent is not administered, although the
proportion of vessels opened is much lower than that seen if thrombolysis is given.
It has been proposed that this phenomenon is due to secondary spontaneous
thrombolytic activity or to a reduction in the degree of vasospasm (Pichard,1981;
DeWood,1986; Gibson, 1986a). This may be the difference between QAMI and
NQAMI, that is, all infarcts result initially from total vessel occlusion but the degree
of occlusion can then vary, with subsequent variation in pathological outcome.
Huey et al showed 23 % of NQAMI related arteries to be patent at the time
of angiography (Huey, 1987). He argued that when patency rates for NQAMI
approach those observed in patients studied after thrombolytic therapy, the need for
thrombolysis in these patients can quite rightly be questioned. This has some
validity, but clearly will not be true for all NQAMI and therefore some patients are
still likely to benefit from thrombolysis. Considering the incidence of AMI, and
from above, that at least 30% of patients placed into this supposedly favourable
prognostic group on admission will develop features of Q-wave AMI by day 3 (and
therefore be placed into a group with a considerably worse early prognosis), the
converse argument that all patients with myocardium at risk of infarction should be
protected by the administration of thrombolytic therapy where this has been shown
to be of benefit can be proposed. This standpoint is currently being investigated by
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the GUSTO-II trial evaluating the comparison of intravenous heparin and
recombinant hirudin for acute coronary syndromes. Although the doses of these
agents have been modified during the trial (GUSTO-IIa, 1994), the investigators are
assessing the relative effect of these 2 treatments upon unstable angina, NQAMI
and ST segment elevation AMI, the concept of "thrombolytic therapy" being applied
to all pharmacological manipulations of the thrombotic process, not only the 3
recognised agents of SK, APSAC and tPA.
1.2.2.2 WHICH PATIENTS BENEFIT FROM THROMBOLYSIS?
Infarct size is the main determinant of survival following AMI
(Braunwald,1987; Serruys,1987); this would be expected to lend weight to the
concept that any degree of myocardial salvage is of benefit. However, this has not
been confirmed as being of statistical benefit by clinical trials. The ISIS-2 study of
SK and/or aspirin versus placebo in AMI in which ECG changes were not required
for the administration of thrombolytic therapy to take place, (clinical suspicion of
AMI being the main entry criterion), showed by retrospective sub-group analysis
that patients with QAMI benefit significantly more from thrombolytic therapy than
those with NQAMI, the latter having no improvement in survival when compared
to the placebo group (ISIS-2,1988). However, patients identified at day 3 as having
NQAMI who had no changes on the admission ECG had a 50% reduction in
mortality with SK compared to placebo (ISIS-2,1988; Boden, 1989c). Those patients
with an abnormal ECG other than ST elevation or depression had a 38% reduction
in mortality compared to placebo, including patients with prominent R waves in V,
and V2, where this was thought to represent a posterior AMI (Anderson, 1993).
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Therefore, it would appear that certain patients without "classical" ECG changes of
ST segment elevation on the admission ECG do benefit from thrombolytic therapy
and consequently it can be argued that there is clinical worth in identifying patients
within this group, who otherwise would not be identified sufficiently early as having
sustained AMI, and would subsequently be treated suboptimally.
The degree of reperfusion obtained appears to significantly affect prognosis.
Thus, patients in whom TIMI grade 3 flow is seen at angiography following the
administration of thrombolytic therapy have a better prognosis than patients in whom
TIMI grades 1 and 2 is seen (Badger, 1987). The GUSTO angiographic substudy has
shown a significant relation between 30 day mortality and vessel patency at 90
minutes. Thus, mortality at 30 days for TIMI grades 0 and 1 (no patency), was
8.9%, for TIMI grade 2, 7.4% and TIMI grade 3, 4.4% (GUSTO-1,1993a). As well
as showing that differences in vessel patency influence 30 day mortality, this study
also revealed differences in early mortality depending upon the degree of
reperfusion. Mortality at 24 hours was highest in those patients with TIMI grade 2
flow at 90 minutes, 2.93%, compared to 2.35% for patients with TIMI grades 0 and
1, and 0.89% for patients with TIMI grade 3 flow (Simes,1995). Why patients with
TIMI grade 2 flow have the worst immediate prognosis is not clear. It has been
proposed that this flow pattern represents microvascular complications distally,
possibly secondary to myocardial necrosis and localised oedema. This degree of
reperfusion may therefore act as a marker, rather than a cause, of less favourable
outcome (GUSTO-1,1993a; Hugenholtz,1993).
These findings have led to the concept of the "open artery hypothesis",
namely that the success of early reperfusion is the primary determinant of difference
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in outcome between the treatment groups. (Topol,1993; Kennedy, 1995). This is
further supported by the fact that it was the degree of reperfusion that determined
prognosis, not the specific thrombolytic regime achieving that particular effect
(Simes, 1995). The general observation that up to 30% of infarct related arteries will
not be reperfused with intravenous thrombolytic therapy, and the suspicion that the
degree of vessel patency was of marked prognostic significance has led to the
evaluation of primary PTCA in the management of AMI. The safety of this
technique was demonstrated in the Primary Angioplasty Registry (Brodie,1994), and
in a large study of 1,000 consecutive patients (0'Keefe,1993). The Primary
Angioplasty in Myocardial Infarction (PAMI) trial compared PTCA with tPA in 395
patients within 12 hours of the onset of symptoms (Stone, 1995). This study showed
that in-hospital, and 6 month, death and re-infarction rates were lower for primary
PTCA compared to tPA, 5.1% vs 12%, and 8.2 vs 17% respectively. TIMI grade
3 flow was restored in 95% of patients in the PTCA arm of this study. Zijlstra et
al showed that late patency (3 months) was higher in a PTCA treated group, and
proposed that this accounted for the improved clinical course in these patients
compared to those receiving SK (Zijlstra, 1993). Similar results were shown by
Brodie et al with 87% of patients having TIMI grade 2 or 3 flow at 6 months
(Brodie,1994). The findings ofPAMI were not supported by Rogers et al who found
no benefit for PTCA compared to thrombolytic therapy (Rogers, 1994). Similarly,
the addition of PTCA to thrombolytic therapy does not appear to confer clinical
benefit (Michels,1995). Although primary PTCA would seem to be the absolute
means of restoring vessel patency, the availability of this technique is likely to be
limited to a relatively small number of centres with the facilities and expertise to
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deliver such a service. What these studies do provide is an indication of the potential
reductions in mortality that may accrue if pharmacological methods to restore
patency increase in efficacy.
Another indication of the impaired survival resulting from failure to restore
vessel patency was seen in a study by Cheriex et al which showed that myocardial
rupture typically occured in patients in whom reperfusion did not take place
(Cheriex, 1995).
Although early administration of thrombolytic therapy is undoubtedly
favourable (in theory completely reversing the changes of the evolving phase
outlined above), especially if administered within 100 minutes of symptom onset,
later administration of thrombolysis does appear to confer some clinical benefit. The
precise mechanism of this is unclear, but it has been reported to limit overall infarct
size (Richardson, 1989), as well as influence the process of ventricular remodelling,
so having a beneficial effect on LV function (O'Rourke, 1988; Ferlinz, 1990). It has
also been suggested that this will reduce the arrhythmogenic potential of the infarct
related area, and so improve prognosis (Ambrose, 1993).
1.2,2.3 RE-OCCLUSION OF THE INFARCT RELATED ARTERY
FOLLOWING THROMBOLYSIS
The patency of the infarct related vessel following AMI is variable. Coronary
artery re-occlusion is seen in up to 33 % of patients receiving thrombolytic therapy
(Lim,1991), and is especially common where high grade stenoses are identified
(Davies,1985), or where flow following thrombolytic therapy is low (TIMI grades
1 and 2) (Badger, 1987; Hellstrom,1991). Re-occlusion is more common in inferior
(20%) than anterior (9%) AMI (Hugenholtz,1987; Schroder, 1987; Bates,1988). The
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fact that up to a third of successfully opened vessels re-thrombose suggests that a
thrombogenic stimulus persists after administration of thrombolytic agents in a
significant number of patients. Findings from the angiographic substudy of
GUSTO-I showed that early (90 minute) assessment of flow in the infarct related
artery could not predict which vessels would re-occlude by day 7, nor did it appear
to be related to the angiographic appearance of the intra-coronary lesion
(Reiner, 1994). However, it needs to be recognised that this study took place only
in patients with ST-segment elevation, who presented early (within 6 hours of
symptom onset). Also, the mean time to treatment in GUSTO-I was 2.7 hours after
the onset of symptoms. These differences from earlier studies may account for the
variations in angiographic data, however, it does not hide the fact that a significant
number of patients will re-occlude after achieving successful reperfusion, and so
lose the benefit of restoration of arterial patency.
The observation from ISIS-2 (ISIS-2,1988) that the addition of aspirin to
streptokinase was synergistic (using early mortality as an endpoint) suggests that
inhibition of platelet function is important in the period immmediately post-infarction
(Davies,1985), and more aggressive thrombolytic regimes are currently under
investigation.
1.2,2,4CLINICAL IMPLICATIONS OF CORONARY ARTERY RE-OCCLUSION
Infarct extension is defined as the occurrence of a new event, namely, chest
pain, arrhythmia or haemodynamic impairment when accompanied by new ECG
changes and or further elevation of cardiac enzymes (Fraker, 1979). A prerequisite
for this to occur is repeat arterial obstruction with insufficient development of
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collateral flow to prevent increased tissue infarction occurring. It is seen in up to
18% of patients post AMI, and usually occurs within 3-10 days after the first AMI
(Fraker, 1979; TIMI,1985; Marmor,1982). Within this time frame, several studies
have shown it to be up to 3 times more common in NQAMI than QAMI
(Marmor,1981; Gibson,1988; Richardson, 1989; Benhorin,1990). Other risk factors
have been identified, namely female gender, obesity and recurring chest pain
(Marmor, 1981). Patients sustaining infarct extension have a greater in-hospital (36%
v 9%), and 1 year mortality (24% v 9%) than equivalent patients with an
uncomplicated recovery (Marmor, 1982).
Re-occlusion has important prognostic consequences since patients in this
sub-group lose all the benefit of thrombolytic therapy (Lim,1991), having
significantly impaired LV function compared to patients with patent infarct related
arteries and an increased incidence of late potentials (Vatterott,1991). It follows that
maintaining patency is important and by implication, detection of re-occlusion is of
great clinical relevance.
The management of patients with coronary artery re-occlusion or infarct
extension is difficult and currently controversial. Generally it is agreed that
thrombolytic therapy is the best approach to limiting a further increase in infarct
size and should be instituted as early as possible. However this can be far from
straightforward, especially if thrombolytic therapy has been given previously. The
role of rescue or salvage PTCA in these patients has been studied and there appears
to be a consensus that if there is good evidence that reperfusion has not occurred,
especially in patients with a first anterior MI (Ellis, 1994), or in patients with
cardiogenic shock, large infarctions, contraindications to thrombolytic therapy or
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previous bypass graft surgery (O'Keefe, 1993) that this is a valid technique with
significant improvement in clinical outcome.
It can now be appreciated that accurate diagnosis of each acute event as it
presents is of paramount importance, for example, failure to reperfuse adequately,
and that, preferentially, this assessment will be performed non-invasively. With an
increasing array of techniques and interventions available immediately post-AMI,
this will allow appropriate and speedy management to be implemented.
1.2.3 SUMMARY
As the pathogenesis of acute coronary artery occlusion has become more
clearly understood, it seems that certain events are common to all acute coronary
syndromes. However, the outcome of such events varies considerably and whether
infarction occurs, either transmural or subendocardial (as a pathological diagnosis),
is dependent upon a number of factors. The process of infarction is not an all or
none phenomenon; it is dynamic, and the outcome of thrombolysis, even if initially
successful, is not guaranteed to remain so. The concept of the "open artery
hypothesis" has led to the desired therapeutic aim of achieving complete reperfusion
in all patients with AMI, new methods for realising this are currently being
assessed. It can be hoped that advances in the development of thrombolytic agents,
adjunctive therapies and the role of PTCA will lead to further reductions in
mortality to add to the considerable achievements that have been realised in the past
decade or so.
Methods available for the diagnosis of infarction and the non-invasive
identification of vessel reperfusion and/or re-occlusion will now be considered.
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1.3 DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION
1.3.1 INTRODUCTION
Currently, the diagnosis of AMI is based upon a triad of chest pain,
recognised changes in the resting 12 lead ECG and a rise in the serum concentration
of certain biochemical markers. The presence of any 2 of this triad by the third day
after presentation is regarded as sufficient to confirm the diagnosis of AMI
(WHO, 1962). With the advent of widespread use of thrombolytic therapy, the
requirement for rapid diagnosis of AMI has developed, as well as the need for
detection of post-thrombolytic events such as reperfusion and re-occlusion of the
infarct related artery.
Each of the three components of the diagnostic triad will now be considered.
1.3.2 CHEST PAIN
Patients presenting to the Accident and Emergency department with chest
pain constitute a large component of all acute medical cases, in one series up to
19% (Karlson, 1991). The task of the admitting physician when making the diagnosis
of AMI is firstly to discriminate pain that is compatible with a cardiac aetiology,
and then to further subdivide this group of patients into those with AMI and those
without. The consequences of mis-diagnosis in this group of patients can be
disastrous, with significant medico-legal implications (Zarling, 1983; Rusnak,1989);
consequently the percentage of patients admitted to a high dependency area such as
the Coronary Care Unit (CCU) who are later found not to have sustained an AMI
can be as high as 70% (Gaspoz,1991).
Since chest pain and a 12-lead ECG are the 2 most readily available
36
diagnostic aids in the acute setting, a number of investigators have attempted to
formulate protocols for stratifying patients at the time of presentation (Pozen,1980
and 1984; Lee, 1985). The characteristics of the presenting symptoms most likely to
be associated with a diagnosis of AMI appear to be:
Sudden onset of pain, duration of pain greater than 60 minutes, pressure or burning
like character of the pain, precordial or left-sided position, previous history of
ischaemic heart disease and age greater than 60 years (Pozen,1984; Lee, 1989;
Berger,1990; Karlson,1991). These characteristics can be formulated into a
diagnostic algorithm, but even if combined with certain ECG criteria, the sensitivity
and specificity of correct diagnosis are only 88% and 74% respectively, with a
positive predictive value of 32% (Goldman, 1988). This is just slightly better than
the average performance of a selection of emergency room physicians. Even in the
best hands, use of this diagnostic tool would result in a significant number of
patients receiving inappropriate treatment (false-positives), and perhaps even more
importantly, a large number of patients not receiving the correct therapy (false-
negatives) (Lee, 1989).
Although a number of diagnostic protocols have been described, they are not
in widespread use and their applicability for use in the district as opposed to the
teaching centres where they were formulated has been questioned (Young, 1987).
Their main use would appear to be excluding low-risk cases from admission to the
CCU, rather than to positively differentiate between those patients with chest pain
of cardiac aetiology who have sustained an AMI and so would benefit from the
administration of thrombolysis, and those who have not. The fact that one group
applied such a protocol to increase the number of patients discharged at 24 hours
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after admission, as opposed to providing a firm diagnosis in the casualty department
serves to illustrate this point (Weingarten,1989). Lee showed that a combination of
the history, ECG changes and early enzyme estimations could separate patients at
risk of serious complications at 12 rather than 24 hours after symptom onset
(Lee, 1991). Similarly, Gaspoz used a diagnostic protocol to decide which patients
would be suitable for admission to an observation ward rather than the CCU, (those
patients with a less than 10% chance of having AMI), the primary objective being
to reduce in-patient management costs rather than identify those patients requiring
thrombolytic therapy (Gaspoz, 1991).
It can be appreciated from above that the nature of chest pain described in
the casualty department is, overall, a poor indicator of the final (discharge)
diagnosis. Patients with pain strongly suggestive of an acute myocardial infarction
are often found to have a non-cardiac aetiology (Karlson,1991), and conversely,
patients suspected of having no underlying acute cardiac pathology may be proven
to have had an AMI in the subsequent days after admission (Goldman, 1982). The
fact that a number of computer-derived protocols have now been formulated but
none appear to be in common use illustrates the difficulties of using a single
symptom (albeit with a number of closely associated clinical features) to make a
diagnosis of such importance. The need for a diagnostic parameter of far greater
specificity is clearly apparent. The applicability of ECG changes in this regard will
now be discussed.
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1.3.3 ELECTROCARDIOGRAPHIC CHANGES ASSOCIATED WITH ACUTE
MYOCARDIAL INFARCTION
The 12-lead electrocardiogram provides a considerable amount of information
in the diagnosis of AMI; as indicated above it forms one third of the triad of AMI
diagnosis. Its advantages are that it is easy to perform, inexpensive, reproducible
and non-invasive. The potential for misinterpretation of the standard 12-lead ECG
exists because:
a) it may not change with sufficient magnitude in response to changes in myocardial
blood flow, b) alterations in flow to a given myocardial territory may not always
result in the same electrocardiographic changes, and c) interpretation of the 12-lead
ECG varies between different observers (Schweitzer, 1990a).
It is accepted that certain changes in the resting 12-lead ECG are associated
with AMI. These are as follows:
O-WAVE AMI
i) The development of new or presumed new Q-waves of greater than 40
milliseconds (ms) duration in 2 or more anatomically contiguous leads by day 3
after the onset of chest pain (Lee, 1985; Turi,1985; Boden, 1989b).
ii) ST segment elevation >0.1 mV at 80 ms after the J point in 2 or more
anatomically contiguous leads on the admission ECG (Turi,1985;
Sharkey, 1988).
iii) A loss of R wave amplitude of > 25 % in the precordial leads compared to
the admission ECG (Lee, 1985).
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NON O-WAVE AMI
i) The development of ST segment depression of >2mm at 80 milliseconds
after the J point or
ii) ST segment elevation of > 1mm amplitude and/or
iii) Associated T wave changes (inversion or pseudo-normalisation)
All of these changes being accompanied by a subsequent rise in certain
serum enzyme concentrations, the ECG abnormalities persisting from the
initial ECG to day 3 (Raunio,1979; Sharkey, 1988; Schweitzer, 1990b).
POSTERIOR AMI
i) The development of an R wave of > 40 ms duration in lead VI, and an R:S
wave ratio of > 1 in lead VI or V2 by day 3 (Boden, 1989b;
Schweitzer, 1990a).
These changes can be incorporated into more detailed ECG classifications,
for example: the Minnesota code (Blackburn, 1969) and the World Health
Organisation code (WHO, 1959). These definitions are by and large accepted, but
they have been in use for some considerable time and are recognised to have
limitations. Generally, problems arise when the initial ECG recorded from a patient
with a history suggestive of AMI does not fit into any one diagnostic category, or
has old changes or features that make interpretation difficult, or does not show any
changes at all.
A number of studies have been performed using these criteria to diagnose
AMI from the admission ECG, AMI being confirmed by subsequent elevation of
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creatine kinase-MB fraction. Rude et al assessed 3697 patients with suspected AMI
and found a sensitivity and specificity for the ECG of 81 and 69% respectively
(Rude, 1983). It was noted that some changes were of more value than others. ST
segment elevation with or without new Q-wave development diagnosed AMI
correctly in over 80% of cases, whereas ST segment depression was accurate in just
over 50%. Lee et al studied 7734 patients attending a casualty department with a
diagnosis of presumed AMI, and revealed that by day 3, only 14% had ECG criteria
for AMI (Lee, 1989). However, the admission ECG was reported as showing
definite changes of infarction in 8% of patients, and of this group only 76% actually
had an AMI. He had previously studied 482 patients admitted with chest pain of
greater than 30 minutes duration and an abnormal ECG, and found almost half to
have no evidence of ongoing ischaemia or infarction (Lee, 1985). In the same study
he found that when used in conjunction with the site, character and associated
features of chest pain, a single 12-lead ECG was of no additional value in helping
to confirm or exclude the diagnosis of AMI. These results are lower than those seen
in similar studies, but do indicate the problems associated with using a single ECG
as the main arbiter of infarction.
In a large study evaluating over 7,000 patients presenting with chest pain
presumed to be cardiac in nature, Karlson noted that of 4,690 patients admitted to
hospital 921 had sustained an AMI (Karlson, 1991). The initial ECG was categorised
as indicating an obvious AMI in just 27% of these 921 patients. The main
conclusion from the author was that a low suspicion of AMI on the presenting ECG
results in a low probability of AMI by day 3 criteria, but the converse argument
follows that if thrombolytic therapy was administered on ECG criteria alone, 73 %
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of patients would have been undertreated in this particular study.
Overall, a number of studies evaluating similar groups of patients have
shown that for AMI, the diagnostic sensitivity of the admission ECG (where the
ECG is abnormal) is 75-94%, but the specificity tends to be lower, of the order of
60-70% (Paton,1957; Bren,1987; Turi,1985).
There are a number of explanations to account for this inability of the ECG
to correctly classify all patients at the time of presentation with suspected AMI.
Firstly, a significant number of patients have persistent ECG abnormalities that do
not permit diagnosis of infarction, for example, left bundle branch block (LBBB),
previous changes of infarction, "strain" pattern of left ventricular hypertrophy etc.
These have been identified in as many as 12% of patients presenting with suspected
AMI (Willich,1987; Robalino,1989; Ohman, 1990a). Although techniques such as
QRST isointegral maps have been shown to be of some diagnostic benefit in these
patients, the fact that it requires up to 87 unipolar electrodes and specialised
software makes it impractical for routine use (Hayashi,1989). Inappropriate ECG
changes (both ST segment elevation and depression), that may accompany conditions
such as acute dissection of the aorta, can also result in an incorrect diagnosis
(Satler, 1984).
Secondly, an evolution in ECG changes following AMI is observed. Initially,
an increase in R wave and T wave amplitude is seen, with associated ST segment
elevation. This progresses to development of Q-waves, loss of R wave amplitude
and T wave inversion (Von Essen, 1985; Klainman,1987). The initial magnitude of
these changes gives a guide to the final ECG appearance but is far from clear. The
pattern of ECG changes at day 3 is relatively easy to discern, but as these changes
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may not develop for up to 30 hours from the moment of infarction (Yusuf,1981),
this makes interpretation of the ECG recorded on day 3 considerably easier than that
recorded on day 1; especially when up to 20% of patients with AMI have been
noted to have no discernible ECG changes on their admission ECG (Timmis,1990).
Thirdly, observer error can account for up to 4% of incorrect diagnoses from
the admission ECG, usually dependent upon the seniority of the physician
interpreting the ECG trace (Lee, 1987a).
Some of these problems have been addressed by such workers as Greenberg,
who has proposed a new diagnostic ECG code based on the region in which changes
occur and their severity (Greenberg, 1987). This produces a 4-point code for each
patient and he states that this provides improved diagnostic and prognostic
information although concedes that problems of interpretation still exist, and certain
patients cannot be satisfactorily categorised, for example, those with a non Q-wave
posterior AMI.
It would appear therefore that the term "myocardial infarction" implies that
some degreee of myocardial necrosis has occurred, but does not indicate either the
magnitude or the location of this. To expect an indirect recording such as a 12-lead
ECG to show consistent features for all types of AMI is simplistic and inevitably
this does not occur.
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1.3.4ELECTROCARDIOGRAPHICDIAGNOSIS OFACUTEMYOCARDIAL
INFARCTION IN THE THROMBOLYTIC ERA
The importance of correctly diagnosing patients at the time of admission to
hospital has been accentuated in light of the greatly increased use of thrombolytic
therapy in the management of AMI. The clinical benefit of early administration of
thrombolytic therapy, and the recognition that the prognostic profiles of QAMI and
NQAMI differ, have made it necessary to delineate more precisely the occurrence
and implications of acute ECG changes in the immediate post-infarct period.
1.3.4.1 ECG PREDICTION OF BENEFIT FROM THROMBOLYSIS
The evidence from numerous large trials of thrombolytic therapy in AMI
suggests definite benefit for patients with ST segment elevation on the admission
ECG (GISSI,1987; ISIS-2,1988; ASSET, 1988; AIMS, 1988). Von Essen et al
showed that if the sum total of ST elevation was <2mV, this had a 100% sensitivity
and 92 % specificity for predicting sub-total coronary artery occlusion as confirmed
at angiography (Von Essen, 1985; Tanabe,1990).
Patients with no ECG changes on admission also seem to benefit from
thrombolytic therapy, but those with ST segment depression or previous infarction
appear to show no significant difference from the placebo group (ISIS-2,1988;
Schweitzer, 1990a), although Dewhurst showed that patients aged less than 75 years
of age who sustained AMI and had only ST segment or "non-specific" ECG changes
had an especially poor prognosis, and so argues that they require more aggressive
management (Dewhurst, 1991). A large number of patients with non-diagnostic ECG
changes or changes that are difficult to interpret, such as "true" posterior infarction,
44
are thought to benefit from thrombolytic therapy (Benhorin,1990). With the
admission ECG usually being the main criterion to determine who receives
thrombolytic therapy, it follows that this latter group of patients in particular is
liable to be undertreated.
In order to improve the current use of the ECG in the diagnosis of AMI and
its influence in determining who receives thrombolytic therapy, certain authors have
proposed that an increase in the number of changes on the admission ECG,
(especially certain ST segment and T wave changes), that allow a patient to be
identified as being in the high risk group for AMI should be permitted (Bren,1987;
Spodick, 1988; Lee, 1989). This suggestion has derived principally from an increased
understanding of the characteristics of QAMI and NQAMI and the realisation that
previously held dogma is far from correct.
1.3.4,2 ECG PREDICTION OF TYPE OF INFARCTION
The correlation between ECG changes and anatomical site or pathological
type of infarction has long been recognised as poor (Wilson, 1944; Spodick, 1983;
Andre-Fouet,1989). The development of Q waves is still often taught as being
secondary to a transmural AMI. However, as long ago as 1944, Q waves were
shown to appear soon after experimental coronary artery occlusion and disappear
when the ischaemic stimulus was removed, i.e. they were transient and not
necessarily synonymous with myocardial necrosis (Bayley,1944). This is supported
by the observation at necropsy that they signified a prior AMI in just over 50% of
cases when inferior or precordial (Horan,1971). Post-mortem studies from as early
as 1934 have shown that patients with QAMI do not always have transmural
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infarction (Barnes,1935; Erhardt,1974; Savage,1977; Raunio,1979), and conversely
patients with NQAMI may have transmural infarction (Myers, 1949; Horan,1971).
Although the validity of post-mortem studies has been questioned because they
inevitably use a select group of patients, usually with more serious multi-vessel
disease (Dwyer, 1990), the consistency of findings of these various independent
studies would appear to confirm their validity.
The time taken for Q-waves to develop is related to coronary artery anatomy
and also can help to predict prognosis. If the time to Q-wave development is greater
than 3 hours there is a far greater chance of a significant collateral circulation being
present and these patients have the same early prognosis as those with NQAMI
(Eisenberg,1991). Initial ST elevation is not a good predictor of who will proceed
to develop Q-waves on the ECG (Boden, 1989b); in addition, Q-waves may be
transient. They have been reported to disappear from the resting 12-lead ECG in 10-
20% of patients over 1-2 years from the date of infarction (Coll, 1988).
A number of studies have shown that up to 50% of infarcts labelled as
NQAMI at day 3 have >lmm ST segment elevation at the time of admission
(Turi,1985; Huey,1987; Boden, 1988; Schweitzer, 1990a). To explain this, it has
been postulated that ST segment elevation is a sign of transmural myocardial
ischaemia, but does not necessarily imply progression to transmural infarction. This
is confirmed by ECG recording during PTCA (Berry, 1989).
1.3.4,3 NON-CLASSICAL ECG CHANGES DURING AMI
ST segment depression and/or T wave changes may occur secondary to
myocardial infarction, and not only myocardial ischaemia as was previously thought.
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Boden et al discovered that 15% of patients presenting with only ST segment and
T wave changes proceeded to develop Q-waves by day 3 (Boden, 1989b). In the
Diltiazem Re-infarction Study (Boden, 1987), 9.2% of patients included in the study
had isolated horizontal ST segment depression with upright T waves on the
admission ECG. Of this group of patients, 40% had a proven posterior AMI by the
third day after admission, according to ECG and enzyme criteria. Those patients
with downsloping ST segment depression and inverted T waves did not develop
changes compatible with posterior AMI, but did show a rise in cardiac enzymes and
so were labelled as having a "true" non Q-wave anterior myocardial infarction. In
another study, up to 50% of patients presenting with ST segment depression had
sustained an AMI (Lee, 1993).
Angiographic studies have demonstrated that occlusion of the left circumflex
artery (LCA) or right coronary artery (RCA) may be associated with ST depression
rather than ST elevation (Boden, 1987; Mamby,1987). In patients with AMI
secondary to occlusion of the LCA, Huey et al found ST segment elevation in just
48%, and no significant ECG changes in 38% (Huey, 1988). This contrasts
significantly to RCA and LAD occlusion where 71 % and 72 % respectively had ST
segment elevation on the admission ECG and is supported by ECG recording during
PTCA, where occlusion of the LAD and RCA produced ST elevation in 84 and 92%
of patients respectively, but LCA occlusion only 32% (Berry, 1989). Landzberg
found that only 27% of patients with LCA obstruction developed Q-waves
(Landzberg, 1991).
This observation may help to explain why in studies where ST elevation was
the main entry criterion to receiving thrombolytic therapy, the LCA was the infarct
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related artery in just 8-17% of cases (TIMI, 1985; Blanke,1984b; Huey,1988).
Administering thrombolytic therapy only when ST segment elevation occurred would
have prevented it being given to 50% and 25% of patients with AMI secondary to
occlusion of the LCA and RCA respectively (Blanke, 1984b). Overall, ST segment
elevation appears to be 91% specific but only 46% sensitive for AMI (Bren,1987).
1.3.4,4 ECG CHANGES AND SITE OF INFARCTION
The association between the leads in which ECG changes occur, and the
infarct related artery, and so the actual area of myocardium affected, is also variable
(Stadius,1985; Huey,1988; Dwyer, 1990). In general, the correlation between
occlusion of the LAD and anterior myocardial infarction is good (Savage, 1977),
with lead V2 being the best for detecting associated ECG changes
(Schweitzer, 1990a). Apical AMI was best detected by the development of new Q-
waves in leads V1-V4 and an associated loss of R waves, but this was only accurate
for 39% of cases (Giannuzzi,1989).
Occlusion of the RCA was seen to give rise to ST segment elevation with or
without new Q-wave development in leads III and aVF in up to 90% of cases
(Blanke, 1984b; Huey,1988). Birnbaum et al regard lead aVL as the best for
detecting inferior myocardial infarction (Birnbaum, 1993). Right ventricular
infarction (secondary to proximal RCA occlusion) is often missed because lead V4R
is not recorded . This lead has been reported to have 100% sensitivity and 82%
specificity for right ventricular infarction (Cohn,1974; Mukhardi,1984;
Robalino,1989). Occlusion of the LCA produces ST segment elevation in leads I,
aVL, V5 and V6 in only 50% of cases (Blanke, 1984b; Huey,1988), with Q-waves
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developing in only 20% of patients (Schweitzer, 1990a). No ECG changes were
reported in 38% of patients with AMI secondary to LCA obstruction (Huey,1988).
LCA occclusion can result in inferior AMI, and is more likely to give rise to a
"true" posterior or isolated lateral infarct (Mamby,1987). Differentiation of RCA
from LCA occlusion from a single ECG is recognised as difficult (Dwyer,1990;
Fuchs,1982). Overall, non-specific ECG findings are more likely to be secondary
to pathology in the LCA than in the LAD or RCA (Blanke, 1984b).
These variations in ECG changes following specific coronary artery
occlusions are mostly thought to be secondary to anatomical variation, for example,
the LAD can terminate at the apex of the left ventricle or it can supply up to 1/3 of
the inferior surface of the LV (Dwyer, 1990). Similarly, the LCA or RCA can be
"dominant", that is, give rise to the posterior descending artery, and so supply
varying amounts of myocardium.
1.3.4.5 CONCOMITANT ST SEGMENT ELEVATION AND DEPRESSION IN
ACUTE MYOCARDIAL INFARCTION
Isolated changes of ST segment elevation or depression in specific groups of
leads on the 12-lead ECG, specifically, leads II, III and aVF (inferior leads), leads
V1-V4 (anterior) and leads I, aVL, V5 and V6 (lateral), are recognised as being
secondary to alterations in myocardial blood supply to relatively discrete areas of
myocardium (Lembo,1986; Boden, 1989a).
Combinations of ST segment elevation and depression in different lead
groups are seen. Up to 72% of patients with ST segment elevation inferiorly may
have ST depression anteriorly, and up to 57% of patients with ST elevation
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anteriorly may have ST depression inferiorly (Raunio, 1979; Katz,1986;
Yousif,1989). A number of explanations have been proposed to explain these so-
called "remote changes" (Schuster, 1981; Gibson, 1982; Camara,1983;
Ferguson, 1984):
i) That differing degrees of infarction have taken place in more than one area
of myocardium, for example, a QAMI inferiorly and a NQAMI anteriorly.
ii) That extension of the infarct has occurred posteriorly.
iii) That coronary artery flow is affected by the altered haemodynamics
accompanying myocardial infarction. This implies that atheromatous disease i s
present in additional vessels to the infarct related artery and that myocardial
ischaemia is produced with ST segment depression being manifest on the 12-
lead ECG.
iv) That "benign" reciprocal changes mirror the electrical changes taking place
elsewhere (Timmis,1993).
This last view (iv), is the least popular because these ECG changes often
occur in areas of the heart that are not truly electrically opposite. For example,
inferior and anterior planes are at 90,° not 180° to one another (Boden, 1989a). The
fact that these changes are not always seen (which would be expected if they were
simply an electrical phenomenon), and the fact that patients with such remote
changes have a significantly worse in-hospital prognosis than patients without such
changes does indeed suggest that they signify some additional abnormality of
myocardial perfusion.
The repeated observation that patients with ST segment depression in
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addition to ST segment elevation do less well than patients with just one of these
ECG abnormalities suggests that more vessels are threatened, probably collaterals,
which results in a greater incidence of subsequent ischaemic events (Boden, 1989b).
Up to 2/3 of patients with remote ECG changes were found to have a stenosis of at
least 70% in the artery supplying that area (Yousif, 1989). Yousif also demonstrated
that remote ECG changes after AMI were shown to be as good as sub-maximal
exercise testing at predicting multi-vessel disease. This finding is contradicted by the
study of Odemuyiwa, who found that remote ST segment depression on the
admission ECG did not predict patients with atheromatous disease in the vessel
supplying that region (for example the LAD in anterior changes)
(Odewuyiwa, 1985).
Shah et al first described the clinical and prognostic implications of
precordial ST segment depression in association with inferior ST segment elevation
(Shah, 1980). In a study comparing patients with first myocardial infarction who had
ST segment elevation inferiorly and ST segment depression in leads V1-V4, patients
in whom precordial ST segment depression persisted after 24 hours had a
significantly worse outcome in terms of morbidity, mortality and LV ejection
fraction as documented by clinical, haemodynamic and non-invasive investigations,
than those in whom it had resolved (Lembo,1986). This finding was confirmed in
similar groups of patients (Bates, 1990; Lee, 1993). Bates concluded that the initial
magnitude of precordial ST segment depression in patients with ST segment
elevation inferiorly helps to identify an important subset of patients with first AMI
who are at added risk. He also advocates using thrombolytic therapy for those
patients with ST segment elevation inferiorly only if they have had pain for less than
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3 hours or if they have ST segment depression anteriorly (Bates, 1988).
One study which contradicts the view that ST segment elevation and remote
ST depression is of increased significance to ST segment elevation alone is that by
Camara et al which identified this particular pattern of ST changes in 25 patients
(Camara,1983). They noted an absence of any correlation between wall motion
abnormalities and resolution of ST segment changes and proposed that this ST
segment abnormality did not indicate underlying myocardial dysfunction because this
change was so common and it could not realistically predict an important subset of
patients.
The general concensus however seems to be that it is persistence of these
changes beyond 24 hours that is important, and that because patients in whom this
occurs have a worse prognosis, an additional insult to the myocardium is likely to
have occurred.
1.3.4,6 DYNAMIC ST SEGMENT CHANGES AND ACUTE MYOCARDIAL
INFARCTION
ST segment changes in response to alterations in myocardial blood flow have
been recognised for a number of years (Eyster, 1939). It was by using direct current
coupled amplifiers to record both epicardial and endocardial waveforms in dogs that
the pathophysiological changes responsible for these variations in the cardiac action
potential were identified (Samson, 1960; Vincent, 1977). Two main effects of
complete or partial occlusion were noted:
i) A variation in resting membrane potential (incraese or decrease) in the
region of myocardium with altered blood flow,
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ii) An alteration in the transmembrane potential waveform (in terms of
amplitude, duration and slope of phase 2 of the action potential), and its time of
onset (delayed activation and repolarisation).
During any alteration in myocardial blood flow subendocardial tissue is first
affected. ST segment and T wave changes therefore represent a diastolic injury
current, because coronary blood flow occurs principally in diastole.
On the surface ECG, loss of resting membrane potential results in the true
baseline (TQ segment) being depressed, this is the most common consequence of
impaired myocardial flow. If the baseline remains in the same position on the ECG
recording, then this gives the impression of ST segment elevation. Conversely, an
upwards shift in this TQ segment baseline gives the impression of ST segment
depression.
Changes to the action potential waveform morphology alter the shape of the
ST segment. These changes occurred less frequently than those to the TQ segment,
and were affected more by variation in heart rate than by alterations in blood flow.
T wave morphology also varies during myocardial ischaemia, principally by a
change in polarity.
1.3.4.7 ECG CHANGES AND CORONARY ARTERY REPERFUSION
ST segment monitoring immediately after myocardial infarction has been
advocated as a non-invasive marker of coronary artery patency. A large number of
studies have used various methods to assess coronary artery reperfusion. These have
all been validated with coronary angiography, although the timing of angiographic
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assessment in relation to the observed ECG changes is not identical for all studies.
That is, some studies relate ECG changes to coronary angiograms performed soon
after the administration of thrombolysis, for example, Hogg et al (Hogg, 1988),
whereas other studies performed angiography considerably later, some 6 days after
thrombolysis, (Richardson, 1988). Considering the fact that coronary reperfusion is
a dynamic, rapidly changing process that is often accompanied by intermittent or
sustained reocclusion, the precise relation between ECG changes and reperfusion
status is difficult to quantify, although from the GUSTO angiographic substudy it
does appear that early, complete reperfusion is of considerable prognostic
significance (GUSTO-1,1993).
Saran et al showed that a reduction in the degree of ST segment elevation of
greater than 25% within 3 hours after the administration of thrombolytic therapy
was compatible with either a patent artery, or preservation of left ventricular
function (Saran, 1990). A fractional change (reduction of ST segment elevation) of
greater than 0.5 within 2 hours of intra-coronary, or 3 hours of intra-venous,
streptokinase therapy was also corresponded to coronary artery patency (Lee, 1989)
Hogg et al measured the sum of ST segment elevation in all the affected
leads of patients with anterior AMI, on admission and at 48 hours (Hogg, 1989).
They demonstrated a significant reduction in the degree of ST elevation at 48 hours
in those patients who received thrombolytic therapy compared to those not being
thrombolysed. However, the confidence limits identified did not allow any individual
patient to be categorised with certainty.
Using 50% resolution of the amount of ST segment elevation on the
admission ECG as a marker of reperfusion, Hohnloser et al found this to give a
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sensitivity and specificity of 60% and 95% respectively (Hohnloser,1991).
Clemmensen found that a 20% resolution of ST elevation measured at the J point
gave a sensitivity and specificity of 88% and 80% (Clemmensen, 1990b), Baskin et
al found a sensitivity of 62% for this amount of ST segment resolution
(Baskin, 1993). An alternative approach was employed by Krucoff (Krucoff,1989),
who used the time to achieve a steady state following thrombolytic therapy as a
marker of reperfusion. This was defined as the time from administration of
thrombolytic therapy to the time when the ST segment level was equally or less
deviated than the quiescent level (inevitably this incorporates a retrospective
component to the analysis). When this steady state was achieved in less than 100
minutes this gave a sensitivity and specificity for reperfusion of 89% and 82%
respectively. The occurrence of reperfusion arrhythmias or time to resolution of
chest pain was found to be of no use in identifying patients who had satisfactorily
reperfused the infarct related artery. (Saran et al,1990; Krucoff, 1989), although
Shah observed that the sudden development of sinus bradycardia, or the onset of an
idioventricular rhythm was associated with reperfusion (Shah, 1993).
It is increasingly recognised that ST segment changes in the immediate post
AMI period, either with or without the administration of thrombolysis are dynamic.
Krucoff et al monitored ST segments continuously and found cyclical changes in
several patients. They concluded, by measuring other clinical variables, that where
ST segments fluctuated, the "quality" of reperfusion was less than when this did not
take place (Krucoff, 1993). Kwon et el identified a group of patients in whom ST
segment re-elevation occurred after resolution. This group had reduced arterial
patency, and more severe residual stenoses than patients without recurrent ST
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segemnt elevation (Kwon,1991). Miida et al quantified this by reporting that if the
sum of ST segment re-elevation was >0.5mV in leads V1-V6, then a greater
amount of myocardium had been damaged prior to thrombolysis than if this re-
elevation was not present (Miida, 1994). This was supported by Kondo et al who
found a similar group of patients to have larger infarcts and a worse prognosis
(Kondo, 1993). Simoons et al acted upon this observation and gave repeat
thrombolysis (tPA) to patients with re-elevation noting an improved outcome than
when this was not done (Simoons, 1993). Only Schechter and colleagues appear to
regard ST segment re-elevation as a favourable finding. They found that patients
with anterior AMI had improved left ventricular function if ST segment re-elevation
was seen. There was neither a positive or negative effect on patients with either
inferior or posterior AMI (Shechter,1992)
Other components of the ECG recording have been evaluated for identifying
reperfusion. Tanabe et al measured the sum of ST segment elevation (EST) and the
sum of R wave amplitude (ER) in a number of patients with anterior AMI
(Tanabe, 1990). All patients categorised as having successful reperfusion had
ER/EST >2.5 or EST <2mV. Using a 48-lead mapping system, unsuccessful
thrombolysis or re-occlusion was demonstrated by a decrease in total R-wave
amplitude, or the number of leads with no R-waves present (Von Essen, 1985).
Late potentials are high frequency, low amplitude signals not usually detected
by routine electrocardiography. They appear to identify patients at risk of future
cardiac events following AMI. When comparing patients with and without coronary
artery reperfusion, a significant difference was identified between the 2 groups, but
there was a far greater overlap than that seen with ST segment shifts, and
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consequently they have no clinical application in this area (Tranchesi,1990).
Significant ECG differences can be identified between groups of patients who
have and have not received thrombolytic therapy. In the TAMI 7 trial, of 11
parameters assessed as non-invasive markers of coronary artery reperfusion, ST
segment recovery was the only one with any useful discriminatory power
(Krucoff,1991). Other authors have reviewed this subject and comment that of the
many methods of interpretation of ST segment changes considered, although overall
there may be differences between the 2 groups, these measurements have no clinical
applicability to individual patients (Bren,1987; Hillis, 1990; Boden,1991). This
finding was confirmed by Zabel et al who found continuous ST segment monitoring
to have similar sensitivity, specificity, positive and negative predictive value to
reporting ST segment changes on 2 ECGs taken 2 hours apart, these being of the
order of 77%, 74%, 89% and 50% respectively (Zabel,1992).
An overview of the studies of early patency assessment using serial ECG
monitoring techniques deduced that rapid resolution of ST-segment elevation of at
least 50% is probably the best criterion of early patency (Klootwijk,1993).
Although at present the application of ECG changes at an individual level is
not completely valid, the possibility of combining one or more of the above
techniques with biochemical or other markers of reperfusion exists. This may allow
application of these techniques to identify more accurately individual patients who
have, or have not, achieved reperfusion of the infarct related artery.
1.3.5 SUMMARY
Most studies utilising the ECG as the main entry criterion for receiving
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thrombolytic therapy exclude a large number of patients in clinical practice who
often provide the most difficult cases to manage. It is clear that there is usually no
difficulty in diagnosing AMI from an ECG with "classical" ST elevation, but
problems of correct diagnosis arise for those patients with a history suggestive of
AMI, but who have a non-diagnostic ECG, that is, non-classical changes, and/or a
past history of one or more of the following which complicates matters further:
Previous AMI, past history of valvular and/or congenital heart disease,
cardiomyopathy, previous coronary artery bypass grafting (CABG) or the presence
of left or right ventricular hypertrophy (LVH or RVH), permanent pacemaker
(PPM), left or right bundle branch block (LBBB or RBBB) or drugs that affect the
resting ECG, such as digoxin. All too often, these are patients that are more likely
to develop infarct extension or have recurrent AMI (especially occurring soon after
the index MI) and they constitute a significant proportion of patients presenting with
symptoms suggestive of acute infarction (Marmor, 1982; Lembo,1986).
It can be appreciated that changes to a particular group of leads on the 12-
lead ECG should not always be regarded as accurately signifying changes in a
particular region of myocardium and, even less so, flow in a particular coronary
artery. ST segment depression does not always denote myocardial ischaemia and
lack of inversion of T waves may actually represent an event of greater importance
than actual inversion of T waves, especially when accompanied by other changes
e.g. anterior ST segment depression. Furthermore, it is not possible to predict from
the admission ECG which patients will develop Q-waves by day 3.
The need for additional means to detect changes in myocardial flow is
apparent. Biochemical tests used in this role will now be considered.
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1.4 BIOCHEMICAL MARKERS OF ACUTE MYOCARDIAL INFARCTION
1.4.1 INTRODUCTION
One of the earliest histological manifestations of myocardial infarction is
disruption of the sarcolemmal membrane (Jennings, 1965). Following disruption,
intracellular proteins are able to escape into the circulation and a number of these
have been assessed as markers of myocardial injury.
Historically, such proteins were used simply as confirmation of the diagnosis
of AMI, but more recently, the need to determine rapidly whether reperfusion of the
infarct related artery has occurred has led to a search for new markers and renewed
interpretation of previously identified ones. These will now be discussed.
1.4.2 ASPARTATE AMINOTRANSFERASE
A rise in serum concentration of aspartate aminotransferase (AST) following
AMI was first reported in 1954 (Karmen, 1954). Peak AST concentration occurs 22
+ 7 hours post-AMI (Muller-Hansen,1989). Until relatively recently AST was in
widespread use in the diagnosis of AMI, but currently it is regarded to be of most
use when diagnosing AMI 48-72 hours after it has actually occurred
(Rotenberg,1989; Pappas,1989); it has no effective role within the recognised time
window of effective thrombolytic therapy AMI (Lott, 1989a).
1.4.3 LACTATE DEHYDROGENASE
Serum concentrations of lactate dehydrogenase (LDH) have been known to
increase following AMI for some considerable time. Total LDH can be of value in
diagnosing AMI up to 72 hours after the onset of chest pain (Rotenberg,1989). Peak
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LDH levels are seen 34+12 hours following AMI (Muller-Hansen,1989), and
consequently in the first few hours following AMI, LDH is of no diagnostic value
(Collinson,1988; Lott, 1989a).
Various isoenzymes of LDH can be measured. For diagnosis of AMI, of
most value is the isoenzyme LDH-1 (alpha-hydroxybutyrate), and the ratio LDH-
1/total LDH (Collinson,1988).
As for AST, LDH has no role to play in the diagnosis of AMI within the
first few hours after the onset of symptoms, but for patients presenting late, that is
greater than 48 hours from the onset of chest pain, LDH-1 was, until recently, the
enzyme of choice for making a retrospective diagnosis of AMI (Roberts, 1988).
1.4.4 CREATINE KINASE
Creatine kinase (CK) release as a diagnostic marker of AMI was first
described by Hughes in 1962. CK concentrations peak at 20 hours after the onset
of symptoms, but, more importantly, levels are seen to rise within a few hours in
some patients (Hughes, 1962).
The time to measure CK can be reduced by using an analyser at the bedside
rather than requiring laboratory analysis. Gibb evaluated a benchtop reflectance
photometer and found its performance satisfactory when compared to laboratory
analysis (Gibb, 1985), as did Downie et al using a bedside assay (Downie, 1993). A
CK result was available from a plasma sample within 4 minutes and gave a result
up to 10 hours earlier than that provided by the "routine" service. This illustrates
the usefulness of such an instrument, but does not eliminate the problems of CK
measurement in the diagnosis of AMI.
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The main disadvantage of CK as a marker of AMI is the fact that it is not
specific to the myocardium, and therefore a rise in serum concentration can occur
in a number of pathological conditions and hence the specificity of the test is
reduced. Lee et al found that a single measurement of CK gave a positive diagnosis
in only 25% of patients within 4 hours from the onset of symptoms, and an overall
frequency of false-positives of 20% (Lee, 1987b). The lack of reliability of a single
measurement is confirmed by a number of other authors (Irvin,1980; Doran,1990).
Creatine kinase is composed of two subunits. One, subunit M, is so called
because it derives principally from skeletal muscle and forms the isoenzyme
CK-MM. The other, subunit B, is most abundant in the brain and forms CK-BB.
The hybrid form, CK-MB is found principally in the heart, where it comprises about
15% of total myocardial CK activity. As well as the three isoenzymes, a number of
isoforms have also been identified, 4 for CK-MM and 2 for CK-MB (Lott, 1989b).
Kontinnen and Somer in 1972 first described the release of CK isoenzymes
following AMI (Konttinen,1972). They showed that the majority of enzyme released
is CK-MM, and that CK-MB as a percentage of total CK ranged from 0-28%. In
most patients a rise in CK-MB can be detected within 6 hours from the onset of
chest pain, a peak value is seen in 10-36 hours and the levels return to normal
within 48-72 hours (Kimmelsteil,1989).
The difference between the diagnostic abilities of CK and CK-MB is
illustrated in a study by Clyne et al (Clyne, 1989). Patients with a normal total CK
but elevated CK-MB had a similar clinical course to patients with raised CK and
CK-MB, and a significantly worse course than patients with neither a CK or CK-
MB rise. He proposed that for accurate diagnosis of AMI, CK-MB must be
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measured. Lott confirmed that CK-MB was of greater diagnostic value than CK
(Lott, 1989a) and the specificity of CK-MB was demonstrated by the fact that 2
sequential negative results had a negative predictive value for AMI of 98%
(Kimmelsteil,1989; Roberts, 1988). This finding is not universal, since Kallner et al
in a comparison of the diagnostic abilities of total CK with CK-MB revealed no
significant differences between the two up to 12 hours from the onset of symptoms
(Kallner, 1989).
The consensus at present is that serial analysis of CK-MB is the most
sensitive, specific and cost effective means of diagnosing AMI. It is regarded as the
gold standard of AMI diagnosis (Lott, 1989a). Roberts advocates that for the
majority of patients there is no need to measure other enzymes, and adds that total
CK and CK-MB should be measured every 4-6 hours (Roberts, 1975). The accepted
criteria for diagnosis are CK-MB activity >5% total CK activity, 12-36 hours after
the onset of symptoms (Vijan,1991).
Wu et al compared the analytical performance of three immunoassays used
to measure CK-MB rapidly, including Hybritech's "ICON QSR CK-MB" (a two-site
immunoassay utilising immunoconcentration) (Wu,1989). Performance criteria
included precision, analytical sensitivity, sample stability. They concluded that there
was no significant difference in the analytical characteristics of these assays but felt
that the ICON method was probably best suited to a rapid diagnostic role, since only
a relatively inexpensive reader is required in addition to the individual test cups.
The limitations of the assay range, namely a lower and upper cut-off of 2 and 50
ng/ml respectively, did not detract from its potential value in the diagnostic setting.
These findings were supported in a similar study in 195 patients presenting with
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chest pain (Collins, 1993).
Mair et al demonstrated that CK-MB mass concentrations are elevated sooner
following AMI than CK or CK-MB activity levels. They suggest that in the post-
thrombolytic era, mass methods of detection should be employed wherever possible
(Mair, 1991b). The improved specificity of a CK-MB mass assay in comparison to
a CK-MB activity assay in patients following PTCA (without evidence of co-existent
AMI) was demonstrated by Hunt et al (Hunt, 1991), who showed 9% of patients to
have a rise in CK-MB activity but not in CK-MB mass concentration. The validity
of this study being supporteded by the observation that Troponin-I levels did not
increase, so confirming that myocardial infarction was unlikely to have occurred.
An alternative approach to using absolute values of CK and its isoenzymes
in making an early diagnosis of AMI is to exploit the fact that a rise in
concentration rather than a particular cut off diagnostic value be employed.
Collinson et al evaluated the slope of the log concentration of a number of enzymes
against time, and found that a slope log CK /hour >0.015 for samples taken on
admission, 6 and 12 hours after the onset of chest pain was both highly sensitive and
specific for the diagnosis of AMI (Collinson, 1988). This finding was confirmed by
Mullen, who found all 16 patients with AMI to have a log CK slope of >0.015
from samples taken 4 to 16 hours after the onset of chest pain (Mullen, 1990).
Collinson has subsequently shown that log slopes of CK-MB activity or
concentration did not yield any further diagnostic information to those of log slope
CK/hour (Collinson, 1989). He advocates that this method could be used at the
bedside, but at present it requires the rapid laboratory analysis of more than one
blood sample for CK as soon as the sample reaches the laboratory, and limits the
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time to diagnosis to 12 hours after the onset of chest pain. Vijan et al using a
similar method of log CK slope/hour found that 22% of patients with AMI were not
diagnosed by this method (Vijan, 1991), although no patients without AMI gave a
positive result; the specificity being 100%, and the sensitivity 78%. It is also
generally agreed that this technique works best for a low initial CK level, if the first
CK-MB is high, the chance of the second level being of sufficient magnitude to
produce a log slope/h >0.015 is reduced (DuFour,1989). For this reason, it has
been suggested that a diagnostic cut-off level be decided upon and used to determine
whether infarction has occurred (Leung, 1991). LaGrenade studied 107 patients with
AMI, and was able to make a correct diagnosis by measuring CK-MB levels on
admission and 8 hours later (LaGrenade, 1987). However, she used an
electrophoretic or chromatographic method to analyse the samples and so the time
delay to diagnosis on a fresh sample would be even greater.
Despite the fact that CK-MB is regarded as the gold standard of AMI
diagnosis, it is fallible (Lott, 1989b; Bakker,1993). This is because it is not entirely
cardio-specific and hence other pathologies can result in a release of CK-MB from
a non-cardiac source. The false-positive rate can be as high as 15% (Lee, 1986),
especially when the total CK concentration is high for example following trauma or
surgery. In such situations, total CK-MB may be elevated, but the percentage of
CK-MB as a fraction of total CK is usually reduced. Thompson studied 146 patients
with a high total CK (> 1000 U/L) and found that a cutoff of CK-MB > 15 U/L,
and a CK-MB proportion of the total CK of >2% gave optimum results for
diagnosis of AMI (Thompson, 1988). The ratio of CK-MB/CK gave a better
specificity than absolute values of CK-MB alone, but resulted in a significant loss
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of sensitivity. Even with these improved criteria a number of false-positive
diagnoses would have been made.
The significance of a minimally elevated CK-MB concentration has also been
called into question. White et al defined positive diagnosis of AMI as a CK-MB
>25 IU/L, and a negative diagnosis as 0 IU/L (White, 1985). Those patients with
a CK-MB of 1-24 IU/L constituted a so-called intermediate group. Initially the
mortality in the intermediate group equalled that of the positive group, but patients
with chest pain alone in the intermediate group had a mortality of 0%, whereas
patients with severe medical problems had a mortality of 33%. He suggested that
in patients with results in this indeterminate range, other factors should be
considered before deciding upon the significance of a minimally elevated CK-MB
concentration, that is, extra-cardiac sources of CK-MB may be responsible.
At present, CK-MB is the best diagnostic marker of AMI due to the fact that
it is relatively cardio-specific, its release kinetics following AMI allow relatively
rapid identification soon after the onset of infarction, and because it has been in
widespread use for a number of years, a large number of assay methods for accurate
and reliable measurement have been developed (Bakker, 1993).
As well as providing information to diagnose AMI, a number of parameters
of CK-MB, and CK, release have been examined, principally in relation to
identifying reperfusion of the infarct related artery and differentiation of QAMI and
NQAMI.
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1.4.4.1 EFFECT OF REPERFUSION ON SERUM CK-MB CONCENTRATIONS
Animal studies show that a rapid release of enzymes occurs following
reperfusion of infarcted myocardium (van der Veen, 1990). Comparing transient and
persistent occlusion of the left circumflex coronary artery in dogs, Roe showed that
following transient occlusion of 2 hours, maximum enzyme release occurred 15
minutes after release of the obstruction, whereas in dogs with persistent obstruction,
peak levels were seen after 9 hours (Roe, 1975). A study in rats gave similar results
(Matsui,1989), and generally, the kinetics of myocardial marker protein appearance
in the plasma compartment depends on perfusion of the infarcted area (Shell, 1983).
This phenomenon has been applied in a number of studies in man.
Nidorf compared early peaking of creatine kinase to reperfusion detected
angiographically (Nidorf, 1988). Initially during a pilot study, CK levels were
measured 6 hours after the onset of symptoms, (immediately after administration of
thrombolytic therapy), and at 12 hours. If the rate of rise of CK concentration was
>7% peak concentration per hour, this gave a 90% sensitivity and 76% specificity
for coronary artery patency. Norris et al also use peak concentration, arguing that
if the concentration of CK 3 hours after thrombolysis was >20% peak concentration
then reperfusion was likely to be present (Norris, 1993). The obvious limitation here
is that information relating to patency is available a minimum of 6-7 hours after
thrombolysis, and this also implies CK analysis is performed almost immediately.
In a comparison of patients who received intra-coronary streptokinase with
those who did not, Blanke found that the time to peak CK was less in the group
receiving thrombolytic therapy; reperfusion was documented angiographically in
these patients (Blanke, 1984a). Two similar studies confirmed this observation
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(Shah, 1993; Ohman,1993). In patients with AMI, those individuals who have
undergone successful reperfusion have peak CK-MB values about 10 hours after the
onset of symptoms. In comparison, patients whose infarct related artery remains
occluded show this peak at about 20 hours (Hackworthy,1988; Zwann,1988).
Lewis et al showed that in the first 150 minutes following thrombolytic
therapy, patients with successful reperfusion had higher actual and relative increases
of CK and CK-MB than patients in whom reperfusion did not occur (Lewis, 1988).
The authors noted that although the results for relative rate of enzyme rise were the
most accurate, these required a knowledge of the peak value, which by definition,
is not available until later. They suggested that using the absolute rates of rise is
sufficient to make an informed pronouncement upon the state of arterial perfusion;
principally whether TIMI grade 3 flow has been restored. Grande et al also
calculated that if the rate constant for increase in concentration of CK was greater
than 0.185 there was a strong likelihood of reperfusion (Grande, 1991). More
contentiously, they proposed that if the first sample was analysed prior to
thrombolysis, then patients with spontaneous recanalisation can be identified (by the
magnitude of the initial marker concentration) and a relatively conservative approach
taken, with the converse approach for those patients in whom reperfusion does not
appear to have occurred.
Other aspects of the pathology of AMI have also been considered with regard
to marker serum profiles. Clemmensen et al compared patients treated with
intravenous streptokinase or placebo. They found that in the treated group CK-MB
appeared more rapidly, and by using ECG estimates of infarct size from the
admission and day 3 ECG's implied that up to 60% of patients in the treated group
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had demonstrated myocardial salvage (Clemmensen, 1990a).
Ong et al performed coronary angiography soon after thrombolysis. They
found that the rate of appearance of CK-MB was related to the severity of the
residual stenosis, an infarct related artery stenosis of 1.2mm being the flow limiting
lesion (Ong, 1991).
Bosker et al compared the time to peak values, and release rates of CK and
LDH-1 and found the accuracy for each of these 4 tests to be of the order of 70-
89% for detecting reperfusion as demonstrated by angiography (Bosker, 1991). The
kinetics of LDH-1 release do not lend themselves to this function, and although a
distinct cut off level did not exist between the 2 groups, a significant difference
between them for time to peak CK and rate of rise of CK was observed. Bosker
therefore appears to have highlighted the problem reported by a number of workers
who feel that non-invasive detection of coronary artery reperfusion can distinguish
between the 2 groups of patients involved, but that at an individual level this is not
precise. Only with the incorporation of more markers or refining the technique and
timing of measurement will this distinction become clearer.
1.4,4.2 COMBINING BIOCHEMICAL AND ECG CRITERIA IN THE
DIAGNOSIS OF REPERFUSION
Hohnloser et al compared the individual and combined predictive abilities of
a number of markers of reperfusion. They found that individually, the time to peak
CK and 50% resolution of ST-segment elevation were moderately sensitive, highly
specific, strongly positive predictors, but relatively weak negative predictors of
coronary artery patency (Hohnloser, 1991). A combined analysis of these 2 markers
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produced a sensitivity of 100%, a specificity of 90%, positive predictive value of
97% and negative predictive value of 100%. The presence of reperfusion
arrhythmias and/or resolution of ischaemic chest pain did not have any worthwhile
contribution to make to the diagnostic process.
1.4.4.3 DIFFERENCES BETWEEN O-WAVE AND NON O-WAVE
MYOCARDIAL INFARCTION
A difference in enzyme release kinetics has been observed between QAMI
and NQAMI. Shell et al examined changes in CK-MB activity within the first 6
hours after admission. They found that in QAMI, only 72% of patients had a raised
CK-MB level, compared to 100% of patients with NQAMI (Shell, 1981). Of the
28% with QAMI and no detectable rise within 6 hours, it took until 12 hours after
the onset of symptoms before a rise was detectable in all patients. Conversely, some
of the patients in the NQAMI group had a detectable rise by 2 hours. A difference
in the time to peak CK-MB was noted for patients with and without definite
evidence for AMI on their admission ECG (Sharkey, 1988). None of these patients
received thrombolytic therapy. Those with a non-diagnostic ECG had an earlier but
smaller peak than those with a diagnostic ECG. The majority of patients in the
diagnostic group (16/21) had QAMI, whereas the majority in the non-diagnostic
group had NQAMI (12/13). These findings are not surprising, but still show that up
to 8% of patients proceeded to QAMI despite presenting with non-specific ECG
changes.
Cox et al compared patients with early (less than 15 hours) and late (greater
than 15 hours) time to peak CK-MB. They discovered a number of differences
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between these 2 groups of patients. The "early" group were older, had an increased
incidence of congestive cardiac failure and arrhythmias, but most significantly, had
a recurrent infarction rate and 4-year mortality far higher than those patients in the
late group (Cox, 1987).
Carpeggiani et al employed a multi-parametric approach to the diagnosis of
NQAMI. They discovered that using conventional criteria of a CK-MB rise to twice
its normal value only 60% of NQAMI were correctly diagnosed in comparison to
a number of other methods aimed at identifying myocardial necrosis, for example,
pyrophosphate scanning, microsphere perfusion scintigraphy and coronary
angiography (Carpeggiani, 1989). They concluded that total CK-MB release in
NQAMI may not be sufficient to allow detection unless frequent sampling is
performed, that is, that because of an earlier peak a rise in serum concentrations
may not be detected. This view is supported by Blanke, who advocates caution with
regard to measuring infarct size from cumulative CK or CK-MB release because of
significantly different rates of enzyme appearance in patients with reperfusion
(Blanke, 1984a). He proposes that measurement of time to peak CK-MB, and
absolute value of peak CK-MB are definite quantities, and these should be used for
early stratification of patients and subsequent management of these two groups of
patients. The observation that enzyme levels peak earlier in NQAMI than in QAMI
could be explained by a "washout" phenomenon in the NQAMI group due to
spontaneous recanalisation and restoration of flow to necrotic myocardium. An
alternative explanation may be that the time of onset of symptoms is less clear in
this group and so is underestimated. Certainly, it seems that patients with NQAMI
have smaller infarcts and also show features of improved myocardial reperfusion in
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comparison to patients with QAMI (Blanke, 1984a; Sharkey, 1988).
Total cumulative release of CK is indicative of infarct size and is an
important prognostic indicator (Hackel,1984). Shah studied patients with inferior
AMI and noted the additional presence or absence of ST-segment depression in the
precordial leads (Shah, 1980). Those patients with ST depression had a higher
morbidity and mortality in the first few days following AMI and had higher peak
CK levels, suggesting that this worse early course was secondary to increased
infarct size.
1.4.5 CREATINE KINASE-MB BANDS
Two isoforms of CK-MB have been described, MBj and MB2. They are
measured by electrophoresis and calculating the ratio of the 2 subforms from the
total CK-MB activity (Christenson,1989). Puleo et al measured actual values and the
ratio of these subforms following AMI, and showed that MB2 activity and the ratio
MB2/MB, began to increase 2 hours after the onset of symptoms (Puleo, 1990). The
first available plasma sample was abnormal for CK-MB subform criteria in 67% of
patients and by conventional CK-MB assay in 27% of patients. Assay of subforms
therefore provided a rapid and reliable diagnosis of AMI within 4-6 hours after the
onset of symptoms, 6 hours before conventional CK-MB assays gave a definite
result.
Christenson et al measured CK-MB isoforms following myocardial
reperfusion with intravenous thrombolytic therapy; recanalisation was demonstrated
by immediate coronary angiography (TIMI3) (Christenson, 1989). They showed that
in comparison to patients without reperfusion, CK-MB2 peaked earlier than CK-MB
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(4.5-8.0 h v 5.75-10.0). A similar association was seen for CK-MM3. Although the
MB2/MB! ratio peaked at 0.75-2.25 hours, this did not distinguish between patients
with and without reperfusion (Christenson,1992). The release of tissue specific CK
isoforms does appear to be related to coronary flow, but isoform ratios have a
relatively weak association, although they may be useful in diagnosing AMI.
Puleo and Perryman also studied CK-MB isoforms following thrombolytic
therapy. They found that the peak ratio MB2/MB, was >3.8 in 18/20 patients with
reperfusion of the infarct related artery compared to <3.8 in 17/19 patients in
whom reperfusion did not occur. The time to peak ratio was of the order of 2 hours
after treatment, so allowing identification of a group of patients who may benefit
from intervention, for example, salvage PTCA or repeat thrombolysis (Puleo, 1991).
Measurement of CK-MB isoforms would appear to have a potential
application in both the diagnosis of AMI, and identifying patients who do not appear
to have reperfused. The main disadvantage in their utilisation would appear to be
that thay are measured by electrophoresis, which is usually a slow process. This
may be overcome by using high voltage electrophoresis, with a reported assay time
of 25 minutes (Puleo, 1990).
1.4.6 CREATINE KINASE-MM BANDS
CK-MM has been found in more than one isoform in the serum of man
(Morelli,1983). Initially, CK-MM3 is released from myocardium, this is converted
to CK-MM2 then CK-MM^. A peak in the ratio of CK-MM3 to CK-MM! is seen
(Collinson,1988). Muller-Hansen describes this peak at 7 hours, and the ratio
MM3:MM, to return to normal within 27 hours. In the presence of a normal CK
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value, a ratio > 1 gives a sensitivity of 86%, but a lower specificity, for
the diagnosis of AMI, and its use in determining who receives thrombolysis would
appear to be limited by this number of false-positive results (Muller-Hansen,1989).
Although this ratio does rise within 12 hours following AMI, the analysis is
performed by electrophoresis, and so requires at least 2 hours separation time.
Consequently, its applicability to routine clinical use remains doubtful.
In a similar study, Jaffe et al, using a nomenclature of CK-MMA,B,c, instead
of CK-MM3 2, showed that following AMI, the ratio of MMA to MMC in the first
available plasma sample was increased at a time when total CK and CK-MB levels
were not raised (Jaffe, 1986). Although he commented that this showed CK isoform
profiles to alter soon after AMI, the analytical process was complicated, requiring
6 hours of electrophoresis and 4 hours exposure to X-ray film.
1.4.7 MYOGLOBIN
The measurement ofmyoglobin following AMI was first described by Kagen
et al in 1975 (Kagen, 1975). Myoglobin is a low molecular weight protein (17,800
D), found in cardiac and skeletal muscle. It is released following tissue necrosis,
and can be measured in serum and urine. It is present in low concentration in the
serum of healthy individuals (6-85 jumol/1).
The main disadvantage in the use of myoglobin as a marker of AMI is that
it is not cardio-specific. If there is concurrent skeletal muscle damage it has no
diagnostic role to play, despite the observation that the ratio of myoglobin to
carbonic anhydrase is elevated after AMI, but is unchanged following trauma to
skeletal muscle because carbonic anhydrase is present in skeletal muscle but not in
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cardiac muscle. It is recognised that this is too cumbersome a technique to be used
clinically (Vaananen,1990).
Cairns et al compared the kinetics of myoglobin release in 21 patients with
QAMI to those of creatine kinase. They found that myoglobin was detected earlier,
peaked earlier and disappeared at a faster rate than CK (Cairns, 1983). This finding
was confirmed by Mair et al using an immunoturbidimetric assay system which gave
a result from a serum sample within 1-2 minutes (Mair, 1991a), and by Kilpatrick
et al although they compared myoglobin to CK-MB (Kilpatrick, 1993). For the first
blood sample obtained after admission, myoglobin was more sensitive, specific and
had greater positive and negative predictive values for AMI than CK activity
measured in the same sample. Carpeggiani et al showed that myoglobin fared better
than CK-MB, correctly identifying 80% of the patients with sustained ST segment
and/or T wave changes that were finally assumed to represent myocardial necrosis
(Carpeggiani, 1989).
A latex agglutination method for detecting myoglobin concentration was
assessed by Collinson et al. This gave a positive result for a level > 100 /^g/L, the
test result being available within 3 minutes. This method had a sensitivity and
specificity of diagnois of 69% and 93% respectively (Collinson, 1988). Ohman et al
used a rapid, non-laboratory based agglutination test for myoglobin and showed it
to be a useful addition in the diagnosis of AMI in those patients without ST
elevation (Ohman, 1990b). Not all workers have found the rapid agglutination test
reliable (Fitzgerald, 1988).
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1.4.7.1 EFFECT OF REPERFUSIQN ON SERUM MYOGLOBIN
CONCENTRATION
Ishii et al compared serum myoglobin levels to CK-MB levels following
thrombolysis (Ishii, 1991). They found that in patients in whom reperfusion was
demonstrated at angiography, the rate of appearance of myoglobin was initially
greater than that of CK-MB, although both were similar at 60 minutes. However,
from 15 to 60 minutes, myoglobin was a more reliable indicator of coronary artery
reperfusion. A similar result was found by Ellis et al who showed that in patients
with successful reperfusion, the time to peak myoglobin occurred earlier with a rise
in concentration of >4.6 being seen in the first 2 hours after thrombolytic therapy
in the majority of patients (Ellis, 1988), whereas the converse applied to those
patients who did not reperfuse. Miiyata et al found a cut-off level >2 at 60
minutes to be diagnostic of reperfusion (Miiyata, 1994). Clemmensen et al showed
that a peak myoglobin value occurring within 4 hours of the administration of
thrombolytic therapy was highly accurate for detecting reperfusion
(Clemmensen, 1991). Abe et al compared the rate of rise after 1 hour of myoglobin
(9.7+9.5 hours), and CK (2.8 + 1.6), and found them to be significantly different
(Abe,S, 1993). Dillon et al measured myoglobin at the time of admission and 60
minutes later and showed that if the rate of rise divided by the value at the time of
commencement of therapy was greater than 0.234 ±_ 0.409 min"1 this was a reliable
indicator for reperfusion to have occurred (Dillon, 1991).
Katus analysed the times to peak value of myoglobin, CK-MB and CK
following recanalisation of the infarct related artery with intra-coronary
streptokinase (Katus, 1988b). In those patients receiving thrombolytic therapy within
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3.5 hours of the onset of symptoms, reperfusion could be predicted with a
probability of 0.9-1.0. In those cases where reperfusion took place greater than 3.5
hours after the onset of symptoms, reperfusion could not be reliably predicted. In
the "early" group, myoglobin values peaked at 5 hours, CK-MB at 11 hours and CK
at 12 hours after the onset of symptoms. Zabel et al also found myoglobin to be the
best predictor of reperfusion at 90 minutes, when compared to CK, CK-MB and
troponin-T (Zabel, 1993).
The measurement of myoglobin and CK concentrations before thrombolysis
is given provides opportunity to determine which patients, if any, have undergone
spontaneous reperfusion. Abe et al comment that if the Myoglobin/CK ratio >5.0
on admission then there is no requirement for thrombolysis (Abe,J, 1993). This
contentious view is not currently accepted as valid clinical practice and would
require 100% sensitivity to ensure that no patients were withheld thrombolytic
therapy incorrectly.
The combination of biochemical marker change and ECG monitoring is
proposed by Baskin et al who argue that the individual sensitivity for predicting
reperfusion is 62% for ST segment resolution and 75% for certain myoglobin
concentration changes. The combination of these 2 parameters would be likely to
increase this significantly (Baskin, 1993). With regard to prognosis, assessing the
size of infarction after reperfusion by calculating the sum concentration can be
determined more quickly using myoglobin than CK, approximately 3 hours to 24
hours respectively (Yamashita,1993).
Myoglobin therefore appears to provide the earliest and most accurate
biochemical prediction of infarct reperfusion and it would appear that measurement
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of myoglobin concentrations can reduce the time following thrombolysis to further
intervention (if available) to about 2-4 hours plus the time to perform the assay. A
major drawback is that infarct reperfusion only seems to be reliably predicted in
those patients that present early, but since this is the group that is most likely to
have myocardium that can be salvaged then this may not be too much of a
disadvantage (Stack, 1983). It is also important to note the observation by Katus et
al that not all patients are likely to show the same biochemical response to
successful reperfusion, and equally, not all patients are likely to benefit from
intervention in the immediate post-infarct period. The need for further studies to
identify which patients benefit most from such management is apparent.
1.4.8 TROPONIN-T
Troponin-T is a contractile protein present in myocardium (Cummins, 1990).
It is one of the proteins of the contractile apparatus that are unique in their primary
structure for cardiac muscle (Katus, 1991a). Cardiac troponin T is a unique
myocardial antigen, and can be readily differentiated from the skeletal muscle
isoform (Editorial, 1991). It has a molecular weight of 37 KDaltons (Potter, 1974).
Troponin-T has been evaluated as a diagnostic marker for AMI. Katus et al
found a sensitivity of AMI diagnosis of 100% (Katus, 1991a). Specificity was less
precise, 48 of 210 patients without AMI also had elevated levels. Of these 37 had
unstable angina and 11 had atypical chest pain. In those patients with unstable
angina, the raised concentrations of troponin T were highly specific for severe
coronary artery narrowing. Bakker et al found similar results with the sensitivity of
diagnosis highest for troponin-T, but specificity lowest, although they did choose a
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diagnostic cut-off of O.lng/ml (Bakker,1994). Increasing the cut-off to >0.5ng/ml
increased specificity, without compromising sensitivity, although this study only
included patients with relatively late presentation (Mair, 1991c). Combining the
measurement of troponin-T with CK-MB in patients presenting early improved the
specificity to 92% (Katus, 1991a).
A number of workers are investigating the diagnostic potential of troponin-T
in patients with unstable angina, and the presence of so-called micro-infarction
(Ravkilde, 1993), as well as using very small rises in troponin-T (just below the AMI
diagnostic cut-off) to indicate prognosis. Those patients with very small increases
appear to have a worse prognosis (Bakker, 1994). In patients with co-existent
trauma, especially skeletal muscle damage, troponin-T was considerably more
accurate than CK-MB at diagnosing AMI, because of its cardio-specificity.
The release kinetics of troponin-T differ markedly from those of CK-MB.
It appears slightly earlier, and peaks on day 1 to a value up to 40 times its "normal"
detectable concentration. It also has a second peak at day 4 and can be measured up
to 12 days after the index AMI. A diagnostic window of 10.5-140 hours from the
onset of symptoms is apparent, casting doubt upon any further role of AST or LDH
in the late or retrospective diagnosis of AMI. Its release kinetics suggest it to be
present both freely in the cytoplasm, and to be structurally bound. The process of
degradation of myofibrillar proteins is time consuming and barely affected by blood
flow to the infarct zone (Sahida,1984). The primary release of troponin T would
seem to be due to leakage from the cytoplasm of ischaemic but partly viable
myocytes, this would explain the small rise seen in patients with unstable angina
(Katus, 1991a). The later peak, usually around day 4 therefore probably reflects
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damage to the subcellular contractile apparatus (Piper, 1984).
1.4,8.1 EFFECT OF REPERFUSION ON SERUM TROPONIN-T
CONCENTRATIONS
The appearance of troponin-T in serum on day 1 following AMI is dependant
upon reperfusion and duration of ischaemia. In patients with early reperfusion a
troponin-T peak is found which is absent in patients with reperfusion occurring more
than 5.5 hours after the onset of symptoms, and in patients in whom reperfusion
does not occur. Katus measured troponin-T levels at 14, 32 hours and peak
concentration after the onset of symptoms and found the ratios: peak/32 hours >1.1
and 14/32 hours >1.0 to be similar with regard to sensitivty (90%), specificity
(100%), positive predictive value (100%) and negative predictive value (65%) in the
differentiation of patients with and without successful reperfusion (Katus, 1991b). It
follows that the level measured at 14 hours will suffice as the "peak" value in the
majority of patients, and more importantly, can be used as such for practical
purposes. This was confirmed by Rempiss et al who reported a probability of
reperfusion of >95% if the peak concentration:38 hour concentration ratio >1.42,
or the peak: 14 hour concentration ratio >1.09, although this technique clearly
requires knowledge of the peak concentration, this would appear to be
approximately 12-15 hours after reperfusion (Remppis, 1994). Utilising an actual rise
rather a rate of rise in concentration, Abe et al found an increase in troponin-T
concentration of 0.5ng/ml to be a highly sensitive indicator of reperfusion
(Abe,S, 1994).
Other isoforms of troponin have been studied in relation to AMI diagnosis.
79
Cummins et al raised antibodies to troponin-I and using radiolabeled scintigraphy
in a dog model showed uptake of labelled antibodies to be up to 24 times greater in
necrotic than in normal myocardium (Cummins, 1990). Studies in man show it to be
both highly sensitive (Adams, 1993) and highly specific for myocardial injury
(Ordonez-Llanos, 1994). At present, there is far less information available for
troponin-I than troponin-T and the latter is presently better established for clinical
purposes.
In summary, troponin-T is not normally detectable in serum. It is a
cardiospecific antigen and because it is mostly located in the sub-cellular
compartment, it is released over a number of days rather than hours. These
characteristics provide it with the ability to become a useful addition to the various
markers currently employed in the diagnosis of AMI, both acutely and
retrospectively, as well as having a potential use in the assessment of infarct size.
1.4.9 CREATINE
Serum creatine concentrations are usually low (DeLanghe, 1988). They
increase slightly with age, and are a little higher in females. The normal range is
of the order of 20-70 /umol/1. Reference values are lower in vegetarian subjects
(DeLanghe, 1989), whereas prolonged bed rest results in increased serum levels
(Zorbas,1990).
Creatine phosphate is found intra-cellularly. It functions as a phosphate
donor, being a store of high energy intra-cellular phosphate. The position of
equilibrium in the reaction creatine ** creatine phosphate favours creatine phosphate
formation. Consequently intra-cellular creatine concentration is usually low
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(approximately 9% of total intra-cellular creatine); intra-cellular creatine phosphate
stores are usually high (approximately 55% of total intra-cellular creatine). About
36% of total intra-cellular creatine exists bound to unknown intra-cellular
components (Savabi,1988).
In conditions of acidosis or hypoxia this situation changes (Sugden,1991;
Carter, 1990). For example, following myocardial infarction, intracellular adenosine
triphosphate (ATP) stores rapidly become depleted, intracellular pH falls and as a
consequence, intracellular free creatine rises. Disruption of the cell membrane
allows creatine to enter the circulation; this is facilitated by its low molecular weight
(m.w. 131).
The renal threshold for creatine excretion is roughly similar in all adults (of
the order of 68+12 /xmol/1), which is slightly higher than the upper limit of normal
serum concentration. If serum creatine concentration becomes elevated, urine
creatine concentration increases. It has been proposed that a concentrating effect
occurs, with urinary concentrations being higher than plasma concentrations
(DeLanghe, 1988).
DeLanghe investigated creatine levels in serum and urine in 22 patients with
QAMI. He found that a detectable rise in serum creatine occurred within 2-4 hours
from the onset of symptoms, but that because of a concentrating effect, levels in
urine were far more discriminatory. He proposed that creatine concentrations in
serum and urine could be used in the early diagnosis of AMI (DeLanghe, 1988).
However, in this study, more than 50% of the patients required urinary
catheterisation, reflecting a group of patients sustaining large infarcts. Although he
showed that interfering effects from other tissues could be discounted, these results
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clearly require validation with a larger, more representative sample of patients being
admitted to a Coronary Care Unit.
1.4.10 MYOSIN
Cardiac myosin light chains are structurally and immunologically specific for
cardiac tissue (Sarkar,1971). They are not normally detectable in serum
(Katus,1984). Katus measured the peak and cumulative myosin light chain (MLC)
concentration following AMI (Katus, 1988a). Whereas cytosolic proteins such as CK
are dependent upon early reperfusion for their appearance in plasma, MLC are
released gradually over a 14 day period. He concluded that they may give rise to
useful prognostic information about infarct size. MLC are measured by a
competitive binding RIA (Hoberg, 1987a), which also makes them unlikely to be
useful for an acute diagnostic purpose.
Hoberg et al compared a number of markers in patients with unstable angina
and found that MLC levels were only increased in patients with a coronary artery
stenosis of at least 70% (Hoberg, 1987b). Patients with 3 vessel disease were also
more likely to have raised levels than those with 1 or 2 vessel disease. They propose
that these small and not uniform rises indicate small areas of necrosis, so called
microinfarcts. Such lesions are noted in patients with unstable angina who have died
with no clinical evidence of infarction (Robbins,1963). If this is indeed the case,
then of the various markers evaluated, MLC appear to be one of the most sensitive
indicators of AMI.
Nicol et al used a newly developed radio-immunoassay for ventricular
myosin light chain 1 (VLC1) and showed that times to appearance (4.7 + 0.68 h)
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and peak value (54.4 + 5.8 h) were similar to those of CK-MB, although VLC1
levels were not influenced by reperfusion therapy (Nicol,1991).
1.4.11 OTHER BIOCHEMICAL MARKERS
A number of other naturally occurring substances have been investigated with
regard to diagnosing AMI.
Protein S100 belongs to the family of proteins that includes calmodulin,
troponin-C and the light chain of myosin. Serum-lOOao protein is the oc-oc isomer
and is present in high concentration in myocardium. Usui et al measured serum-
lOOao levels by enzyme immunoassay and found them to peak 8 hours after
admission and to gradually return to normal. There was satisfactory discrimination
between patients with AMI and patients with angina pectoris (Usui, 1990).
Endothelin is a vasoactive peptide recently isolated from the supernatant of
endothelial cells in culture. It is a potent constrictor of isolated coronary arteries
from animals and humans. Stewart et al measured endothelin-1 levels in patients
with AMI. They found that plasma levels increased rapidly after AMI, reaching a
peak 6 hours after the onset of pain, and returned to normal by 24 hours, except in
patients with haemodynamic disturbance whose levels were generally higher and
remained elevated for up to 72 hours (Stewart, 1991). There was no correlation of
peak CK with endothelin in either of the 2 groups of patients, suggesting that the
stimulus for enothelin release is not myocardial necrosis, but more likely to be a
manifestation of endothelial disruption, myocardial ischaemia or depressed left
ventricular function.
A rapid increase in renal permeability to plasma proteins after trauma, burns,
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surgery or ischaemia is recognised, this appears to be proportional to the severity
of the insult (Fleck, 1985). Gosling et al measured urinary albumin concentration
following AMI and found a significantly higher urinary albumin:creatinine ratio in
the AMI compared to non-AMI group (Gosling, 1991). Urinary IgG:creatinine ratios
also increased, suggesting the proteinuria to be at least partly secondary to an
increase in glomerular permeability. This would be compatible with the suggestion
that myocardial ischaemia/necrosis results in a systemic increase in vascular
permeability as part of the acute inflammatory process (Suval, 1987). A combination
of albumin:creatinine and IgG:creatinine ratios gave a sensitivity and specificity of
AMI diagnosis of 82% and 96% respectively, and the speed with which these can
now be performed by immunoturbidimetry may allow urine to be incorporated into
the diagnostic process. The main difficulty related to obtaining a sample of urine,
in this study the range of times from onset of symptoms to passing the first urine
sample was 2-24 hours (mean 10.9) in the AMI group, compared to 1.5-24 hours
(mean 11.1) in the non-AMI group.
Bhatnagar et al measured blood taurine levels in patients with presumed
cardiac chest pain and found levels to be higher in patients with AMI or unstable
angina than controls (Bhatnagar, 1990). Taurine levels were higher in patients with
AMI than unstable angina but they commented that, at present, they did not feel that
the test could reliably discriminate between these 2 acute coronary syndromes.
2,3-butanediol is a product of intermediary metabolism. Heer et al measured
it in blood samples taken after AMI and showed levels to be higher in comparison
to a control population, but within the AMI group only 64% had an elevated level
considered to be diagnostic (Heer, 1990). The release characteristics were completely
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different for 2,3-butanediol in comparison to CK; whereas levels of the former had
returned to normal within 24 hours, levels of CK-MB continued to be elevated for
at least 48 hours or so.
Peripheral atrial natriuretic factor (ANF) levels increase following AMI
(Gutierrez-Marcos, 1991). Ngo et al suggest that this can be used to aid in the
diagnosis of AMI, but ANF levels are affected by giving thrombolytic therapy,
presumably secondary to the haemodynamic effects of intravenous streptokinase.
Ray et al argue that because of this, ANF cannot be used as a reliable indicator of
AMI (Ray, 1990), this view is shared by Tan et al who observed no relationship
between ANF values and the clinical course following AMI (Tan, 1989).
1.4.12 SUMMARY
The criteria for a suitable test of acute myocardial infarction are:
It must be available 24 hours a day, be rapidly interpretable and be diagnostic very
early after the onset of symptoms. In the post thrombolytic era it is an advantage if
it can make a contribution towards assessing coronary artery reperfusion.
It is clear that of the markers outlined above, some meet these criteria more
so than others, but it is also apparent that that they all have disadvantages as well
as advantages. The need to consider and evaluate these and other markers in the
roles of diagnosis and differentiation of AMI, as well as assessing the effects of
thrombolysis is real, especially in light of continuing developments in the
management of the various subsets of patients identified post-AMI.
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AIMS OF THE INVESTIGATION
1) To compare serum and urinary creatine concentrations to recognised
biochemical markers in the early diagnosis of acute myocardial infarction.
2) To evaluate the role of serum and urinary creatine concentrations and other
biochemical markers in the differentiation of acute Q-wave and non Q-wave
myocardial infarction.
3) To evaluate the role of serum creatine and other biochemical markers in
conjunction with recognised electrocardiographic criteria, in the non-invasive
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Patients admitted to the Coronary Care Unit at Pinderfields General Hospital with
a differential diagnosis including acute myocardial infarction were studied.
Informed consent was obtained prior to study entry.




12-lead electrocardiograms were recorded by aHewlett-Packard "Pagewriter"
electrocardiograph, with the patient in the supine position. Standard electrode
positions were used, except for a modified precordial V5 position, once the Holter
monitor had been hooked-up to the patient. Disposable "Medicotest" electrodes were
used for each patient.
3.2.2 AMBULATORY ST SEGMENT MONITORING
3.2,2.1 INTRODUCTION
24 hour ambulatory monitoring of heart rhythm and ST segments was
performed in all patients. The usefulness of these two aspects of electrocardiography
to monitor myocardial infarction and ischaemia, and the effects of thrombolysis in
the immediate post-infarct period is currently of great interest.
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3.2.2.2 TECHNICAL CONSIDERATIONS
The electrocardiogram is composed of a number of signals of varying
frequency, the lowest frequencies being in the ST segment, the highest frequencies
are found in the QRS complex. The American Heart Association has issued which
it regards should be met by recorders used for ambulatory monitoring of the
electrocardiogram (Report, 1975; Knoebel, 1989). There is a consensus that the range
of frequencies monitored is at least 0.5-60 Hz (Bragg-Remschel,1982; Tayler,1988;
Silber,1990), with appropriate low frequency recording characteristics (<2dB at
0.05Hz with minimal phase shift (Rotman, 1988)), since an inadequate low frequency
response results in artificial ST segment/T wave changes (Hinkle,1967). The
sampling frequency should be twice the upper frequency cut-off, namely 120 Hz
(Reynolds, 1990). A linear phase response should be present within the band width
0.5-60 Hz (Tayler,1988).
Continuous tape recording has a number of inherent technical problems. It
is important to keep the recording head clean and aligned with the tape, and it
should be regularly de-magnetised (Krucoff,1989). Tape speed should be uniform
so as to eliminate tape motion artefact (Reynolds, 1990). This is especially important
when heart rate variability analysis may also be required. If the tape is repeatedly
analysed, information can be lost, especially if the x60 speed is used for analysis
(Rotman, 1988).
3.2,2,3 ELECTRODE POSITIONS
The number of channels which can be recorded at any one time is limited to
the type of recorder. Some authors claim that recording from less than 12 leads is
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not ideal and should therefore be discouraged (Saran,1990); whilst some advocate
using recorders with 3 channels (so allowing an inferior, anterior and lateral lead
position to be monitored) (Krucoff,1989). However, most commercially available
recorders have 2 channels on which to record, and when used appropriately, this
number is regarded as sufficient (Rotman,1988).
Within the limitations imposed by recording from only 2 channels it is
important to ensure that the electrode posistions selected will detect all ECG changes
that may occur. It is generally agreed that for antero-lateral myocardial ischaemia,
bipolar lead CM5 (reference electrode manubrium sterni, active electrode V5), is
most effective at detecting ST segment changes in this territory (Quyyumi,1986;
Huey,1987). Silber et al reported a 96% sensitivity for this lead configuration for
all anterior ST segment changes (Silber, 1990), Quyyumi et al reported a sensitivity
of 93 % (Quyyumi, 1986). Using this lead position, Hoberg et al detected ST segment
changes in all 26 patients undergoing angioplasty to any coronary artery
(Hoberg, 1987).
However, Jespersen and Rasmussen showed that this lead position failed to
detect ST segment changes occurring interiorly in 1 of 30 angioplasty cases
(Jespersen, 1988), and Quyyumi et al found similar results in 1/3 of angioplasties to
the right coronary artery (Quyyumi, 1986).
In light of this, a number of modifications to standard lead positions have
been tried, to try to improve the sensitivity and specificity of ST segment changes
detection associated with ischaemia of the inferior myocardium. Thus, a modified
orthogonal y lead (-ve electrode at the superior angle of the scapula, +ve electrode
above the left iliac crest) and a modified lead III have been shown to be more
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effective than lead CM5 at detecting inferior ST segment changes (Huey,1987;
Hombach,1990). Osterhues affirms that a Nehb-D like lead position (indifferent
electrode placed in the right first intercostal space, midclavicularly and the exploring
electrode beneath the scapula) significantly increases detection of inferior ST
segment changes (Osterhues, 1994). It has been suggested therefore that for a 2
channel system a combination of lead CM5 and one of these leads be used
(Rotman,1988; Hombach,1990).
In order to minimise artefactual interference of the ECG signal it is essential
that attachment of the electrodes and cables to the patient be given detailed attention.
The skin-electrode interface is very important, being the first step in obtaining a
good quality recording (Balasubramanian,1980; Krucoff, 1989).
3.2.2,4 ST SEGMENT ANALYSIS
When analysing the ST segment either by visual or automated means, a
single "normal" ECG waveform acts as a template, as in the Neilson arrhythmia
detection algorithm (Reynolds, 1990). False positive events are minimised by the use
of intelligent rate adaptive thresholds. This approach of updating a stored normal
QRS provides a means of compensating for changes in morphology arising from the
following factors that influence ST segment interpretation:
Left and right ventricular hypertrophy, electrolyte imbalance, conduction
disturbances, autonomic change, certain drugs, hypertension, mitral valve prolapse,
posture and hyperventilation (Huey,1987; Rotman,1988).
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A number of points on the ECG waveform act as reference points for ST









P = start of P wave
R = R wave
S = S wave
T = start of T wave
ST1 = J point (end of QRS complex)
ST2 = J point + t (where t = fixed interval, usually 80 milliseconds)
Isoelectric line = horizontal line through preceding TP points
m — gradient of slope ST1 to ST2
a = area bounded by ST1 and ST2 verticals, slope ST1 to ST2, and the isoelectric
line.
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The isoelectric line is taken as a horizontal between the preceding T and P
points. The fiducial point is measured at an interval before the R wave, for example
56, 64 or 72 milliseconds (ms) (Silber,1990). For the measurement of both ST
segment elevation and depression, the J point (ST1) is decided upon by manual
technique and acts as the reference for all other measurements (Gallino,1984;
Rotman,1988).
Measurement of ST segment elevation is considered valid at the J point,
(Saran, 1990; Hogg, 1988), although Huey et al measured it at J+40ms (Huey, 1987).
A given value for ST segment elevation at any one time is calculated by taking the
mean of three consecutive complexes (Hogg, 1988; Saran, 1990).
There is some debate as to how to measure ST segment depression.
Measurement of ST2 is usually made 80 ms after the J point by the majority of
investigators (Quyyumi,1986; Huey, 1987). However, ST segment changes are also
regarded as valid if measured at 60 ms after the J point (Krucoff, 1989), or 96, 104
or 112 ms after the R wave (Silber,1990).
True ST segment depression is interpreted as at least 1mm depression at both
ST1 and ST2, that is, horizontal or downsloping depression (Ribisl, 1993). If
depression of only one of these points is used, this overestimates the incidence of
ischaemic change by 20% (Rotman,1988).
A gradient of the slope joining ST1 and ST2 of greater than 1 mV/s is
regarded as significant, although this has only 50% of the sensitivity of
ST segment depression at detecting ischaemia. An area under the isoelectric line that
is bounded by the ST segment of greater than 10mVs (465) is regarded as having
only 10% of the sensitivity of ST segment depression for this purpose
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(Rotman,1988).
If a change in the ST segment is to be regarded as significant, it must be
present for a certain length of time. The exact duration is not clear, but a range of
30 to 60 seconds has been suggested (Silber,1990). There must be at least 1mm
amplitude (Balasubramanian,1980; Quyyumi,1986; Krucoff,1989) and a return to
baseline values for at least 2 minutes before a subsequent episode can be regarded
as distinct from its predecessor (Gallino,1984). As for ST segment elevation
measurement, the mean of 3 consecutive PQRST complexes at any given time
during the recording is regarded as the actual value at that particular moment in
time (Saran,1990).
Due to the large amount of data acquired by any one 24 hour recording, the
automated analysis of tapes by a computer with an algorithm for detecting the above
changes is used. This has been shown to be at least as accurate, and in some cases,
more accurate, than visual inspection of the tapes (Gallino,1984; Rotman,1988).
3.2.3 ST SEGMENT MONITORING PROCEDURES USED
3.2.3.1 AMBULATORY RECORDER
Reynolds Medical "Tracker" recorders which allow 2 separate channels and
a time signal to be recorded continuously, were used. Reynolds "Tracker" recorders
meet the technical requirements outlined above, and are deemed suitable for high
quality ambulatory ECG monitoring. The Tracker uses a direct recording system for
the detection of arrhythmias, and ST segment monitoring is performed following all
QRS complexes of less than 110ms duration (Tayler, 1988).
In accordance with the manufacturer's instructions, a new Duracell 9V
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battery and TDK D90 tape cassette were used for each recording. A new tape was
used for each patient, to allow a permanent record to be kept.
At the start of each recording the tape was calibrated (1mm = lmV).
Although re-calibration during recording has been suggested by some authors
(Rotman,1988), this was not performed. Where possible, prior to commencing
recording the patient was placed in a number of different positions (supine, left
lateral, right lateral and sitting), these were correlated with the time on the recorder
clock. This allowed for any baseline variation or ST segment changes associated
with patient movement to be identified, and excluded from subsequent analysis.
3.2,3.2 ELECTRODE POSITIONS
A combination of leads CM5 and modified lead III were used for all patients,
with electrodes being placed in the right infraclavicular, left infraclavicular, left 5th
intercostal space in the mid-clavicular line and right 5 th intercostal space midway
between the sternum and mid-clavicular line. These electrode positions were chose
because all electrodes could be attached to the front of the patient's chest. Since all
patients were confined to bed rest, it was felt that electrodes attached to the back of
the chest would be prone to increased interference artefact and even become
dislodged.
Prior to attaching the skin electrodes, satisfactory position was assessed by
using suction electrodes and a monitor cable (connected to the "Tracker") attached
to a bedside ECG monitor. This provided confirmation that the proposed electrode
positions gave an ECG signal that would be suitable for subsequent analysis. Once
the electrode positions were verified, the following skin preparation was performed:
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The skin was shaved (if necessary), cleansed with alcohol, and lightly abraded with
a gauze swab. The electrode position was marked with a water resistant pen to allow
repeat electrode placement if necessary. Skin impedance was considered satisfactory
if less than 5kOhms. Pre-gelled electrodes (3M Health Care "Red Dot" diaphoretic
electrodes) were used. Electrodes were sited over a bony prominence to reduce
muscle artefact; movement of free cables and the recorder-cable junction was kept
to a minimum by taping the leads to the patients chest.
3.2.3.3 ANALYSIS OF TAPE RECORDINGS
Tape analysis was performed by a Reynolds "Professional" analyser. Analysis by
the "Professional" system employs the Neilson arrhythmia detection algorithm.
Tapes were analysed up to a maximum speed of 24 hours of recording in 10
minutes. This provided heart rate and ST segment analysis on both channels with
time channel calibration.
Within each individual tape analysis, a number of options were available. An
ST overview was provided which allowed the complete 24 hour period to be visually
assessed for regions of interest. Once these regions had been identified that portion
of the recording could be recalled and subjected to further, more detailed, analysis.
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3.2.4 BLOOD SAMPLES
Twenty millilitre (ml) blood samples were taken into plain tubes and allowed
to stand, for no longer than 4 hours. The tubes were centrifuged at 500g for 10
minutes, the serum separated and decanted into sterile 5ml plastic containers in at
least 2 aliquots, and frozen immediately. Serum samples were stored at -70°C. All
samples were given a unique identification code and labelled with permanent, water
resistant marker pen.
For analysis to be performed, serum samples were thawed slowly to room
temperature, mixed thoroughly and centrifuged at lOOOg for 5 minutes. Samples
were then transferred to individual cups compatible with the various auto-analysers
used for the assays described below.
3.2.5 URINE SAMPLES
Urine samples were collected in as sterile a manner as possible (as for a mid
stream specimen of urine). They were placed immediately into sterile 20ml
containers and refrigerated. Within no more than 4 hours an individual sample was
divided into 2 x 5ml aliquots, placed into sterile plastic containers and frozen.
Samples were stored at -70°C. All samples were given a unique identification code
and labelled with permanent, water resistant marker pen.
For analysis to be performed, urine samples were thawed slowly to room
temperature, mixed thoroughly and centrifuged at lOOOg for 5 minutes. Samples
were then transferred to individual cups compatible with the various auto-analysers
used for the assays described below.
100
3.2.6 BIOCHEMICAL ASSAYS
3.2.6.1 CREATINE KINASE-MB MASS DETERMINATION
3.2.6.1.1 PRINCIPLES UNDERLYING ASSAY PROCEDURE
Measurement of serum CK-MB concentrations was performed by a
commercially available assay, ICON QSR CK-MB (Hybritech, Nottingham, UK).
The assay detects CK-MB in serum by using two different monoclonal antibodies
that react with two different regions of the CK-MB molecule. One monoclonal
antibody binds to the B subunit, the other binds to the M subunit.
The antibody to CK-B is contained in the test zones of the ICON QSR filter
membrane and captures and immobilises the CK-MB molecules contained in the test
sample. The antibody to CK-M is chemically linked to the enzyme alkaline
phosphatase, and binds to the CK-MB molecules immobilised on the test membrane.
The immobilised CK-MB molecules are thus "sandwiched" between the solid phase
and enzyme linked monoclonal antibodies.
3.2.6.1.2 ASSAY PROCEDURE
All assays were performed on fresh serum from blood samples which had
been taken no greater than 4 hours prior to the assay. All reagents and test materials
were brought to room temperature prior to the start of the assay. Good attention to
detail was employed to ensure that there was accurate pipetting technique, no
contamination of solutions,and the avoidance of air bubble formation in the
specimen cup or when adding solutions to the test membrane. Reagents from each
individual kit were only used for that particular kit.
Initially, 75yu.l of specimen pre-treatment solution was pipetted into a
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specimen cup, followed by 300^1 of serum. These were mixed and allowed to
incubate for one minute. (This stage is designed to remove any heterophilic
anti-mouse antibody contained in the specimen sample that would react with the
anti-CK-M and anti-CK-B monoclonal antibodies). After incubation, 300 /xl of this
treated sample was pipetted onto the test membrane and allowed to drain
completely. The solution containing anti-CK-M antibody linked to alkaline
phosphatase was added; 3 drops in rapid succession to the centre of the test
membrane. After a further 3 minutes, a wash solution was applied, allowed to drain,
and the repeated. A solution containing a substrate for alkaline phosphatase was
added; 3 drops in quick succession to the test membrane. The development of a
colour change during this stage was dependent upon the presence of alkaline
phosphatase, which was related directly to the binding of anti-CK-M to the test
membrane. After a 3 minute interval, a wash solution was added to quench the
reaction, and allowed to drain.
A dedicated ICON reader was required to read the test cylinder. This was
standardised prior to each measurement. The ICON reader compared colour
development at the test zones with that of the calibrator zones. The test cylinder was
inserted into the reader and the reflectance at 585nm was read; the response was
directly proportional to the amount of enzyme bound to the membrane, which itself
was directly prortional to the amount of CK-MB present in the specimen. A value
of mass concentration of CK-MB was given with a range of 2-50 ng/ml. Each test
cylinder had 4 zones, 2 duplicate test zones, 1 high and 1 low calibrator zone. If the




Positive and negative control specimens were provided by the manufacturer
to allow comparison of assay performance during the course of the study.
Inter-assav variability
A positive control (range 5-15ng/ml) measurement was made each time an
assay run was performed. The figure below shows the results of this, indicating the
variation in measurement of CK-MB mass between assays.
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Intra-assav variability
Randomly chosen samples were subjected to multiple assays, within a
particular assay run. A total of 36 samples on 36 days were assessed, each sample
being assayed 3 times. The range of CK-MB mass measurements was 1-90 ng/ml,
the variation in measurement was ± 6.4%.
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3.2.6.2 CREATINE KINASE-MB ACTIVITY ASSAY
The Kodak Ektachem slide method was used for this assay.
3.2.6.2.1 RATE METHODOLOGY
The Kodak Ektachem method employs a change in reflectance density of a
variety of colourimetric indicators to calculate the initial concentration of a
particular analyte in the test sample. For example, the concentration of CK-MB in
the original sample is calculated from the rate of change of chromophore production
during a 5 minute incubation period, the reflection density is read at 670nm and
compared to a standard curve previously established during calibration of each batch
of assays performed.
The Kodak Ektachem method mostly uses multiple-point rate tests, a total
of 54 reflectance measurements being taken at the appropriate wavelength setting
every 5-7 seconds. The reflection density is calculated from the measured
reflectance. The change can either be a positive one, e.g. colour increasing, or a
negative one, e.g. a fading of colour.
An algorithm is used to eliminate aberrant results (a maximum of one
excessively high or low result being allowed for each sample), and the maximum
rate of change in reflection density is calculated from a linear region of the graph
chosen between early measurements (taken prior to the reactions reaching a steady
state), and later readings beyond defined tolerances of slope and rate.
A calibration curve is formed from readings taken from a number of samples
of known concentration of the substance being measured. When a reading for a
particular sample is decided upon, this is compared to the calibration curve and a
concentration of the analyte in the test sample calculated.
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All subsequent analyses described that use the Kodak Ektachem analyser
work on this underlying principle.
3.2.6.2.2 ASSAY PROCEDURE
The slide contained a dry, multi-layered analytical element coated on a
polyester film support. The assay used anti-human CK-M antibody to inhibit CK-M
subunit activity. The remaining CK-B activity, (which is presumed to be
proportional to 50% of the CK-MB activity) was assayed in the folllowing way:
An 11 /d drop of patient sample was added to the slide, and evenly distributed by








H202 + dye precursor






dye + 2 H202
The main disadvantage of this method was the assumption that CK-BB levels
in peripheral blood were sufficiently low that they did not interfere with the assay.
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3.2.6.3 SERUM AND URINARY CREATINE ASSAY
3.2.6.3.1 ASSAY PROCEDURE
A commercially available kit (Boehringer Mannheim Creatinine PAP) that
is normally used to measure creatinine concentrations was modified to allow
measurement of creatine in serum and urine samples. The method has been
described previously (Beyer, 1993). By omitting the first step of this assay, creatine
is measured in the following way by an automatic analyser and uses an enzymatic
colorimetric method:
creatine + HzO -» sarcosine + urea
sarcosine + 02 + H20 -> glycine + formaldehyde + hydrogen peroxide
hydrogen peroxide + quinone-imine dye +
2,4,6-tribromo-3-hydroxy benzoic acid + -» H20 +
4-aminophenazone quinone-imine dye hydrogen bromide
-» coloured dye
It is assumed that the rate of formation of quinone-imine dye is proportional
to the initial concentration of creatine in the test sample. Solutions of known
creatine concentrations are used to calibrate the analyser. The absorbance of the
final solution is read in a spectrophotometer at 510nm; this initial reading is denoted
as A,. The absorbance is then read 15 minutes later, this value is denoted as A2.
The concentration of creatine in the initial sample is calculated by subtracting Aj
from A2, and comparing this absorbance value to the creatine concentration
corresponding to that from the calibration curve.
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Interfering substances
The only substance shown to interfere significantly with this assay is
bilirubin, and even then only at a concentration of greater than 50mg/l; this results
in artificially low values of creatine being derived.
Because the assay employs colorimetry, there is a possibility that turbid
samples may give rise to artificially high levels. For this reason, lipaemic samples
were not included in this analysis.
3.2.6.4 SERUM AND URINARY CREATININE ASSAY
A similar method was used to measure serum and urine creatinine
concentrations, except that the first step of the assay (Boehringer Mannheim
Creatinine PAP) was included. This step involves the hydrolysis of creatinine to
creatine by creatininase, the creatine generated by this step is then subjected to the
same process as described above.
Within the system of coupled enzymatic reactions used in this assay, the
creatininase step is highly specific with regard to its substrate. To confirm the
selectivity of the assay for creatine or creatinine (by performing or omitting the first
step of the assay procedure), "control" samples of known concentrations of creatine
and creatinine were made up by an independent operator. These were included in
the test runs, the concentrations of these "control" samples were not revealed to the
investigators until all the results had been obtained.
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3.2.6.4.1 SAMPLE STABILITY
Fuller and Elia (Fuller, 1988) studied creatinine to creatine conversion and
found it to be an enzyme independent process. The position of equilibrium was in
favour of creatine formation at pH 5.0, and in favour of creatinine formation at pFl
3.7. However, 24 hours was required for 5% conversion in either direction, and this
was maximal at physiological temperatures. At 4°C, conversion was negligible, and
if samples were frozen, no conversion was detectable. In this study, all urine
samples were stored at 4°C for a maximum of 4 hours before being frozen, and
during analysis were kept at room temperature for only a few hours.
3.2.6.5 MYOGLOBIN ASSAY
3.2.6.5.1 PRINCIPLES UNDERLYING ASSAY PROCEDURE
Serum myoglobin concentrations were analysed using either the Behring
"Turbitimer" or "Nephelometer" analyser. These are quantitative assay systems that
work on an identical immunochemical method. Polystyrene particles coated with
anti-human myoglobin antibody agglutinate in the presence of myolobin in the serum
sample. This agglutination results in an increase in turbidity which is measured
photometrically. Quantitative determination of the serum myoglobin concentration
is achieved by measuring the maximum velocity of agglutinate formation (Vmax), and
the time required to reach Vmax. The temperature of the reaction is measured
automatically from the temperature of the cuvette holder and the temperature of the
reagent vial. Myoglobin concentration is calculated by comparing the parameters
described above with a calibration field. A separate reference curve is calculated for
different batch of reagent, prior to using the analyser.
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3.2.6.5.2 ASSAY PROCEDURE - TURBITIMER
The reagent was provided as a lyophilisate which was resuspended just prior
to use in a buffer solution. All reagent and buffer was stored as recommended by
the manufacturer and used prior to the expiration date. The reagent was warmed to
room temperature prior to use.
Initially, 50/d of undiluted serum sample was pipetted into a plastic cuvette.
The cuvette was placed into the chamber provided in the Turbitimer. Then, 500/xl
of reagent was added to the serum sample to initiate the reaction. The mean reaction
time was 80 seconds. The myoglobin concentration of the serum sample was
determined automatically and printed in units of /xg/1.
Inter-assay variation was determined by measuring apolipoprotein control
serum CHD at various times during each run of assays. Individual serum samples
were also remeasured during the same, and different batches of reagent to determine
intra- and inter-assay variability.
3.2.6.5.3 ASSAY PROCEDURE - NEPHELOMETER
All reagents and solutions were warmed to room temperature prior to use,
stored in accordance with the manufacturer's instructions and used prior to the
expiry date. Serum samples are placed into cups and positioned on the analyser. All
steps in the assay protocol are performed automatically by the Nephelometer.
Patient samples are automatically diluted 1:20 with N Diluent.
Then, 80/d of diluted sample is added to 20/xl of N myoglobin supplementary
reagent working solution and 75/xl N reaction buffer and pipetted into a cuvette.
Then, 75/0 of N myoglobin reagent and 75/xl of N reaction buffer is added to the
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cuvette.
The reaction time is 12 minutes and the result is automatically determined
and printed in units of |iig/l. The measuring range is 25-400jUg/l. If the initial assay
is greater than the upper range limit the analyser repeats the above steps, but with
the sample diluted to 1:100. For accuracy and precision control, N myoglobin
control is assayed with serum samples both within and between batches of reagents.
The limitations of lipaemic samples described in the Turbitimer assay method
also apply with this method, although dilution to 1:100 allowed for more lipaemic
samples to be assayed with the Nephelometer than with the Turbitimer.
Limitations and interferences
The assay range was 50-650jug/l. Any samples with a result greater than
650yLtg/l were diluted with physiological buffered saline and re-assayed. Interference
from haemolysed and icteric samples did not occur. Lipaemic samples were unable
to be assayed if the analyser deemed the sample excessively turbid, despite dilution
with physiological buffered saline.
3.2.6.6 TROPONIN-T ASSAY
3.2.6.6.1 PRINCIPLES UNDERLYING ASSAY PROCEDURE
An automated enzyme-immunological test for the quantitative determination
of troponin-T was used for this assay (Boehringer Mannheim New Diagnostics
ELISA Troponin-T).
This is a one-step enzyme-linked immunosorbent assay (ELISA). Under
physiological conditions, no myocardial troponin-T is present in serum. Only after
110
degradation of the contractile actin-troponin complex are measurable concentrations
found.
The principle of the assay is that the test sample is added to a tube coated
with streptavidin. A solution containing buffer, biotinylated anti-troponin-T
antibodies and troponin-T-antibody-peroxidase conjugate is then added. The
incubation phase consists of any troponin-T in the sample being sandwiched between
the biotinylated anti-troponin-T antibodies and the troponin-T-antibody-peroxidase
conjugate. A wash phase then takes place to remove any unbound troponin-T-
antibody-peroxidase conjugate. A chromogen is then added (di-ammonium 2,2'-
azino-bis (3-ethylbenzo- thiazoline-6-sulphonate)) (ABTS), which reacts with the
peroxidase and so produces a colour. The absorbance of this final solution is
compared to a calibration curve that has been previously calculated, and the
concentration of troponin-T in the original sample derived from this.
3.2.6.6.2 ASSAY PROCEDURE
All samples were brought to room temperature prior to use. Then, 200 jul of
test sample and 1 ml of incubation solution were added to a tube coated with
streptavidin. The incubation phase lasted 1 hour. The sample tube was washed with
a washing solution, and 1 ml of substrate/chromogen solution added. A further
incubation phase of 25 minutes followed, the absorbance of this final solution was
then read at 422 nm.
Six standard samples of known troponin-T concentration were included in
each assay run, these were analysed twice and the results obtained used to form the
calibration curve. The measuring range of the assay was 0-12 ng/ml, and the lower
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detection limit for myocardial damage was 0.1 ng/ml.
3.2.6.7 CREATINE KINASE ASSAY
3.2.6.7.1 PRINCIPLES UNDERLYING ASSAY PROCEDURE
This assay was performed by an automated analyser (Kodak Ektachem
Clinical Chemistry Slide).
The analysis uses creatine phosphate and adenosine diphosphate (ADP) as
substrates for a reaction that generates adenosine triphosphate (ATP) and creatine.
Hydrogen peroxide is formed in equivalent amounts to ATP, and this oxidises a dye
precursor. The rate of dye production is monitored by reflectance spectrophotometry
at 670 nm. Reflectance density is measured at 37°C. The rate of change in
reflection density is used to calculate enzyme activity in International Units per litre
(U/L).
The reaction sequence can be summarised as follows:
Creatine phosphate + ADP ->
ATP + glycerol -»
(^-glycerophosphate + 02 -*
H202 + leucodye -»
Creatine + ATP
a-glycerophospate + ADP
Dihydroxyacetone phosphate + H202
Dye + H20
Note: The first reaction is catalysed by creatine kinase
A peroxidase catalyses the final reaction to enable hydrogen peroxide to
oxidise the dye precursor
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3.2.6.7.2 ASSAY PROCEDURE
Using the principle described above (page 100), lljul of sample was
deposited on the slide, and evenly distributed due to the presence of surfactant. This
spreading layer contained N-acetylcysteine which activated the creatine kinase. The
reagent layer contained those components necessary for the reactions described
above, the reflectance density after the final reaction was measured by the analyser.
The dynamic range of the assay is 20-1600 U/L, the upper limit of normal taken as
300 U/L.
Interferine substances
Significant haemolysis is known to interfere with the assay. The nature of
collection of samples in this study ensured that haemolysis of samples did not occur
to interfere with particular assay in this way.
3.2.6.8 ASPARTATE AMINOTRANSFERASE ASSAY
An automated analyser was used to perform this assay (Kodak Ektachem).
The analytical slide contains a number of reagents that enable the following
reactions to take place when a sample of test serum is added to the slide:
Aspartate + a-ketoglutarate -* oxaloacetate + glutamate
Oxaloacetate + NADH + H+ -> Malate + NAD+
The first reaction is catalysed by aspartate aminotransferase in the presence
of sodium pyridoxal-5-phosphate. A high concentration of pyridoxal-5-phosphate
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allows rapid activation of aspartate aminotransferase and obviates the need for a
long pre-incubation phase.
The second reaction is catalysed by malate dehydrogenase in the presence of
reduced nicotinamide adenine dinucleotide (NADH). The rate of oxidation ofNADH
is monitored by reflectance spectrophotometry at 340 nm. The concentration of
aspartate aminotransferase in the original sample is calculated from the rate of
change in reflection density, in comparison with a calibration curve of known
aspartate aminotransferase concentrations.
3.2,6.9 QUALITY CONTROL OF LABORATORY BASED ASSAYS
The precision of each assay was assessed by using replicate samples in
individual assay runs, and the accuracy determined by using recognised control
samples of known concentration. As would be expected for commercially provided
assays performed on an automated analyser, both precision and accuracy were high.
BIOCHEMICAL MARKER SD CV (%) CC
CK-MB ACTIVITY 6.5 4.6 0.99
MYOGLOBIN 22.6 5.2 0.95
TROPONIN-T 0.1 9.8 0.99





SD = Standard deviation
CV = Coefficient of variation
CC = Correlation coefficient
114
3.2,6.9 SAMPLE STABILITY
Serum from a number of patients was retested for CK-MB mass, CK-MB
activity, myoglobin and troponin-T, in more than one batch of assays to determine
the stability of stored frozen samples, as well as to establish the effects of thawing
and refreezing. The following figure shows the results of 2 analyses, performed 6
months apart:
Figure 1. STABILITY OF STORED SERUM SAMPLES FOR 4 MARKERS
CK-MB MASS - SAMPLE STABILITY CK-MB ACTIVITY - SAMPLE STABILITY
150
no/ml
2 DO 250 aao
MYOGLOBIN - SAMPLE STABILITY TROPONIN-T - SAMPLE STABILITY
Thousands
fiaA
fiafl Thousands 10 12 14 1fl
Regression coefficients
CK-MB mass = 0.99




3.3 DATA COLLECTION. STORAGE AND RETRIEVAL
Once collected, all data were manually recorded onto proformas, information
being recorded by patient number. Data were stored on paper, and in spreadsheet
format using Quattro Pro v4.0 (Borland International), on a personal computer,
Viglen Genie Executive 4DX266. Statistical analysis was performed by Oxstat V,
(Microsoft Corporation). Graphics were generated using Harvard Graphics v3.0,
(Software Publishing Corporation). All text was written, stored and printed from
Wordperfect 5.1, (Wordperfect Corporation).
3.4 STATISTICS
Serum and urine concentrations are given as mean ± standard error (SEM).
Where comparisons of 3 or more markers was made, an analysis of variance
(ANOVA) was performed initially. If this showed significant differences between
the variables, then paired comparisons were made by Student's t-test for paired or
unpaired samples, as appropriate (Daly, 1991).
Sensitivity, specificity, positive and negative predictive value were calculated by the
respective formulae given in chapter 4. These indicators of diagnostic accuracy were
compared by McNemar's test for comparison of paired proportions
(Freedman,1987).
Diagnostic cut-offs for coronary artery reperfusion were made from receiver
operating curves (ROC). The cut-off being taken as the point on each curve judged
best according to ROC analysis (Hanley,1983).
Stability of stored samples was determined by simple regression analysis.
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Chi-square (x2) test was used to compare independent sets of proportions in 2 or
more groups (Daly, 1991).




A proforma was completed at the time of admission detailing the following:
Date of admission
Time of admission
Time of onset of symptoms
Pre-admission medication
Intra-muscular injection administered prior to admission to the Coronary Care Unit.
Following admission, the following information was also recorded:
Time of hook-up of ambulatory monitor
Time of 12-lead ECG recordings
Time of blood samples
Time of urine samples
Drugs administered during the study, especially, time of commencement of
intra-venous thrombolytic therapy
12-LEAD ELECTROCARDIOGRAPHY
12-lead electrocardiograms were taken on admission, at 3 hourly intervals until 12
hours from the onset of symptoms, and on days 2 and 3.
AMBULATORY MONITORING
A Reynolds "Tracker" ambulatory monitor was hooked-up to the patient at the time
of admission and a continuous tape recording made for 24 hours.
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BLOOD SAMPLES
Twenty millilitre blood samples were taken on admission, at 2 hourly intervals until
6 hours from the onset of symptoms, and at 3 hourly intervals until 12 hours from
the onset of symptoms.
URINE SAMPLES
A 20 millilitre urine sample was collected as soon as possible after admission, and
all subsequent urine voided thereafter until 12 hours from the onset of symptoms.
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CHAPTER 4 - RESULTS:
BIOCHEMICAL DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION
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4.1 BIOCHEMICAL DIAGNOSIS AND DIFFERENTIATION OF ACUTE
MYOCARDIAL INFARCTION
4,1.1 PATIENT CHARACTERISTICS
One hundred and ninety one patients were recruited into the study. All
patients, or a relative, gave informed consent at the time of entry. Patients were
divided into certain categories on the basis of the admission ECG. The admission
ECG was used as the discriminating factor because it was readily available for all
patients, and because it is independent of the biochemical markers. Separation of
patients into groups must be performed without using biochemical criteria to enable
a valid comparison of the biochemical markers (Freedman, 1987). Analysis of the
admission ECG was performed independently of all other data, and the division of
patients into the following groups was made before analysis of the biochemical data.
1) Group A - ECG on admission diagnostic of acute myocardial infarction, using the
following recognised ECG criteria:
ST segment elevation > 0.1mV in 2 or more adjacent limb leads
ST segment elevation > 0.2mV in 2 or more adjacent chest leads
R wave in lead VI > 1/4 height of ensuing S wave
2) Group B - ECG on admission not diagnostic of AMI but AMI proven at day 3
by accepted biochemical criteria (in accordance with the World Health Organisation
guidelines (WHO, 1962)). In our laboratory these were:
Creatine kinase > 2x upper limit of normal (300 U/L)
Aspartate aminotransferase > 2x upper limit of normal (80 U/L)
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3) Group C - ECG on admission non-diagnostic of AMI and biochemical changes
at day 3 non-diagnostic of AMI.
To allow comparison between QAMI and NQAMI, those patients identified
as having sustained AMI (Groups A and B) were also divided into either of the
following 2 types:
1) Type 1 - ECG on day 3 positive for Q waves, defined as the presence of Q
waves in 2 or more adjacent limb leads or 2 or more adjacent pre-cordial leads, a
Q wave having to be at least 1/4 the height of the ensuing R wave, and greater than
0.04 seconds in duration.
Note: If Q waves were present on the admission ECG and the Q wave distribution
was unchanged on the day 3 ECG, patients were still assigned to this group.
2) Type 2 - ECG on day 3 negative for Q waves as defined above.
It follows that only patients without Q waves on any ECG in the first 3 days after
admission qualified for this group.
The following table lists the patient characteristics for all patients and sub-groups:
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Table 1. PATIENT CHARACTERISTICS
Patient
Group




All patients 191 116 37-86 62.6
All infarcts 104 72 37-86 64.2
Group A 56 41 37-84 64.9
Group B 48 31 40-86 63.3
Group C 87 43 37-78 60.5
Type 1 58 46 37-84 64.4
Type 2 46 26 40-86 63.6
Males 116 116 37-84 61.4
Females 75 0 42-86 64.8
Group A males 41 41 37-84 63.9
Group A females 15 0 48-86 67.6
Group B males 31 31 40-79 61.6
Group B females 17 0 42-78 66.4
Type 1 males 46 46 37-83 63.8
Type 1 females 12 0 48-74 66.9
Type 2 males 26 26 40-86 61.0
Type 2 females 20 0 42-86 67.0
Of those patients in groups A and B, the subdivision into types 1 and 2 was:
Type 1 Type 2 Total
Group A 43 13 56
Group B 14 34 48
Total 58 46 104
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Age differences between patient groups
Analysis of the means of the above groups by analysis of variance (ANOVA)
gave a variance ratio of 2.10 with 688 total degrees of freedom. This was
statistically significant, p<0.05. Differences between the mean ages for the
following comparisons were identified, (Student's t-test for means of unpaired
samples), mean ages in brackets:
Group A (64.9) vs Group C (60.5) p=0.015
Type I (64.4) vs Group C (60.5) p=0.026
Females (64.8) vs Males (61.4) p=0.02
Type 2 females (67.0) vs Type 2 males (61.0) p=0.02
Group B females (66.4) vs Group B males (61.6) p=0.062
4.1.1.1 DISCUSSION
Age distribution in patient groups
Patients in group A were older than patients in group C, as were patients
with type 1 infarction. This combination is not surprising since 77% of patients in
group A had type 1 infarcts, and patients with infarction would be expected to be
older than a control population admitted to CCU with chest pain of presumed
cardiac cause. Generally, females were older than males, and specifically, females
with type 2 infarction were significantly older than males with type 2 infarcts. This
has been shown previously (Willich,1987). There was a trend for females in group
B to be older than males, p=0.06.
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Sex distribution in patient groups
A comparison of sex distribution in the various groups revealed a significant
preponderance of females in group C, x2 =10.16, p<0.005. There was also a
larger than expected proportion of female patients with type 2 infarction,
X2 =6.16, p < 0.01. Neither of these results is unexpected as these observations have
been made previously, but they confirm that patient demographics in this study were
similar to those documented in previous studies of patients with chest pain
suggestive of AMI admitted to a coronary care unit.
Infarct type
Analysis of the distribution of infarct type in groups A and B revealed an
excess of patients with type 1 infarction in group A, and type 2 infarction in group
B, x2 =23.64, p<0.005. That is, patients with an admission ECG which is
diagnostic of AMI are more likely to have QAMI, whereas patients with a
non-diagnostic admission ECG are more likely to have NQAMI.
The total proportion of patients with NQAMI was 46%. This is higher than
the figure reported in most studies. This can be explained by the strict ECG criteria
used to classify patients into type 1 and type 2 infarction, namely, the requirement
of a Q-wave to be greater than 1/4 the height of the ensuing R wave, and to be at
least 0.04 seconds in duration.
All patients with chest pain suggestive of a cardiac aetiology were recruited
into the study, patients were not excluded on the basis of a previous cardiac history.
The day 3 ECG was chosen as the reference point for classification into type 1 or
type 2 because, as discussed above, Q-waves can be transient in the first few days
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after AMI. Although it could be argued that if Q-waves are present in the inferior
leads on admission, and are present in the same leads at day 3 that these are not
"new", this is not guaranteed to be so. Consequently, the presence of Q-waves on
the day 3 ECG as defined by the above criteria and used in this study is precise.
This ensured that subjective interpretation of deciding whether the presence of Q-
waves at day 3 is related to the current, or previous, infarction was removed from
ECG analysis.
It is also important to note that the separation of patients into infarct types
was performed prior to information being available from the biochemical analysis,
and that this ECG classification was used, without variation, for all subsequent
comparisons between the patient groups for the various biochemical markers being
evaluated.
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4.1.2 DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION IN
INDIVIDUAL PATIENT GROUPS
One of the primary endpoints of this project was to evaluate the capability
of serum and urine creatine concentrations to diagnose acute myocardial infarction.
The other biochemical markers measured are recognised to be of value for this
purpose, but their ability to differentiate between the various patient groups as
detailed above, is not well known.
This section compares differences in serum and urine concentrations for each
individual marker for the various patient groups.
4,1.2.1 PEAK SERUM AND URINE CONCENTRATIONS WITHIN 12 HOURS
OF THE ONSET OF SYMPTOMS
The period of 12 hours from the onset of symptoms was chosen as the period
of assessment. This is in accordance with current understanding of the time window
in which thrombolytic therapy is likely to be of clinical benefit.
To compare serum and urine concentrations between the groups, the peak
concentration within this period was chosen as the "representative" figure for
analysis. Further analysis of serum concentrations at different time intervals
following the onset of symptoms is performed later in this chapter. Tables 17-21,
pages 150-163 list, by patient group, peak concentrations within 12 hours of
symptom onset. The means of peak serum or urine concentration were assessed
initially by ANOVA. If a significant difference was detected, then the various
groups were compared to one another, in pairs, using an independent t-test. The
following tables and figures show the results for the various markers.
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4.1.2.1.1 RESULTS: CREATINE AND CREATININE
Table 2. MEAN SERUM CREATINE CONCENTRATIONS
Patient group Mean concentration (^mol/1) S.E.M.
All infarcts 70.86 3.67
Group A 65.89 3.99
Group B 76.68 6.39
Group C 74.64 4.32
Type 1 67.14 4.08
Type 2 74.80 6.35
One way ANOVA, variance ratio=0.774, P=NS








infarcts Group A Group B Group C Type 1 Type 2
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Table 3. URINE CREATINE CONCENTRATIONS - Available samples
Patient group Mean concentration (/*mol/l) S.E.M.
All infarcts 160.78 27.77
Group A 189.20 50.92
Group B 134.89 25.84
Group C 269.63 52.80
Type 1 204.11 47.42
Type 2 109.27 22.1
One way ANOVA, variance ratio =1.96, P=NS
Figure 3. URINE CREATINE CONCENTRATIONS - Available samples
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A number of patients were unable to provide a sample of urine for analysis, they
were divided amongst the groups as follows:




Urine passed within 12 hours
of symptom onset (n)
No urine passed within
12 hours of symptoms
(n)
Group A 44 12
Group B 45 3
Group C 74 13
Type 1 48 10
Type 2 41 5
A comparison of the groups by chi-squared test revealed a significant
difference in inability to pass urine between groups A and B, x2=4.77, p<0.05.
There was no significant difference found between all patients with AMI and group
C, x2=0-007, or between type 1 and type 2 infarction, x2=0.81.
Since urine creatine concentrations were being assessed for their ability to
diagnose AMI, it is inappropriate not to include all patients studied. Thus, if a urine
sample is not provided, such a patient should not be excluded from the analysis as
this may bias the results (Harris, 1981). Consequently, if a value of 0/*mol/l was
substituted for those patients who were unable to provide a sample of urine within
12 hours of symptom onset, the results for peak urinary concentration were as
follows:
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Table 5. MEAN URINE CREATINE CONCENTRATIONS - All patients
Patient group Mean concentration (jimol/I) S.E.M.
All infarcts 138.4 23.6
Group A 148.7 38.6
Group B 126.5 24.7
Group C 232.4 44.8
Type 1 168.9 38.9
Type 2 97.4 20.3
One way ANOVA, variance ratio= 1.79, p=NS
Figure 4, URINE CREATINE CONCENTRATIONS - All patients
URINE CREATINE - ALL PATIENTS
300
250
i nfarcts Group A Group B Group C Type 1 Type 2
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Because of the close biochemical association between creatine and creatinine,
and the fact that analysis of these two substances was performed by the same assay
system, albeit with a modification to measure creatine, serum and urine
concentrations of creatinine were analysed in a similar manner to above.
Table 6. MEAN SERUM CREATININE CONCENTRATIONS
Patient group Mean concentration (jimol/l) S.E.M.
All infarcts 105.3 37.4
Group A 109.6 42.7
Group B 100.3 29.8
Group C 99.4 26.8
Type 1 105.8 32.9
Type 2 103.7 43.1
One way ANOVA, variance=0.72, p=NS
Figure 5. SERUM CREATININE CONCENTRATIONS
SERUM CREATININE
infarcts Group A Group B Group C Type 1 Type 2
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Table 7. URINE CREATININE CONCENTRATIONS - Available samples
Patient group Mean concentration (/imol/1) S.E.M.
All infarcts 8345 643
Group A 9677 996
Group B 7042 780
Group C 5349 407
Type 1 8984 945
Type 2 7596 849
One way ANOVA, variance=4.61, p<0.01
Figure 6. URINE CREATININE CONCENTRATIONS - Available samples
URINE CREATININE - AVAILABLE SAMPLES
Thousands
12
infarcts Group A Group B Group C Type 1 Type 2
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Table 8. URINE CREATININE CONCENTRATIONS - All patients
Patient group Mean concentration (jimol/1) S.E.M.
All infarcts 7141 621
Group A 7603 947
Group B 6889 778
Group C 4550 402
Type 1 6858 901
Type 2 5656 834
One way ANOVA, variance—2.89, p<0.05
Figure 7. URINE CREATININE CONCENTRATIONS - All patients
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For urine creatinine concentrations in all patients the following significant
differences were identified:
Groups compared t-statistic p-value
Group C 3.35 <0.001
All infarcts
Group C 3.36 0.001
Group A
Group C 2.96 0.004
Group B
Group C 3.26 0.001
Type 1
Group C 2.71 0.008
Type 2
4.1.2.1.1.1 DISCUSSION
These results show that within 12 hours of the onset of symptoms, neither
serum nor urinary creatine concentrations were able to differentiate any group with
AMI from control subjects. The range of serum concentrations was especially low.
Although patients in group B and type 2 had higher mean concentrations than
patients in group A and type 1, this was reversed for urinary concentrations, with
group A and type 1 having higher means than group B and type 2. From above
(page 81), it was proposed on theoretical grounds that urinary creatine
concentrations should reflect serum concentrations but with a concentrating effect,
clearly this was not apparent in this study population. Problems with using urine as
a diagnostic test because of its unavailability in some patients have been noted
previously (Suval, 1987). Lack of sample availability was observed in all 3 patient
groups, although this was only significantly different between groups A and B, the
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former having more anuric patients up to 12 hours after symptoms had begun. This
would be expected, because these patients have larger infarcts with increased
haemodynamic compromise.
Why such a discrepancy exists between this study and that of DeLanghe et
al is unclear (DeLanghe, 1988). Theirs is the only study in the literature which
reports the value of creatine as a diagnostic marker of AMI. All patients in this
study had large infarcts, and the control population was "normal" subjects, not an
equivalent group of hospitalised patients. Of the 22 patients with AMI, 12 had
bladder and/or arterial catheters inserted, the mean CK rise was over 3000U/L. The
mean serum concentration in their control population was approximately 45/xmol/l,
this was lower than the mean concentration of patients in group C, 74.6/xmol/l. The
effects of stress on serum and urine creatine levels are not known, but the metabolic
role of creatine may lead to it being affected by an increase in circulating
catecholamine levels at the time of admission to CCU, irrespective of the aetiology
of chest pain, as for patients in group C.
There was no close correlation between either serum, or urine concentrations
of creatine and creatinine, so confirming that the assays used to measure these 2
substances were different. The quality control data for the 2 assays showed their
respective accuracy in the measurement of these 2 quantities, therefore it would
appear to be justified to state that creatine and creatinine were assayed separately
and specifically. There were no significant differences between the groups for serum
creatinine concentrations, and although urine concentrations were different, this
reflected the type of infarction, namely urine was more concentrated for patients
with larger infarcts (group A and type 1), than patients with smaller infarcts (group
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B and type 2), than patients without infarction, (group C). It follows that the
unavailability of urine was the same for creatinine as for creatine, and since this was
evident for 28 of the 191 patients in the study, the usefulness of urine creatinine in
any diagnostic capacity is severely limited and as such it can have no role as a
diagnostic marker in the early post-AMI period.
Now, serum CK-MB mass, serum CK-MB activity, serum myoglobin and
serum troponin-T concentrations will be considered.
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4.1.2.1.2 RESULTS: CK-MB MASS. CK-MB ACTIVITY. MYOGLOBIN
AND TROPONIN-T
Table 9. MEAN SERUM CK-MB MASS CONCENTRATIONS
Patient group Mean concentration (ng/ml) S.E.M.
All infarcts 69.97 8.91
Group A 96.59 14.93
Group B 38.92 5.88
Group C 1.34 0.10
Type 1 101.57 15.34
Type 2 38.63 6.05
One way ANOVA, variance ratio = 16.58, p<0.01.
Figure 8. SERUM CK-MB MASS CONCENTRATIONS
SERUM CK-MB MASS
120
infarcts Group A Group B Group C Type 1 Type 2
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The following table shows the significant differences identified between pairs of
groups.
Table 10. SERUM CK-MB MASS - GROUP COMPARISONS






















These results are discussed at the end of this section (page 147)
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Table 11. MEAN SERUM CK-MB ACTIVITY
Patient group Mean concentration (U/L) S.E.M.
All infarcts 103.81 11.74
Group A 144.5 19.32
Group B 56.3 7.49
Group C 8.95 0.42
Type 1 140.53 18.72
Type 2 57.59 8.26
One way ANOVA, variance ratio=19.18, p<0.01
Figure 9. SERUM CK-MB ACTIVITY CONCENTRATIONS
SERUM CK-MB ACT I V ITY
200
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The following table shows the significant differences identified between pairs of
groups.
Table 12, SERUM CK-MB ACTIVITY - GROUP COMPARISONS






















These results are discussed at the end of this section (page 147).
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Table 13. MEAN SERUM MYOGLOBIN CONCENTRATIONS
Patient group Mean concentration 0*g/l) S.E.M.
All infarcts 953.64 134.87
Group A 1390.13 219.69
Group B 444.42 101.16
Group C 38.44 3.03
Type 1 1168.34 159.05
Type 2 476.34 107.99
One way ANOVA, variance ratio= 14.78, p<0.01.
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The following table shows the significant differences identified between pairs of
groups.
Table 14. SERUM MYOGLOBIN - GROUP COMPARISONS






















These results are discussed at the end of this section (page 147).
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Table 15. MEAN SERUM TROPONIN-T CONCENTRATIONS
Patient group Mean concentration (ng/ml) S.E.M.
All infarcts 3.74 0.48
Group A 5.62 0.79
Group B 1.56 0.28
Group C 0.05 0.01
Type 1 5.31 0.77
Type 2 1.76 0.34
One way ANOVA, variance ratio = 19.49, p< 0.001.
Figure 11. SERUM TROPONIN-T CONCENTRATIONS
SERUM TROPONIN-T
infarcts Group A Group B Group C Type 1 Type 2
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The following table shows the significant differences identified between pairs of
groups.
Table 16. SERUM TROPONIN-T - GROUP COMPARISONS























The results for the 4 markers, CK-MB mass and activity, myoglobin and
troponin-T are all similar. Analysis of variance on the means of all groups shows
significant differences between them. Comparing the groups in pairs also shows
similar findings for all 4 markers. There are differences between group C and all
patients with infarction (groups A and B combined), as well as between group C and
the 4 sub-groups individually, namely groups A and B, and types 1 and 2. It would
be expected that significant differences would be seen between patients with and
without infarction. Similarly, all 4 markers would be expected to discriminate group
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C from all sub-groups of AMI, as they have all been shown to be selective for AMI
in numerous previous studies.
What is of interest is that the peak serum concentration within 12 hours of
the onset of symptoms is able to differentiate between patients in the various groups.
Thus it can discriminate between patients with and without diagnostic ECGs on
admission (groups A and B), as well as those patients who do or do not develop Q-
waves by the third day after infarction (types 1 and 2). Comparison of group A with
type 1, and group B with type 2 was not statistically significant for any marker,
conversely, comparison of group A with type 2, and group B with type 1 gave
similar results to those listed for comparison of group A with group B and type 1
with type 2. This is expected because of the considerable overlap between group A
and type 1, and group B and type 2. The number of patients in this study was too
small to identify any differences between these latter particular types of patients. It
may be that with larger numbers differences would be identified, although the
overlap noted between group A and type 1 in this study would be expected to persist
in any similar patient population.
In terms of stratifying patients and commencing appropriate treatment as
soon as possible after the onset of symptoms, these results are of potential clinical
significance. Firstly, they show overwhelmingly that patients with non-diagnostic
ECG's can be identified by a number of markers soon after the onset of infarction.
Secondly, they show that from a biochemical perspective certain patient groups
appear to diverge at a very early stage, and as such can be distinguished by
biochemical criteria within 12 hours of symptom onset. Admittedly, in this study the
classification of patient groups was made retrospectively, and importantly, the
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diagnosis of infarction was made using biochemical markers that are now
increasingly recognised as having being superseded by the markers under evaluation
in this study (although creatine kinase and aspartate aminotransferase are still the 2
most commonly used markers of infarction employed in clinical chemistry
laboratories in the UK). The above findings, and those described later, should be
tested in a prospective fashion with the cut-offs for differentiation of patient groups
established prior to patient recruitment.
However, as the management of patients with AMI becomes increasingly
varied, the recognition that early identification of patient subgroups can be achieved
by biochemical means raises the possibility of tailoring the immediate post-AMI
management to the specific type of infarction sustained. As indicated above, further
studies will be required to assess the effects on prognosis of stratification of
treatment in this way.
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Table 17, Peak serum and urine concentrations within 12 hours of onset of











9 90 111 1311 0.56 40 63
10 50 72 1191 1.36 50 NIL
15 260 319 640 17.60 50 NIL
17 240 313 1611 16.30 44 62
26 70 113 356 13.40 33 81
32 400 442 718 18.20 65 185
33 180 240 2160 11.60 96 859
34 26 36 305 1.99 73 108
36 60 92 514 1.85 30 112
40 80 110 658 1.51 71 34
42 100 149 1608 13.10 45 78
49 27 24 104 1.10 71 42
53 240 285 3260 15.70 62 267
59 700 883 4986 21.30 67 NIL
63 39 70 361 6.80 62 54
66 130 193 409 4.80 62 14
71 16 45 352 0.70 53 30
80 110 157 1062 1.50 67 33
82 130 200 5391 3.40 36 NIL
83 46 73 537 6.90 65 NIL
85 80 106 1920 5.80 38 10
89 22 41 272 0.30 65 326
91 90 144 1050 5.74 75 26
92 <2 7 24 0.33 97 162
96 2 15 65 0.92 72 169












108 <2 22 95 0.25 54 40
109 60 100 805 1.02 50 NIL
111 100 148 2490 1.04 62 13
115 42 75 1245 3.45 30 NIL
121 38 23 321 0.59 70 NIL
123 32 43 478 0.55 33 77
127 60 85 1350 4.54 85 11
135 280 397 2570 14.70 36 28
136 90 134 1860 10.60 81 NIL
138 6 45 403 1.60 40 59
141 18 32 294 1.15 39 NIL
142 110 149 1280 12.90 62 144
147 60 82 489 2.28 113 364
149 120 161 1440 4.73 73 NIL
150 160 196 2890 5.83 178 1723
154 100 141 2360 1.10 11 225
155 70 102 174 4.18 59 57
157 4 74 540 0.73 61 53
159 18 75 1370 0.33 63 20
161 320 412 4060 8.44 122 112
163 50 81 468 2.89 71 NIL
164 60 92 318 1.55 120 1045
167 150 221 2300 16.50 62 402
169 36 51 112 4.10 53 NIL
171 15 25 65 0.62 56 23
173 130 197 2520 1.69 60 NIL
187 210 265 2760 13.44 92 393












193 90 126 740 9.82 64 21








= Serum concentration of CK-MB mass in ng/ml
= Serum concentration of CK-MB activity in U/L
= Serum concentration of myoglobin in yu.g/1
= Serum concentration of troponin-T in ng/ml
= Serum concentration in pimol/1
= Urine concenbtration in /xinol/1
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Table 18. Peak serum and urine concentrations within 12 hours of onset of











1 50 57 419 2.47 37 21
4 19 25 144 0.05 133 4
7 90 120 855 2.09 95 492
13 19 19 113 0.11 44 23
27 33 58 226 2.71 65 185
29 11 21 60 0.30 67 174
31 70 79 322 0.53 48 256
35 80 115 1740 2.09 44 137
39 <2 10 308 0.84 74 44
44 10 22 26 0.79 55 29
47 8 21 24 0.45 28 36
52 80 121 105 1.70 72 51
54 20 39 282 8.94 39 37
57 13 21 78 0.37 159 88
60 18 17 212 0.17 102 337
64 42 35 678 3.99 54 15
65 41 33 137 0.48 65 242
67 8 10 55 0.32 119 36
73 220 267 4487 2.52 137 73
74 2 10 24 0.25 45 25
76 12 25 55 0.50 73 323
78 6 14 1092 0.23 228 NIL
81 18 31 106 1.86 160 31
94 41 79 189 0.58 73 34
95 50 86 616 7.39 55 76












113 9 21 138 0.25 74 15
116 34 59 122 3.39 91 NIL
118 6 10 108 0.61 48 54
120 39 53 636 2.28 64 33
122 43 23 144 0.43 102 47
125 170 215 226 1.95 61 98
129 8 23 112 6.90 53 44
132 90 145 1360 4.20 232 562
134 22 23 107 0.45 84 53
144 80 104 728 1.65 29 204
148 25 25 340 0.94 52 46
153 40 66 782 0.23 49 509
168 29 63 201 0.99 50 8
172 36 94 607 0.51 45 47
176 44 72 227 0.91 91 692
179 18 42 850 0.22 76 340
180 48 47 739 2.87 56 15
183 44 86 584 0.24 32 45
184 6 14 50 0.13 49 15
186 33 48 158 1.20 118 450
189 21 49 336 1.59 75 7
195 35 48 138 0.38 64 12
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Table 19. Peak serum and urine concentrations within 12 hours of symptom











2 <2 9 24 0.00 58 59
3 <2 4 24 0.00 44 38
5 <2 6 101 0.00 113 75
6 3 12 129 0.00 121 82
8 <2 15 24 0.00 48 71
11 <2 13 24 0.02 67 268
14 <2 10 24 0.01 69 749
16 <2 8 24 0.03 57 147
18 <2 13 24 0.04 55 13
19 <2 6 24 0.03 84 28
20 <2 6 24 0.00 69 94
21 3 8 24 0.02 29 17
22 <2 15 24 0.07 56 19
23 <2 10 24 0.00 98 171
28 <2 7 24 0.09 75 590
30 <2 8 24 0.06 36 67
37 <2 7 24 0.10 84 401
38 <2 8 24 0.09 42 22
41 <2 6 76 0.15 78 48
43 <2 6 24 0.18 50 29
45 <2 6 24 0.14 103 786
46 2 18 96 0.13 219 46
48 <2 6 24 0.12 292 951
50 <2 8 24 0.10 57 817
51 <2 5 24 0.10 16 114












56 <2 7 24 0.12 90 969
58 <2 5 24 0.19 132 125
61 <2 6 24 0.14 63 NIL
62 3 9 24 0.10 50 NIL
68 2 12 59 0.25 50 10
69 <2 23 24 0.13 79 259
70 <2 5 24 0.19 69 23
72 <2 4 24 0.00 132 NIL
75 <2 7 24 0.00 61 30
77 <2 7 24 0.03 116 2252
79 2 6 24 0.00 86 487
84 <2 7 24 0.01 102 14
86 2 12 24 0.07 96 58
87 <2 8 24 0.00 49 10
88 <2 10 59 0.01 90 28
93 <2 9 32 0.14 48 16
97 <2 3 24 0.09 35 NIL
98 3 15 57 0.10 63 39
101 2 8 29 0.12 61 86
102 8 9 53 0.11 88 6
103 <2 10 50 0.11 38 47
105 <2 7 138 0.16 63 84
106 <2 8 24 0.10 196 655
107 <2 6 24 0.12 41 NIL
112 <2 8 30 0.05 46 15
114 2 8 24 0.07 41 43
117 <2 8 24 0.04 46 7












124 <2 3 31 0.01 58 40
126 2 11 75 0.09 53 12
128 <2 5 28 0.00 118 NIL
130 <2 6 35 0.00 110 111
131 <2 12 48 0.00 35 10
133 <2 6 32 0.00 40 26
137 <2 7 45 0.00 70 45
139 <2 7 28 0.00 60 14
140 <2 4 29 0.00 84 123
143 2 7 41 0.00 70 NIL
145 2 11 41 0.00 60 NIL
146 <2 6 33 0.02 51 101
151 <2 7 52 0.00 72 NIL
152 4 10 32 0.03 84 119
156 <2 13 36 0.04 65 42
158 2 15 194 0.10 47 19
160 <2 10 54 0.00 88 43
162 <2 2 26 0.00 59 45
165 <2 14 47 0.01 107 753
166 <2 12 41 0.01 107 25
170 <2 22 49 0.05 25 NIL
174 <2 8 30 0.01 97 702
175 <2 7 42 0.02 46 7
177 <2 8 26 0.01 115 67
178 <2 7 26 0.01 75 56
181 <2 12 22 0.00 83 953
182 <2 13 36 0.02 38 5












188 <2 18 27 0.06 71 NIL
190 <2 11 29 0.01 43 43
192 <2 12 47 0.02 78 60
194 <2 11 43 0.03 96 587
196 3 10 102 0.04 92 570
158
Table 20, Peak serum and urine concentrations within 12 hours of onset of











4 50 25 144 0.05 133 4
9 90 111 1311 0.56 40 63
15 260 319 640 17.60 50 NIL
17 240 313 1611 16.30 44 62
26 70 113 356 13.40 33 81
32 400 442 718 18.20 65 185
33 180 240 2160 11.63 96 859
34 26 36 305 1.99 73 108
35 80 115 1740 2.09 44 137
36 60 92 514 1.85 30 112
39 <2 10 308 0.84 74 44
42 100 149 1608 13.10 45 78
49 27 24 104 1.10 71 42
53 240 285 3260 15.70 62 267
59 700 883 4986 21.30 67 NIL
63 39 70 361 6.80 62 54
64 42 35 678 3.99 54 15
66 130 193 409 4.80 62 14
80 110 157 1062 1.50 67 33
81 18 31 106 1.86 160 31
82 130 200 5391 3.40 36 NIL
83 46 73 537 6.90 65 NIL
89 22 41 272 0.30 65 326
92 <2 7 24 0.33 97 162
95 50 86 616 7.39 55 76












111 100 148 2490 1.04 62 13
113 9 21 138 0.25 74 15
115 42 75 1245 3.45 30 NIL
116 34 59 122 3.39 91 NIL
123 32 43 478 0.55 33 77
125 170 215 226 1.95 61 98
127 60 85 1350 4.54 85 11
135 280 397 2570 14.70 36 28
136 90 134 1860 10.60 81 NIL
138 6 45 403 1.60 40 59
141 18 32 294 1.15 39 NIL
142 110 149 1280 12.90 62 144
144 80 104 728 1.65 29 204
147 60 82 489 2.28 113 364
149 120 161 1440 4.73 73 NIL
150 160 196 2890 5.83 178 1723
153 40 66 782 0.23 49 509
154 100 142 2360 1.10 11 225
155 70 102 174 4.18 59 57
157 4 74 540 0.73 61 53
159 18 75 1370 0.33 63 20
161 320 412 4060 8.44 122 112
163 50 81 468 2.89 71 NIL
164 60 92 318 1.55 120 1045
167 150 221 2300 16.5 62 402
168 29 63 201 0.99 50 8
171 15 25 65 0.62 56 23












176 44 72 227 0.91 91 692
179 18 42 850 0.22 76 340
187 210 265 2760 13.44 92 393
193 90 126 740 9.82 64 21
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Table 21. Peak serum and urine concentrations within 12 hours of onset of











1 50 57 419 2.47 37 21
7 90 120 855 2.09 95 492
10 50 72 1191 1.36 50 NIL
13 19 19 113 0.11 44 23
27 33 58 226 2.71 65 185
29 11 21 60 0.30 67 174
31 70 79 322 0.53 48 256
40 80 110 658 1.51 71 34
44 10 22 26 0.79 55 29
47 8 21 24 0.45 28 36
52 80 121 105 1.70 72 51
54 20 38 282 8.94 39 37
57 13 21 78 0.37 159 88
60 18 17 212 0.17 102 337
65 41 33 137 0.48 65 242
67 8 10 55 0.32 119 36
71 16 45 352 0.70 53 30
73 220 267 4487 2.52 137 73
74 2 10 24 0.25 45 25
76 12 25 55 0.50 73 323
78 6 14 1092 0.23 228 NIL
85 80 106 1920 5.80 38 10
91 90 144 1050 5.74 75 26
94 41 79 189 0.58 73 34
96 2 15 65 0.92 72 169












104 26 43 287 0.66 98 36
108 <2 22 95 0.25 54 40
118 6 10 108 0.61 48 54
120 39 53 636 2.28 64 33
121 38 23 321 0.59 70 NIL
122 43 23 144 0.43 102 47
129 8 23 112 6.90 53 44
132 90 145 1360 4.20 232 562
134 22 23 107 0.45 84 53
148 25 25 340 0.94 52 46
169 36 51 112 4.10 53 NIL
172 36 94 607 0.51 45 47
180 48 47 739 2.87 56 15
183 44 86 584 0.24 32 45
184 6 14 50 0.13 49 15
186 33 48 158 1.20 118 450
189 21 49 336 1.59 75 7
191 2 14 408 0.12 62 NIL
195 35 48 138 0.38 64 12
197 8 43 343 1.42 71 22
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4.1.3 ASSESSMENT OF RELATIVE DIAGNOSTIC POWER OF THE
BIOCHEMICAL MARKERS
It has been established that of the biochemical markers used in this study,
only CK-MB mass and activity, myoglobin and troponin-T were significantly
discriminatory in the diagnosis of AMI; using peak serum concentration within 12
hours of symptom onset as the value for comparison.
In order to identify any difference in the diagnostic abilities of these markers,
it was decided that diagnostic cut-offs would be established for each marker. These
could then be used to determine the diagnostic accuracy of individual markers, and
also allow comparison of diagnostic ability and time taken to diagnose AMI between
the 4 markers.
These cut-offs were determined before the study began, and, were not altered
at any stage during the study, nor modified for any of the analyses performed. They
were:
CK-MB mass (Hybritech) >5ng/ml
CK-MB activity (Kodak) >20U/L
Myoglobin > 100yu.g/l
Troponin-T >0.2ng/ml
Having established a serum concentration for each marker that was diagnostic
for AMI, the biochemical data were assessed to determine which markers were able
to successfully identify patients with AMI within 12 hours of the onset of symptoms,
and to show which patients were incorrectly labelled as having sustained AMI. The
results of this analysis are listed in tables 29-32, pages 200-209.
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The success or failure of a diagnostic test are determined by its ability to
discriminate between patients that do or do not have a particular pathology
(Freedman, 1987). The sensitivity, specificity, positive and negative predictive value
are indicators of this. They are defined as follows:
Sensitivity = True positive (and test positive)
All true positive
i.e. the probability of a positive result in patients with AMI.
Specificity = True negative land test negative)
All true negative
i.e. the probability of a negative result in patients without AMI.
Positive predictive value = True positive
True positive and false positive
i.e. the probability that a patient has sustained an AMI if the test result is positive.
Negative predictive value = True negative
True negative and false negative
i.e. the probability that a patient has not sustained AMI if the test result is negative.
These measures of diagnostic accuracy were calculated for the various patient
groups and are listed below:
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a) DIAGNOSIS OF AMI IN ALL PATIENTS WITH AMI.





Sensitivity 93.3 89.4 88.5 95.2
Specificity 98.8 97.7 94.3 98.9
+ve predictive
value
99.0 97.9 94.8 99.0
-ve predictive
value
92.4 88.5 87.2 94.5
bt DIAGNOSIS OF AMI IN GROUP A PATIENTS





Sensitivity 91.1 94.6 92.9 98.2
Specificity 98.8 97.7 94.3 98.8
+ve predictive
value
98.1 96.4 91.2 98.2
-ve predictive
value
94.5 96.6 95.3 98.9
c) DIAGNOSIS OF AMI IN GROUP B PATIENTS





Sensitivity 95.8 83.3 83.3 91.7
Specificity 98.8 97.7 94.3 98.9
+ve predictive
value
97.9 95.2 88.9 97.8
-ve predictive
value
97.7 91.4 91.1 95.6
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d) DIAGNOSIS OF AMI IN PATIENTS WITH TYPE 1 INFARCTION





Sensitivity 94.8 96.6 94.8 98.3
Specificity 98.8 97.7 94.3 98.9
+ve predictive
value
98.2 96.6 91.7 98.3
-ve predictive
value
96.6 97.7 96.5 98.9
el DIAGNOSIS OF AMI IN PATIENTS WITH TYPE 2 INFARCTION





Sensitivity 91.3 80.4 80.4 91.3
Specificity 98.8 97.7 94.3 98.8
+ve predictive
value
97.7 94.9 88.1 97.7
-ve predictive
value
95.6 90.4 90.1 95.6
4,1.3.1 SPECIFICITY
Overall, the specificity of the 4 biochemical markers was high, ranging from
94.3% - 98.8%. The same specificities have been listed in all 5 tables because the
data for patients in group C is constant. The number of patients in group A and
group B is smaller than the total number of patients sustaining AMI (as this is the
sum of these 2 groups). However, as a proportion of all patients studied, the
numbers of patients in these subsets are valid, and in any subsequent patient
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population, are likely to be similar. Although the relatively large number of patients
used to calculate specificity and, in particular, negative predictive value may be
considered high, it should be noted that this relates to prediction of diagnostic
accuracy for a patient in a particular subset. It is statistically more correct to use a
representative sample of patients when assessing the precision of a diagnostic test
(Ranshoff,1978). In the case of this study, patients being admitted to CCU with a
diagnosis of presumed AMI. It could equally be argued that the specificity of any
given marker with a smaller number of control subjects would be similar, because
the number of false positive tests should reflect the total number of patients
sampled. That is, there is no reason to suspect that the indications for admission to
CCU for patients in group C should change in accordance with the AMI sub-group
being studied. Those patients identified as having false-positive tests within 12 hours
from the time of admission, and their probable reason for this are shown in the
following table:
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102 59 M 8 ng/ml 8 hours N.C.C.P.
CK-MB
Activity
69 53 F 20.8 U/L 6 hours U.A.
170 73 F 21.8 U/L 2 hours Collapse
Myoglobin 5 73 F 101 fig/1 6 hours Collapse
6 64 M 119 ftg/1 7 hours Collapse
105 70 M 127 fig/1 5 hours P.E.
158 70 M 107 fig/1 8 hours N.C.C.P.
196 68 M 102 Mg/1 5 hours Collapse









= Non-cardiac chest pain,
= Unstable angina
= Pulmonary embolism
= Collapse ?uncertain cause
4.1.3.2 COMPARISON OF THE RELATIVE DIAGNOSTIC ABILITIES
OF THE FOUR BIOCHEMICAL MARKERS
The above tables indicate the actual values of sensitivity, specificity, positive
and negative predictive value for the 4 markers shown to be of proven value for the
diagnosis of AMI. However, these tables do not permit discrimination of one
marker against another because they do not compare directly the ability to diagnose
or exclude infarction for individual patients, only for each patient group as a whole.
Such an analysis should be performed by a comparison of paired proportions such
as McNemar's test, which compares untied observations i.e. differences rather than
similarities between biochemical markers for any patient group (Daly, 1991).
McNemar's test was performed for all the paired group comparisons between all 4
markers. The results are shown in the following table:
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Table 23. COMPARISON OF DIAGNOSTIC POWER OF 4 BIOCHEMICAL
MARKERS OF AMI
Paired Markers Patient Group McNemar x2 P value
CK-MB mass
CK-MB activity
All infarcts 2.7 NS
CK-MB mass
Myoglobin
All infarcts 1.9 NS
CK-MB mass
Troponin-T
All infarcts 0.4 NS
CK-MB activity
Myoglobin
All infarcts 0.1 NS
CK-MB activity
Troponin-T
All infarcts 4.5 <0.05
Myoglobin
Troponin-T
All infarcts 4.6 <0.05
CK-MB mass
CK-MB activity
Group A 2 NS
CK-MB mass
Myoglobin
Group A 0.2 NS
CK-MB mass
Troponin-T
Group A 4 <0.05
CK-MB activity
Myoglobin
Group A 0.2 NS
CK-MB activity
Troponin-T
Group A 2 NS
Myoglobin
Troponin-T
Group A 1.8 NS
CK-MB mass
CK-MB activity
Group B 6 <0.02
CK-MB mass
Myoglobin
Group B 4.5 <0.05
CK-MB mass
Troponin-T
Group B 0.7 NS
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Paired Markers Patient Group McNemar x2 P value
CK-MB activity
Myoglobin
Group B 0 NS
CK-MB activity
Troponin-T
Group B 2.7 NS
Myoglobin
Troponin-T
Group B 1.6 NS
CK-MB mass
CK-MB activity
Type 1 1 NS
CK-MB mass
Myoglobin
Type 1 0.3 NS
CK-MB mass
Troponin-T
Type 1 3 NS
CK-MB activity
Myoglobin
Type 1 0 NS
CK-MB activity
Troponin-T
Type 1 2 NS
Myoglobin
Troponin-T
Type 1 2 NS
CK-MB mass
CK-MB activity
Type 2 3.6 NS
CK-MB mass
Myoglobin
Type 2 4.5 <0.05
CK-MB mass
Troponin-T
Type 2 0.1 NS
CK-MB activity
Myoglobin
Type 2 0.1 NS
CK-MB activity
Troponin-T
Type 2 2.7 NS
Myoglobin
Troponin-T
Type 2 2.8 NS
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4.1.3.3 DISCUSSION
The above analysis compared the accuracy of AMI diagnosis of 4
biochemical markers in comparison to a control population of patients admitted to
a CCU with chest pain shown subsequently not to be AMI. The diagnosis of all
patients with AMI, and smaller subgroups within this total, were considered.
For all patients with AMI, a significant difference was found between
troponin-T and both CK-MB activity and myoglobin, the former being the better
indicator of AMI. Troponin-T had greater values for all 4 measures of diagnostic
accuracy, but especially for sensitivity, 95.2% vs 89.4% and 88.5%, and negative
predictive value, 94.5% vs 88.5% and 87.2% respectively. There was a trend for
troponin-T to be better than CK-MB mass, 0.05<p<0.10, with troponin-T having
greater values for all 4 diagnostic indicators despite statistical significance not being
achieved. Overall, troponin-T is clearly the most accurate predictor of AMI within
12 hours of the onset of symptoms for all patients with AMI. This is in accordance
with other researchers who advocate it as the best marker and suggest that it has
superseded CK-MB as the biochemical "gold standard" of AMI diagnosis
(Katus, 1991;Bakker, 1994).
Why troponin-T was significantly better than CK-MB activity, but not
CK-MB mass is of interest. Overall, CK-MB mass was a better indicator of AMI
within 12 hours of symptom onset than CK-MB activity. The 2 methods had similar
specificities and positive predictive values, but CK-MB mass had greater sensitivity
and negative predictive value than CK-MB activity. McNemar's test compares
differences rather than similarities between pairs of markers, and it follows that
overall more differences existed between CK-MB activity and troponin-T, than
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between CK-MB mass and troponin-T; this was especially so for patients with type
2 infarction. This may be related to the method of measuring this enzyme. CK-MB
mass detects actual quantities and gives a concentration in ng/ml. CK-MB activity
measures the ability of the enzyme to catalyse a reaction, and in patients with
smaller infarcts or a slower rise in enzyme concentration, this could explain why it
was less good at detecting AMI within 12 hours of symptom onset.
Turning to group A, the only significant difference identified was that
between troponin-T and CK-MB mass. Reference to table 29, page 200 shows that
in this group, CK-MB mass was non-diagnostic for 5 patients, CK-MB activity for
3, myoglobin for 4 and troponin-T for only 1 patient. Again, because of the nature
of the statistical comparison, significance was only reached for CK-MB mass. This
shows the influence of such small increments of inaccurate detection of AMI. Thus,
CK-MB mass failed to detect only 2 more patients than CK-MB activity, (the 2 were
concordant for the 3 patients for which CK-MB activity was non-diagnostic), but
against a marker with the sensitivity and specificity of troponin-T, this small
difference had an effect. Why CK-MB mass should be the least accurate in this
group is difficult to explain. From above it follows that it should be as least as
accurate as CK-MB activity, and as patients in group A have larger infarcts overall
there should not be a problem with the diagnostic threshold being reached. For 2 of
the patients this however was the case, a concentration of 4ng/ml being recorded.
With small numbers of patients making such a statistical difference it would be of
interest to see if this phenomenon repeated itself in a similar study, or whether it
was an aberration of this particular study.
The contrast in the results for group B patients is striking. The significant
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differences in this subset were between CK-MB mass and CK-MB activity, and
CK-MB mass and myoglobin, the former having the best diagnostic accuracy.
Reference to table 30, page 203 shows that the reason for this is the considerably
greater sensitivity of CK-MB mass, with it being non-diagnostic for just 2 patients
compared to 8 patients for both CK-MB activity and myoglobin, and 4 patients for
troponin-T. Again, it is unclear why CK-MB mass was so different in this group.
Group B patients have non-diagnostic ECGs and, usually, smaller infarcts in
comparison to patients in group A (Chouhan,1991). Consequently, the time taken
for serum concentration to increase is greater, which explains why CK-MB activity
and troponin-T with a slower rise in serum levels have relatively more patients not
being diagnosed within the 12 hour time limit. However, this time factor should not
apply to myoglobin, and the chosen cut-off, namely, 100^g/l is comparable to that
used in earlier studies (Cairns, 1983;Mair, 1991a). Previous workers have shown the
sensitivity of myoglobin to be lower than CK-MB for ajl patients with AMI. The
above results suggest that this reduced diagnostic sensitivity applies specifically to
a patient subgroup with smaller infarcts (who do not achieve the diagnostic cut-off
within a relatively short time from the onset of symptoms), rather than to all patients
with AMI, because a similar problem was not identified for patients in group A.
For patients with type 1 infarction there were no significant differences
identified between any of the groups. This can be explained by the observation that
for any of the 4 markers there was a maximum of 3 patients with AMI who were
not correctly diagnosed. There was a trend for troponin-T to be better than CK-MB
mass and myoglobin, 0.05<p<0.10, but this did not achieve the required statistical
significance.
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It would appear that although there is a considerable overlap of patients
between group A and type 1, some differences between the diagnostic abilities of
the markers exist for these 2 patient subsets. The clinical significance of this is
unclear, but even within as little as 12 hours from symptom onset, subtle
biochemical differences appear to have developed between group A and type 1.
This observation also supports the decision to use the day 3 ECG as a
reference for the type of AMI, that is QAMI or NQAMI. The above results indicate
that the biochemical changes that have occurred 12 hours after symptom onset are
very similar in type 1 patients, and that this seems to represent a more homogeneous
group than those patients with admission ECGs diagnostic of AMI (group A). One
reason for this may be that group A patients are subjected to a variety of treatments,
(in particular the administration of thrombolysis), and so the opportunity to alter the
pathological changes occurring in the newly ischaemic myocardium exists,
presumably with effects on the serum biochemical profile. Conversely, type 1
patients probably represent a group who share a common pathological response to
the effects of acute coronary occlusion, and consequently manifest a common ECG
abnormality at day 3.
Patients with type 2 infarction showed similar results to those in group B.
The only significant difference identified was that between CK-MB mass and
myoglobin. There were trends for CK-MB mass and troponin-T to be better than
CK-MB activity, 0.05<p<0.10, and for troponin-T to be better than myoglobin,
0.05 <p<0.10. Reference to table 32, page 208 shows why this is so, with CK-MB
mass failing to successfully diagnose AMI in just 4 patients, troponin-T in 5, CK-
MB activity in 9 and myoglobin in 10 patients. In much the same way that a small
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difference in the patients that constituted group A and type 1 had effects upon
statistical significance between the various markers for these 2 groups, so too did
a similar variation in those patients that constituted group B and type 2. Whereas
for type 1 there were less patients incorrectly diagnosed than in group A, there were
actually more patients incorrectly diagnosed in type 2 than group B. However, these
increased numbers only resulted in a significant difference being identified between
CK-MB mass and myoglobin, and not between CK-MB mass and activity as was
noted in group B. Thus, the diagnostic abilities of the 2 assays of CK-MB were
more similar for type 2 infarction than they were for patients with non-diagnostic
ECG's.
From the above discussion, it follows that some patients who were not
correctly diagnosed by some markers have transferred from group A to type 2. This
is understandable because patients with diagnostic ECGs are more likely to receive
thrombolytic therapy and so convert what initially is more likely to become a QAMI
into a NQAMI. Despite this, the majority of patients with type 2 infarction are also
included in group B.
In a similar way that biochemical differences were seen between patients in
group A and type 1, so differences were also identified between patients in group
B and type 2. Once again, this adds weight to the suggestion that pathophysiological
differences develop very early from the time of coronary artery occlusion. For these
2 patient subsets in particular, these differences are likely to be related to the effects
of treatment, and/or coronary artery reperfusion; be it therapeutic or spontaneous.
This is because patients in group B are likely to be undertreated as the admission
ECG is non-diagnostic of AMI and confirmation of infarction will be made
retrospectively by measurement of cardiac enzymes. These patients will tend to
develop NQAMI, but will be joined in this group by patients with diagnostic
admission ECG's who have been successfully treated with thrombolytic therapy, that
is, have achieved reperfusion of the infarct related artery.
As stated previously, the numbers of patients studied were too small to show
any significant differences between group A and type 1, or between group B and
type 2. Further studies, biochemical or otherwise, may reveal more subtle
differences within these 2 pairs of patient groups, despite their initial similar
appearances.
The above discussion has compared the 4 markers with regard to their
abilities to differentiate between the various groups of patients with AMI. The
management of patients with acute coronary syndromes always includes the
important clinical issue of excluding patients with non-cardiac chest pain. Since
patients with AMI are often treated in an intensive environment, and since up to
20% of general medical admissions can be due to chest pain where a cardiac
aetiology has to be confirmed or excluded, the swift, accurate diagnosis of patients
with non-cardiac pathologies is of undoubted significance, especially with the cost
of health care provision assuming an ever increasing importance in day to day
clinical practice.
The above analysis considered peak serum concentrations within 12 hours of
symptom onset. The specificities for all 4 markers were high, ranging from 94-99%,
but for all patients with AMI, and for the various sub-groups, troponin-T
consistently had the highest specificity and negative predictive value. Therefore, if
the desired clinical endpoint was to exclude AMI, taking one blood sample 12 hours
after the onset of symptoms to measure troponin-T would achieve this with a very
high degree of confidence. The analysis of troponin-T is currently the slowest of the
4 markers, although newer methods are currently being developed (Mach,1995).
Allowing for this technical delay, if the most rapid analytical technique in this study
was used, namely for CK-MB mass, a specificity and negative predictive value of
98.8% and 92.4% respectively could be achieved within 20 minutes of a blood
sample being taken. Assuming that most patients present within a few hours of the
onset of symptoms, these results show that within a few hours of admission a
definite indication as to the likelihood of chest pain not having a cardiac aetiology
can be made.
This analysis does not consider the question of exactly how soon after the
onset of symptoms a diagnosis of acute myocardial infarction can reliably be made
(or excluded); this will be considered in the next section.
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4.1.4 TIME TO DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION
4.1.4.1 COMPARISON BETWEEN MARKERS FOR SAME PATIENT GROUP
With the increased clinical need to recognise patients that have sustained
myocardial infarction as soon as possible after the onset of symptoms, the data were
analysed to assess any difference in the time taken to make a positive diagnosis of
AMI. The earliest time that an individual marker reached the relevant diagnostic
threshold was calculated. In those patients where a positive diagnosis was not made,
a time of 12 hours was used. This time was decided upon because all blood samples
were collected until 12 hours from symptom onset. It is of statistical importance to
include all patients in the analysis and not only those that give a positive result, so
as to avoid bias (Harris, 1981). The data used for these calculations are listed in
tables 29-32, pages 200-209. The mean times to diagnosis for the patient groups are
listed below, and illustrated in the figures that follow:
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Table 24, MEAN TIME + S.E.M IN HOURS AFTER THE ONSET OF






All infarcts 5.67 ± 0.28 6.89 ± 0.32 5.32 ± 0.33 6.40 ± 0.32
Group A 5.55 ± 0.40 6.20 ± 0.38 4.82 ± 0.38 5.93 ± 0.38
Group A - T 5.57 + 0.43 6.16 ± 0.41 4.70 ± 0.38 5.86 + 0.41
Group A - NT 5.42 ± 0.68 6.43 ± 1.13 5.86 ± 1.42 6.43 ± 1.13
Group B 5.81 ± 0.40 7.71 ± 0.53 5.90 ± 0.57 6.96 ± 0.54
Group B -T 6.31 ± 0.68 8.00 ± 0.95 6.00 ± 1.09 7.15 ± 0.91
Group B - NT 5.63 ± 0.49 7.60 ± 0.64 5.86 ± 0.67 6.89 ± 0.67
Type 1 5.21 + 0.36 6.12 + 0.38 4.63 ± 0.38 5.95 ± 0.41
Type 2 6.26 ± 0.44 7.87 ± 0.52 6.17 ± 0.57 6.98 ± 0.51
Abbreviations
Group A - T = Group A patients receiving thrombolytic therapy (n=49)
Group A - NT — Group A patients not receiving thrombolytic therapy (n=7)
Group B - T = Group B patients receiving thrombolytic therapy (n=13)
Group B - NT = Group B patients not receiving thrombolytic therapy (n=35)
There were no significant differences identified between any comparisons of
thrombolysed and non-thrombolysed patients for specific markers within the
individual patient groups A or B. Because of the reduced numbers of patients in the
thrombolysed and non-thrombolysed categories, the following analysis compared
whole groups of patients. Where relevant, comments are made concerning the
subgroup categories in the discussion that follows the figures below.
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Figure 12, TIME TO DIAGNOSIS - ALL INFARCTS
Figure 13. TIME TO DIAGNOSIS - GROUP A
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Figure 14, TIME TO DIAGNOSIS - GROUP B
Figure 15. TIME TO DIAGNOSIS - TYPE 1 INFARCTS
TIME TO DIAGNOSIS-TYPE 1

















Figure 16. TIME TO DIAGNOSIS - TYPE 2 INFARCTS
TIME TO DIAGNOSIS-TYPE 2
CK-MB CK-MB Myoglobin Troponin-T
mass activity
The mean times to AMI diagnosis in the separate groups were assessed by ANOVA.








All infarcts 415 5.02 <0.01
Group A 223 2.71 <0.05
Group B 191 3.14 <0.05
Type 1 231 3.20 <0.05
Type 2 183 2.36 NS
Having established significant differences between the markers for the various
groups, pairs of markers were compared using Student's t-test for paired samples.
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Results are only given for comparisons between patient groups where a significant
difference was identified.






































































For all patients with AMI (groups A and B combined), myoglobin was able
to diagnose AMI more rapidly than CK-MB activity or troponin-T. Also, CK-MB
mass was significantly faster than CK-MB activity. The observation that myoglobin
is the most rapid indicator of AMI has been made previously (Cairns, 1983), but the
difference between CK-MB mass and CK-MB activity is less well known. This
relates to the different methods of measurement of this enzyme. The mass method
detects the presence of CK-MB in the sample, and gives a concentration
accordingly. The activity method depends upon CK-MB being of sufficient
concentration to catalyse a reaction. It would appear that in the first few hours after
the onset of infarction, there is a lag period in which sufficient CK-MB is present
to permit detection by the mass assay, but insufficient is present to reach the
diagnostic cut-off chosen for the activity assay. This is not important when the time
to diagnosis is irrelevant, as has been the case historically with CK-MB being the
"gold standard" of AMI diagnosis (usually at day 3), but clearly, when time is
important, a significant methodological difference is illustrated by this analysis.
Why myoglobin is such a rapid marker of AMI is not entirely clear. It has
a molecular weight considerably lower than that of CK-MB (Kagan,1975), and
hence it could be supposed that it would be released from infarcting myocytes more
rapidly once the plasma membrane had become disrupted, resulting in a more rapid
increase in serum concentration. As discussed above, the release kinetics of
troponin-T are such that a rapid rise in serum concentration is unlikely to occur.
Therefore, although it appears to be the most accurate marker for AMI diagnosis,
it is of more limited value in rapid diagnosis.
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Consequently, for all of the 4 markers considered to be reliable indicators
of AMI, myoglobin is the best for early detection of all patients with AMI. As
discussed previously, accurate exclusion of the diagnosis of AMI can be made
within 12 hours of the onset of symptoms. Although myoglobin has the lowest
specificity of the 4 markers evaluated in this study, it has been shown to have a
specificity and negative predictive value of 94.3% and 87.2% respectively. This
degree of exclusion of AMI, combined with an ability to provide this assessment
within 5.5 hours of the onset of symptoms, as well as to be measured relatively
rapidly in the laboratory make it suitably qualified as the best marker to provide a
rapid exclusion of infarction. If any clinical doubt persists as to the validity of this,
then within a couple of hours or so, troponin-T can provide an even more sensitive
and specific indication as to whether or not myocardial infarction has occurred.
The time to diagnosis of AMI in patients in group A only reveals significant
differences between myoglobin and troponin-T, and myoglobin and CK-MB activity.
All markers had lower mean times to diagnosis for group A compared to all patients
with infarction, but the relative decrease in time to diagnosis for CK-MB activity
was greater than that for CK-MB mass, hence the fact that there was no significant
difference between these 2, unlike for all patients with AMI. The effect of
thrombolysis has to be discussed for group A patients. Analysis of the effects of
reperfusion is performed in detail in chapter 5, but of the 56 patients in group A,
49 received thrombolytic therapy, compared to 13 of the 48 patients in group B. It
is well known that successful reperfusion results in an earlier time to peak
concentration (Blanke, 1984a;Ishii, 1991). Also, it has been shown that patients in
group A are more likely to have QAMI, with larger infarcts. Therefore, using a
diagnostic cut-off, it is not surprising that patients in group A reach this threshold
earlier than either all patients with infarction, or patients in group B. Similarly, a
more rapid and larger CK-MB rise in this group will lead to sufficient enzyme being
released for the diagnostic cut-off for CK-MB activity, as well as CK-MB mass,
being realised, and therefore no significant difference in the time to diagnosis for
these 2 markers would be expected. Similar, but not identical results to the whole
of group A were seen for those patients within the group receiving thrombolytic
therapy. This is not surprising since they constitute 88% of the total group. Thus,
significant differences were seen between CK-MB activity and myoglobin, p=0.001,
myoglobin and troponin-T, p=0.023, and in addition to the results for the whole
group, myoglobin was also significantly more rapid in diagnosing AMI than CK-MB
mass, p=0.005. However, as mentioned above, this finding is probably related to
restoration of coronary artery patency and is discussed further in chapter 5.
Comparison of mean times to diagnosis for group B showed that CK-MB
mass achieved diagnosis significantly earlier than CK-MB activity. Myoglobin also,
was more rapid than CK-MB activity. All markers had slower times to diagnosis for
group B than for all patients with AMI, and group A. This is in accordance with the
above explanation, that is, patients in this group are more likely to have smaller
infarcts and some will not achieve successful coronary artery reperfusion. The mean
times to diagnosis were similar for myoglobin and CK-MB mass; those of CK-MB
activity and troponin-T were also of similar magnitude to one another.
The release kinetics of the 2 slower markers reduce their effectiveness in the
diagnosis of this important patient group, namely, those patients without diagnostic
admission ECGs. Studies of thrombolytic therapy, in particular, ISIS-2, have
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demonstrated that certain patients with non-diagnostic admission ECGs benefit from
thrombolysis, in particular, patients with a normal ECG on admission, and those
with new left bundle branch block (ISIS-2,1988). This viewpoint has been reinforced
more recently (Anderson, 1993). Therefore, it can be argued that early identification
of these patients by biochemical means when the ECG is unhelpful is of clinical
significance.
Considering the advantages of the bedside test of CK-MB mass measurement
to a more complicated laboratory based system for myoglobin, there seems little
doubt that until a bedside assay is developed for myoglobin with the same relative
accuracy as the monoclonal antibody system used in the Hybritech ICON method,
then measurement of CK-MB mass will continue to have distinct clinical advantages
over myoglobin for the purpose of rapid AMI detection.
When the subgroups within group B were analysed separately, it was seen
that there were no significant differences between any of the 4 markers for those
patients receiving thrombolytic therapy, although as shown above, there are only 13
patients in this group. In the larger group of 35 non-thrombolysed patients, findings
were similar but not identical to the group as a whole. Thus, there were significant
differences seen between CK-MB activity and CK-MB mass, p< 0.001, and between
CK-MB activity and myoglobin, p=0.003. There was also a trend for CK-MB mass
to achieve a more rapid diagnosis than troponin-T, p=0.08. Therefore, within this
group of patients with a non-diagnostic ECG on admission, in which some patients
are known to benefit from the administration of thrombolytic therapy, CK-MB mass
and myoglobin will achieve a diagnosis within the order of 6 hours from the time
of onset of symptoms.
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The results for patients with type 1 infarction are similar to those for all
patients with infarction, with myoglobin being the most rapid marker, closely
followed by CK-MB mass, with CK-MB activity and troponin-T having similar and
significantly slower times to diagnosis. Of all the patient subgroups, the times to
diagnosis are fastest for all 4 markers for type 1 infarction (note, troponin-T almost
identical for type 1 and group A, 5.95+0.41 and 5.93+0.38 hours respectively).
It is interesting to note that what is presumed to be a pathological classification of
patients, namely, QAMI can be differentiated biochemically very early in its clinical
course. This is even more surprising considering the fact that the ECG changes used
to categorise these patients were made at day 3. This biochemical observation may
have clinical validity, especially if the management of patients becomes more
specific, with increasing numbers of clinical trials assessing prognosis by different
management strategies in the early post-AMI period.
Patients with type 2 infarction showed similar results to those in group B.
That is, myoglobin and CK-MB mass were significantly faster at diagnosing AMI
than CK-MB activity. All markers without exception had the slowest times to
diagnosis in this subgroup, the reasons for this have been alluded to above. These
are the patients that at day 3 are shown to have NQAMI. They are constituted
largely from patients in group B who have had small infarcts and/or have not
achieved successful reperfusion. Although as was discussed earlier, some patients
in group A were also assigned to type 2, and it was presumed that some of these
had successful reperfusion, reference to table 40, page 219 shows that this was true
for just 5 patients. Because of the relatively small numbers of patients in the study,
and the small crossover of patients from group A to type 2 who behaved in this
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way, they did not influence the overall interpretation of the times to diagnosis for
patients in this sub-group. However, as for patients with QAMI, biochemical
differences are seen in patients in whom a pathological difference is suspected. As
has been suggested earlier, this observation has been made retrospectively. It would
be of interest to test this prospectively, with pre-determined cut-offs, especially in
relation to management of the various sub-groups in the early post infarct period.
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4.1.4.2 ASSESSMENT OF ABILITY OF INDIVIDUAL MARKERS TO
DIFFERENTIATE PATIENT SUB-GROUPS
The preceding analysis compared differences between the ability of individual
markers to diagnose AMI in patient subgroups within 12 hours of the onset of
symptoms. Certain differences between the release kinetics of the 4 markers were
noted. However, although myoglobin may be released more rapidly than troponin-T
for example, it is not clear whether there are any differences between patient groups
for an individual marker. Therefore, to determine whether differences existed
between the groups for any of the individual markers, an ANOVA was performed
for each marker using all 4 groups. Table 24 is repeated below. Figures 17-20,
which follow, show the times to diagnosis for each individual marker, and table 27
shows the results of the ANOVA.
Table 24, MEAN TIME + S.E.M IN HOURS AFTER THE ONSET OF






All infarcts 5.67 ± 0.28 6.89 ± 0.32 5.32 ± 0.33 6.40 ± 0.32
Group A 5.55 ± 0.40 6.20 ± 0.38 4.82 ± 0.38 5.93 ± 0.38
Group A - T 5.57 ± 0.43 6.16 ± 0.41 4.70 ± 0.38 5.86 ± 0.41
Group A - NT 5.42 ± 0.68 6.43 ± 1.13 5.86 ± 1.42 6.43 ± 1.13
Group B 5.81 ± 0.40 7.71 ± 0.53 5.90 ± 0.57 6.96 ± 0.54
Group B - T 6.31 ± 0.68 8.00 ± 0.95 6.00 ± 1.09 7.15 ± 0.91
Group B - NT 5.63 ± 0.49 7.60 ± 0.64 5.86 ± 0.67 6.89 ± 0.67
Type 1 5.21 ± 0.36 6.12 ± 0.38 4.63 ± 0.38 5.95 ± 0.41
Type 2 6.26 ± 0.44 7.87 ± 0.52 6.17 ± 0.57 6.98 ± 0.51
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Figure 17, TIME TO DIAGNOSIS OF AMI - CK-MB MASS
TIME TO DIAGNOSIS
CK-MB MASS
infarcts Group A Group B Type 1 Type 2






i nfarcts Group A Group B Type 1 Type 2
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Infarcts Group A Group B Type 1 Type 2
Figure 20. TIME TO DIAGNOSIS OF AMI - TROPONIN-T
TIME TO DIAGNOSIS
TROPONIN-T
infarcts Group A Group B Type 1 Type 2
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Hybritech CK-MB 207 1.22 NS
Kodak CK-MB 207 4.41 <0.01
Myoglobin 207 2.66 <0.05
Troponin-T 207 1.69 NS
It can be appreciated that differences between the groups were only detected
for CK-MB activity and myoglobin. As for previous results, having established a
significant difference by ANOVA, pairs of markers were compared using Student's
t-test for unpaired samples. Only positive comparisons are given in the following
table:











































Despite the observation made in the previous discussion that the time
required to diagnose AMI when compared to all patients with AMI appeared to be
lowest for group A and type 1, and highest for group B and type 2, table 28
demonstrates that statistical significance for differences between the groups for an
individual marker was seen for only 2 markers, CK-MB activity and myoglobin.
Since any clinical application of these observations is likely to be the
differentiation of type of AMI, and since the final classification of AMI subgroup
for an individual patient will depend upon the severity of infarction and subsequent
response to treatment (including thrombolytic therapy), the analysis of these "within
marker" differences will be considered for each patient group as a whole, rather
than subdividing patients into those that did or did not receive thrombolysis or other
therapies within the 3 days following their presentation. Also, the design of this
study, and the numbers of patients recruited, do not provide sufficient statistical
power for these various subgroup comparisons.
Firstly, considering myoglobin. Because this marker provides the most rapid
overall diagnosis, it follows that it potentially has a clinical advantage if within this
diagnostic window it can further differentiate between AMI subgroups.
Although a difference was seen between group A and type 2, this is of little
significance, because group A is readily identified by the ECG criteria referred to
earlier in this chapter (page 123). However, the observation that myoglobin can
discriminate between patients with QAMI and NQAMI as early as 7 hours after the
onset of symptoms is of interest. It demonstrates that the difference between these
patients, who have been separated by ECG criteria at day 3, is likely to be genuine,
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and further that the pathophysiological changes accompanying these 2 types of
infarction are not entirely the same. It also shows that the means of deciding who
has or has not had QAMI that is, all patients with Q waves (new or old) also
appears to have validity.
As the management of AMI becomes more varied and selective according
to patient subgroup, accurate methods for stratifying patients soon after AMI will
be required. These results show that measurement of a few blood samples in the
immediate post-AMI period is able to achieve this with considerable statistical
significance. It is likely that other criteria will also be required to increase the
accuracy of the separation into type 1 or type 2. This was decided upon at day 3,
because as has been mentioned earlier, the presence or absence of Q waves in the
immediate post-AMI period is not constant, and therefore the ECG is of limited use
early on. These criteria are likely to consist of other biochemical indicators, a
diagnostic algorithm being produced to most accurately classify patients as soon as
possible after the onset of symptoms.
Also of interest are the results for CK-MB activity. This marker was the
slowest of all markers used, being significantly tardier than myoglobin or CK-MB
mass. However, not only was it able to discriminate between the same 2 pairs of
groups as myoglobin, but it also showed a difference between groups A and B, and
also type 1 and group B. The differentiation of groups A and B is of some interest
because although these 2 groups of patients are readily separated by the admission
ECG, the classification of patients into these 2 groups is retrospective at day 3,
because criteria other than ECG changes are required to diagnose group B. The fact
that patients in group B can be differentiated by biochemical criteria within 6-8
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hours from the onset of symptoms, despite the ECG appearances, is of potential
clinical significance.
CK-MB activity was also able to discriminate between patients with type 1
infarcts and group B. This is not surprising, considering the overlap between
patients in group A and type 1, but does illustrate that patients with non-diagnostic
ECGs can also be separated from patients with QAMI, and this can be achieved
within a few hours of admission. It also reinforces the proposition that patients with
type 1 AMI have pathological differences compared to patients in group B. The fact
that patients with type 1 infarcts have an earlier time to diagnosis suggests that they
are likely to have larger infarcts, with or without an increased amount of arterial
reperfusion, this is usually dependent upon whether thrombolysis is administered.
The effects of coronary artery reperfusion will be discussed in chapter 5.
Once again, these results demonstrate differences between the patient sub¬
groups of considerable statistical significance. The clinical application of these
observations may be of relevance with easier and rapid bedside assay techniques
being developed. The prospective validation of these findings is also required to
establish appropriate diagnostic serum concentrations of these 2 markers.
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4.1.5 CONCLUSIONS
1) Serum or urine creatine concentrations are not valid markers of the early
diagnosis of acute myocardial infarction.
2) All 4 recognised markers, namely, CK-MB mass and activity, myoglobin and
troponin-T are highly accurate in the diagnosis of all patients with AMI.
3) All 4 markers can differentiate, by serum concentration, between patients
with diagnostic and non-diagnostic admission ECG's, and also between
patients with Q-wave and non Q-wave myocardial infarction.
4) For all patients with AMI, troponin-T has the greatest diagnostic ability
within 12 hours of the onset of symptoms.
5) For all patients with AMI, and for all 4 sub-groups myoglobin provides the
most rapid diagnosis.
6) Within patient sub-groups, differentiation, by time to diagnosis, can be made
by myoglobin and CK-MB activity between QAMI and NQAMI.
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9 7 7 7 11
10 6 6 3 3
15 4 4 4 4
17 3 3 3 3
26 3 3 3 3
32 3 12 3 12
33 6 6 3 6
34 12 12 12 12
36 6 6 3 6
40 6 6 6 6
42 8 8 5 3
49 4 8 4 8
53 3 3 3 3
59 4 4 4 4
63 5 5 5 5
66 5 5 5 5
71 4 7 4 7
80 7 7 7 7
82 3 5 2 5
83 2 3 3 3
85 2 2 2 2
89 4 12 4 4
91 5 5 5 5
92 ND ND ND 2
96 ND ND ND 4









108 ND 1 ND 5
109 5 7 5 7
111 4 5 4 12
115 6 6 4 6
121 8 10 8 10
123 3 5 2 5
127 9 7 3 5
135 6 7 6 9
136 6 6 4 6
138 5 7 3 7
141 3 3 3 3
142 4 4 4 2
147 1 4 3 6
149 5 5 3 5
150 4 4 4 5
154 5 7 5 9
155 10 10 10 10
157 ND 9 5 9
159 4 5 4 8
161 2 5 2 5
163 2 2 2 2
164 6 6 6 6
167 2 6 2 4
169 8 8 8 8
171 9 9 ND 9
173 3 3 3 3
187 4 4 4 4
191 ND ND 2 ND
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Patient CK-MB CK-MB Myoglobin Troponin-T
number Mass Activity
193 3 3 2 3
197 7 9 7 9
ABBREVIATIONS
CK-MB mass = Time to diagnostic cut-off in hours from time of symptom onset
CK-MB activity — Time to diagnostic cut-off in hours from time of symptom onset
Myoglobin = Time to diagnostic cut-off in hours from time of symptom onset
Troponin-T = Time to diagnostic cut-off in hours from time of symptom onset
ND = Non-diagnostic, i.e. diagnostic cut-off not realised within 12 hours
of the onset of symptoms
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1 9 9 9 9
4 3 5 3 11
7 7 7 4 7
13 10 ND 10 ND
27 12 12 12 12
29 7 12 ND ND
31 4 12 2 12
35 4 4 4 4
39 ND ND 1 1
44 5 5 ND 5
47 9 9 ND 5
52 6 6 6 6
54 7 7 5 7
57 5 10 ND 5
60 10 ND 10 ND
64 2 2 2 2
65 4 7 4 7
67 6 ND ND 4
73 7 11 4 11
74 ND ND ND 7
76 8 11 ND 5
78 3 ND 1 3
81 5 5 2 5
94 6 6 6 6
95 4 4 2 4









113 6 12 12 10
116 2 1 1 1
118 7 ND 5 2
120 3 1 1 1
122 3 12 3 9
125 9 9 9
129 1 1 1 1
132 1 1 1 1
134 5 5 5 12
144 6 4 4 4
148 7 9 7 12
153 8 8 8 12
168 4 6 4 6
172 6 8 3 11
176 5 7 5 7
179 8 12 6 12
180 2 4 2 4
183 5 7 4 9
184 4 ND ND ND
186 4 4 4 4
189 4 5 3 5
195 8 8 8 10
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4 3 5 3 11
9 7 7 7 11
15 4 4 4 4
17 3 3 3 3
26 3 3 3 3
32 3 12 3 12
33 6 6 3 6
34 12 12 12 12
35 4 4 4 4
36 6 6 3 6
39 ND ND 1 1
42 8 8 5 3
49 4 8 4 8
53 3 3 3 3
59 4 4 4 4
63 5 5 5 5
64 2 2 2 2
66 5 5 5 5
80 7 7 7 7
81 5 5 2 5
82 2 5 2 5
83 3 3 3 3
89 4 12 4 4
92 ND ND ND 2
95 4 4 2 4









111 4 5 4 12
113 6 12 12 10
115 6 6 4 6
116 2 1 1 1
123 3 5 2 5
125 9 9 9 9
127 9 7 3 5
135 6 7 6 9
136 6 6 4 6
138 5 7 3 7
141 3 3 3 3
142 4 4 4 2
144 6 4 4 4
147 1 4 3 6
149 5 5 3 5
150 4 4 4 5
153 8 8 8 12
154 5 7 5 9
155 10 10 10 10
157 ND 9 5 9
159 4 5 4 8
161 2 5 2 5
163 2 2 2 2
164 6 6 6 6
167 2 6 2 4
168 4 6 4 6
171 9 9 ND 9
173 3 3 3 3
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Patient CK-MB CK-MB Myoglobin Troponin-T
number Mass Activity
176 5 7 5 7
179 8 12 6 12
187 4 4 4 4
193 3 3 2 3
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Table 32. TIME TO DIAGNOSIS - TYPE 2 AMI.
Patient CK-MB CK-MB Myoglobin Troponin-T
number Mass Activity
1 9 9 9 9
7 7 7 4 7
10 6 6 3 3
13 10 ND 10 ND
27 12 12 12 12
29 7 12 ND ND
31 4 12 2 12
40 6 6 6 6
44 5 5 ND 5
47 9 9 ND 5
52 6 6 6 6
54 7 7 5 7
57 5 10 ND 5
60 10 ND 10 ND
65 4 7 4 7
67 6 ND ND 4
71 4 7 4 7
73 7 11 4 11
74 ND ND ND 7
76 8 11 ND 5
78 3 ND 1 3
85 2 2 2 2
91 5 5 5 5
94 6 6 6 6
96 ND ND 2 4
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5.1 ANALYSIS OF CORONARY ARTERY REPERFUSION BY
ELECTROCARDIOGRAPHIC AND BIOCHEMICAL CRITERIA
5.1.1 INTRODUCTION
The need for non-invasive assessment of coronary artery reperfusion has
become apparent with an ever increasing array of therapies designed to open an
occluded artery. These include both medical and interventional treatments. Methods
of achieving this have concentrated on 2 of the means utilised in the diagnosis of
AMI, namely electrocardiographic changes, and changes in serum concentration of
certain biochemical markers. In order to allow comparison between the biochemical
markers used in this study it was necessary to use a technique to diagnose
reperfusion that is exclusive of them (Freedman,1987). The use of coronary
angiography as the "gold standard" of determining coronary artery patency at a
particular moment in time is generally accepted. Although patency after
thrombolysis may be variable, previous studies relating ST segment changes to early
coronary angiographic appearances after thrombolysis suggest that this does allow
comparison between groups of patients that have, or have not achieved successful
reperfusion (Klootwijk, 1993). More recently, early, complete reperfusion of the
infarct related artery has been shown to be of clinically significance, immediately
and 30 days after AMI (GUSTO-1,1993). Although the limitations of not using
coronary angiography to document vessel patency in this study were recognised, it
was still considered valid, albeit with appropriate reservations, to utilise a change
in the amount of ST segment elevation after the onset of AMI as the means of
determining whether or not coronary artery reperfusion had taken place.
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5.1.2 CLASSIFICATION OF PATIENTS INTO SUCCESSFUL OR
UNSUCCESSFUL REPERFUSION STATUS
As outlined above, in order to compare the relative properties of the 4
biochemical markers in the diagnosis of reperfusion, a means of classifying patients
into those who had, or had not reperfused was required. Consideration of previous
studies suggested that a sensitivity of 80-90%, and specificity of 70-80% could be
realised by using appropriate ECG criteria. It was felt that if this degree of accuracy
could be realised, then this would allow valid comparison of the various biochemical
markers.
Therefore, since the resolution of ST segment elevation by at least 50%
within 120 minutes from the administration of thrombolysis is recognised by a
number of authors as being highly suggestive of recanalisation of the infarct related
artery (Lee, 1989; Saran,1990; Flohnloser, 1991); and also incorporating information
on reperfusion arrhythmias, that is disorders of cardiac rhythm thought to be related
to restoring blood flow to ischaemic myocardium (Shah, 1993); an analysis of all
patients in group A was made.
Group A was chosen because, as defined on page 123, all patients in this
group had ST segment elevation on the admission ECG. It follows from above that
this is a necessary prerequisite to identify, by ECG criteria, which patients have, or
have not reperfused. The classification of patients into successful or unsuccessful
reperfusion is shown in table 40, page 231.
From a total of 56 patients in group A, 31 were considered to have achieved
successful reperfusion. Of these 56 patients, 49 received thrombolytic therapy, and
of these 49 patients, 31 successfully reperfused. None of the 7 patients not receiving
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thrombolytic therapy were considered to have achieved successful reperfusion.
Chi-squared analysis of the effect of thrombolysis on reperfusion status gave
X2= 10.05, p<0.005.
The 56 patients in group A were further classified into 44 having type 1
infarction, and 12 as having type 2 infarction. Of the 44 patients with type 1, 25 had
successful reperfusion; of the 12 patients with type 2, 6 achieved reperfusion.
Chi-squared analysis of the association of type of infarction and reperfusion status
gave x2==0.12, p=NS.
Reviewing the ECGs for each patient in group A showed that by ECG
criteria, 20 patients had an anterior infarct, and 36 an inferior infarct. Of the 20
patients with anterior MI, 11 reperfused successfully, and of the 36 patients with
inferior infarction, 20 achieved reperfusion. Chi-squared analysis of the relationship
between infarct location and reperfusion status gave x2=0.003, p=NS.
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5.2 EFFECT OF REPERFUSIQN STATUS ON BIOCHEMICAL MARKER
SERUM CONCENTRATION PROFILE
It is recognised that successful reperfusion of a coronary artery results in
characteristic alteration of the biochemical profile (Blanke, 1984a; Ellis, 1988;
Remppis,1994). Biochemical data for the 4 markers in the study proven to be
diagnostic for AMI, namely, CK-MB mass and activity, myoglobin and troponin-T
were analysed. Serum concentrations on admission, and, 2 and 4 hours later were
measured. In the 49 patients in group A in whom thrombolytic therapy was
administered, serum concentrations 2 and 4 hours after thrombolysis were used for
the analysis. The time to peak serum concentration (after thrombolysis or after
admission) was also measured. The ratios: admission:2 hour, and admission:4 hour
were calculated. These ratios, and times to peak concentration are shown in tables
41-44, pages 234-245.
5.2.1 Determination of cut-off ratios for diagnosis of reperfusion status for each
of the biochemical markers
Whereas for the diagnosis of AMI, diagnostic cut-offs had already been
established prior to commencing the study, no similar diagnostic criteria were
available for determining which patients had or had not achieved successful
reperfusion. These were decide upon by plotting receiver operating characteristic
(ROC) curves for each of the markers at 2 and 4 hours. Sensitivities and specificites
were assessed for a number of ratios chosen arbritarily, these were: > 1.5, >2.0,
>3.0, >4.0 and >6.0. The results of this analysis are shown in the table below.
These data were used to construct ROC curves for each of the 4 markers. These are
shown in figures 21 and 22.
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Table 33. Sensitivities and specificities of diagnosis of coronary artery reperfusion









CK-MB Mass (>1.5) 97 36 100 8
Activity (>1.5) 77 68 97 48
Myoglobin (>1.5) 100 52 100 48
Troponin (>1.5) 81 52 94 32
CK-MB mass (>2.0) 87 60 100 36
Activity (>2.0) 68 80 97 64
Myoglobin (>2.0) 87 64 94 64
Troponin (>2.0) 68 64 90 48
CK-MB mass (>3.0) 68 88 94 56
Activity (>3.0) 52 92 77 72
Myoglobin (>3.0) 81 88 87 68
Troponin (>3.0) 65 68 90 52
CK-MB mass (>4.0) 55 88 94 76
Activity (>4.0) 45 92 74 80
Myoglobin (>4.0) 71 92 81 80
Troponin (>4.0) 52 84 84 68
CK-MB mass (>6.0) 45 96 87 84
Activity (>6.0) 32 100 58 100
Myoglobin (>6.0) 58 96 77 96
Troponin (>6.0) 39 88 74 80
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Figure 21. ROC CURVES FOR ALL MARKERS AT 2 HOURS
CK-MB MASS - 2 HOURS CK-MB ACTIVITY - 2 HOURS
MYOGLOBIN - 2 HOURS TROPONIN-T - 2 HOURS
X axis = 1-specificity, Y axis = sensitivity
Figure 22, ROC CURVES FOR ALL MARKERS AT 4 HOURS
CK-MB MASS - 4 HOURS CK-MB ACTIVITY - 4 HOURS
MYOGLOBIN - 4 HOURS TROPONIN-T - 4 HOURS
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A point on each curve was chosen that best differentiated those patients that had and
had not undergone coronary artery reperfusion (Hanley,1983). These are shown
below. In order to maintain consistency during the subsequent analysis, once
selected these diagnostic criteria were fixed and unchangeable.
Marker Pre:2 hour ratio Pre:4 hour ratio
CK-MB mass >3 >4
CK-MB activity >2 >3
Myoglobin >3 >4
Troponin-T >4 >4
5.2,2 COMPARISON OF INDIVIDUAL MARKER ABILITY TO DETERMINE
SUCCESSFUL OR UNSUCCESSFUL REPERFUSION
A similar analysis to that used to determine any variation between the
markers in the diagnosis of AMI was performed. Thus, the markers were compared
to one another in order to determine any difference in their abilities to diagnose
reperfusion at 2 and 4 hours after thrombolysis (or admission). The data were taken
from tables 41-44, pages 234-245 and analysed by McNemar's test for comparison
of paired proportions. The results are shown in the following 2 tables:
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Table 34. Comparison of diagnostic accuracy of assessment of coronary artery
reperfusion 2 hours after the administration of thrombolytic therapy (or admission')
Paired markers Sensitivity Specificity McNemar x2 P value
CK-MB mass 68 88 0 NS
CK-MB activity 68 80
CK-MB mass 68 88 1.6 NS
Myoglobin 81 88
CK-MB mass 68 88 2.8 NS
Troponin-T 52 84
CK-MB activity 68 80 1.3 NS
Myoglobin 81 88
CK-MB activity 68 80 2.8 NS
Troponin-T 52 84
Myoglobin 81 88 5.4 <0.05
Troponin-T 52 84
Table 35. Comparison of diagnostic accuracy of the assessment of coronary artery
reperfusion 4 hours after the administration of thrombolytic therapy for admission!
Paired markers Sensitivity Specificity McNemar x2 P value
CK-MB mass 94 76 5 <0.05
CK-MB activity 77 72
CK-MB mass 94 76 2.7 NS
Myoglobin 81 80
CK-MB mass 94 76 1.3 NS
Troponin-T 84 68
CK-MB activity 77 72 0.5 NS
Myoglobin 81 80
CK-MB activity 77 72 0.5 NS
Troponin-T 84 68




Within 2 hours of the administration of thrombolytic therapy, one significant
difference was identified between the markers with regard to identifying which
patients had successfully reperfused. This was between myoglobin and troponin-T.
The explanation for this was sensitivity of diagnosis, that is, 81 % for myoglobin and
52% for troponin-T. The reason for the poor results for troponin-T is the slow rise
in serum concentration of this marker because of its release kinetics as described
earlier. Reference to table 44, page 243 shows that a large number of patients had
very low ratios for troponin-T at 2 hours, because of this.
The sensitivity for both CK-MB mass and CK-MB activity was 68%, the
former having a better specificity, 88% vs 80% respectively. Both of these markers
had a lower sensitivity than myoglobin, but with all 3 having similar specificities,
there were no statistical differences identified between them.
Both CK-MB mass and activity showed a trend towards better diagnosis than
troponin-T, 0.05 < p < 0.10. The similar findings between CK-MB mass and activity
are a little surprising considering the differences seen between them with regard to
the time of diagnosis of AMI. What this probably reflects is that if reperfusion takes
place a large efflux of CK-MB occurs. The diagnostic threshold for CK-MB activity
is then likely to be realised, and with this a sufficiently high ratio to predict
successful reperfusion, although it is interesting to note that from the ROC curves,
CK-MB activity had the lowest ratio for diagnosis of reperfusion of all 4 markers
at both 2 and 4 hours. The similarities in diagnostic ability at 2 hours for CK-MB
mass and CK-MB activity therefore would appear to be due to differences in release
kinetics between where reperfusion does occur (where a large amount of CK-MB
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is likely to be released quickly), compared to a slower steadier release for AMI
where reperfusion does not occur. Also, choosing a fixed time interval of 2 hours
does not permit the flexibility of smaller time increments used in the time to
diagnose AMI analysis and so restricts any diagnostic advantage that CK-MB mass
may have over CK-MB activity.
The comparison at 4 hours reveals only one significant difference, this time
between CK-MB mass and CK-MB activity. The major change between the results
for 2 and 4 hours is the greatly increased sensitivity for CK-MB mass. This is
because a ratio has been used, and very often the initial value for CK-MB mass was
less than 2ng/ml. Consequently, a relatively small rise in serum concentration is
required for the ratio to increase above 4, whereas, for CK-MB activity, with a
higher initial numerical concentration, allied to a slower rise in serum concentration,
results in significantly poorer diagnostic accuracy; although it generally does have
higher serum concentrations at 4 hours. The disadvantage to this for CK-MB mass
is seen in the results for specificity, with a large number of patients having false-
negative results. Consequently the specificity for CK-MB mass is lower at 4 hours
compared to 2 hours, 76% vs 88% respectively. A similar phenomenon is seen for
troponin-T because it too has very low initial concentrations. Although the time
taken for serum concentrations to rise is greater than that for CK-MB activity (see
later in this chapter), this is not reflected in the results for sensitivity which are
quite high, but is seen in the results for specificity because, with so many ratios of
large magnitude, there will be an increased possibility of patients with a false-
negative diagnosis.
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The results for myoglobin confirm what would be expected for this marker.
Thus, after 4 hours, serum concentrations are at a peak and the differences in terms
of ratios between reperfused and non-reperfused patients are less clear.
Consequently, the sensitivity of diagnosis is the same at 4 hours as at 2 hours, that
is, 81%, but the specificity has reduced from 88% to 80%. Thus, its diagnostic
advantage has been removed and this is reflected in the observation that it is not
significantly different to any of the other 3 markers.
As stated in the introduction to this chapter, although the limitations of using
a change in the degree of ST segment elevation within 2 hours from the
administration of thrombolytic therapy are recognised, within the design of this
particular study, this was the main determinant of coronary artery reperfusion,
which had to be decided upon independently of serum concentrations of the various
biochemical markers. Separation of the 2 subgroups within group A, namely
successful or unsuccessful reperfusion, was made by this non-invasive criterion,
with the predicted sensitivity and specificity given above.
Therefore, the differences between the biochemical markers discussed above
have to be viewed in this light. The fact that statistically significant differences were
identified may be valid, but the findings in this study should be assessed with
appropriate caution before they are applied in a more general manner to other
patients being treated with thrombolytic therapy.
However, the fact that by using this non-invasive indicator of vessel patency
all 7 of the patients in group A who did not receive thrombolytic therapy were
considered not to have achieved reperfusion, and the fact that the nature of the
results is in accordance with that from previous studies where angiography was
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used, does suggest that there is likely to be a reasonable degree of validity of these
findings. It follows that to verify them more thoroughly, they would need to be
assessed prospectively and ratified by coronary angiography, performed at various
times after thrombolysis.
Although coronary angiography does permit an assessment of vessel patency
at any one particular moment in time, it has already been mentioned that patency
is a dynamic, rather than fixed commodity. Consequently, a marker of "overall"
patency, for example within the first few hours after thrombolysis may actually have
more clinical value than a statement that the infarct related artery was patent at a
given time, with no subsequent angiographic information as to the accuracy of that
statement sometime later. Therefore, if non-invasive markers of restoration of vessel
patency can be evaluated with intensive and inevitably costly studies, it may be that
they will gain the upper hand ultimately in predicting which patients have achieved,
and maintained, successful reperfusion status. At present this is of course
hypothetical, but such an attempt to utilise ST segment variation and serum
concentrations of biochemical markers, will inevitably increase dramatically the
numbers of patients benefitting from the current belief of the "open artery
hypothesis" with their management aimed at achieving this desired condition.
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5.3 ASSOCIATION OF REPERFUSION STATUS WITH TIME TO PEAK
SERUM CONCENTRATION
In addition to comparing the rate of rise in serum concentration for each
marker, the time to peak concentration following thrombolysis (or admission where
thrombolysis was not administered) was also assessed. The data for this analysis are
listed in tables 41-44, pages 234-245. Mean concentrations of time to reach peak
serum concentration are shown in table 36, and figure 23 below:
Table 36. MEAN TIME TO PEAK SERUM CONCENTRATION - GROUP A
Biochemical marker Reperfusion - YES
Mean + SEM (hours)
Reperfusion - NO
Mean + SEM (hours)
CK-MB mass 6.71 ± 0.44 9.32 ± 0.44
CK-MB activity 9.06 ± 0.39 10.28 ± 0.30
Myoglobin 4.10 ± 0.42 7.04 ± 0.54
Troponin-T 9.68 ± 0.46 11.16 ± 0.20
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Figure 23. MEAN TIME TO PEAK SERUM CONCENTRATION - GROUP A
TIME TO PEAK CONCENTRATION









CIC-MB mass CK-MB activity Myoglobin Troponin-T
ANOVA was performed for the mean concentrations to time to peak serum
concentrations for all patients in group A, and for the 2 subdivisions within this,
namely, successful and unsuccessful reperfusion status. The results are shown
below:
Patient group Variance ratio p value
Group A - All patients 31.6 p<0.01
Group A - Reperfusers 35.3 p<0.01
Group A - Non-reperfusers 20.6 p<0.01
The effect of successful reperfusion on the time to peak concentration was
assessed for each individual marker (table 37), and also between the 4 markers
(tables 38 and 39). As previously, only significant results are listed.
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Table 37. INDIVIDUAL MARKER COMPARISON OF MEAN TIME TO
PEAK SERUM CONCENTRATION: REPERFUSION YES/NO
Marker Reperfusion No reperfusion t statistic p value
CK-MB mass 6.71 9.32 4.18 p< 0.001
CK-MB activity 9.06 10.28 2.37 p=0.021
Myoglobin 4.10 7.04 4.37 p< 0.001
Troponin-T 9.68 11.16 2.74 p=0.008
Table 38. BETWEEN MARKER COMPARISON OF MEAN TIME TO PEAK
SERUM CONCENTRATION - SUCCESSFUL REPERFUSION
Paired markers Mean time to peak (h) t statistic P value
CK-MB mass 6.71 4.62 p<0.001
CK-MB activity 9.06
CK-MB mass 6.71 5.10 p<0.001
Myoglobin 4.10
CK-MB mass 6.71 4.62 p<0.001
Troponin-T 9.68
CK-MB activity 9.06 9.01 p<0.001
Myoglobin 4.10
CK-MB activity 9.06 1.26 p=0.217
Troponin-T 9.69
Myoglobin 4.10 10.56 p<0.001
Troponin-T 9.68
226
Table 39. BETWEEN MARKER COMPARISON OF MEAN TIME TO PEAK
SERUM CONCENTRATION - UNSUCCESSFUL REPERFUSION
Paired markers Mean time to peak (h) t statistic p value
CK-MB mass 9.32 2.13 p=0.043
CK-MB activity 10.28
CK-MB mass 9.32 3.99 p< 0.001
Myoglobin 7.04
CK-MB mass 9.32 3.73 p< 0.001
Troponin-T 11.16
CK-MB activity 10.28 7.29 p<0.001
Myoglobin 7.04
CK-MB activity 10.28 3.22 p=0.004
Troponin-T 11.16
Myoglobin 7.04 10.56 p< 0.001
Troponin-T 11.16
5.3.3 DISCUSSION
The results from table 37 show that for all 4 markers the time to peak serum
concentration was significantly lower in those patients who achieved successful
reperfusion. This is an expected finding, in accordance with previous studies, but
does suggest that the electrocardiographic means used for determining coronary
artery reperfusion in this study is valid, although appropriate reservation (as outlined
above) should be applied to the following discussion.
A comparison between the 4 markers for patients who either did or did not
reperfuse reveals similar, but not identical, findings for both sets of patients.
The time to peak serum concentration for myoglobin is significantly lower than the
other 3 markers. CK-MB mass has the next lowest times, with CK-MB activity and
troponin-T being significantly slower. In patients with reperfusion, CK-MB activity
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and troponin-T were not significantly different, in those patients where reperfusion
did not occur, CK-MB activity was significantly faster than troponin-T.
These results reinforce the findings seen in the time to diagnosis analysis, in
which it was seen that serum concentration of myoglobin rises first, followed by
CK-MB mass, and then CK-MB activity and troponin-T. It follows that if
reperfusion occurs there will be a greater and more rapid efflux of all markers, the
release kinetics of the different markers determining their relative times to peak
concentration. Troponin-T overall has the slowest rise in serum concentration, this
is particularly so when reperfusion does not occur.
The clinical relevance of peak serum concentrations is potentially less than
that of serum concentration ratios at fixed times after the administration of
thrombolysis or admission. However, with myoglobin peaking at a mean of 4.1
hours after thrombolysis, and CK-MB mass at 6.7 hours, the time window for
presumed myocardial salvage is still present and can be detected easily by frequent
blood sampling after thrombolysis. Once a lack of reperfusion has been
demonstrated by biochemical criteria, a decision could be taken to repeat
thrombolysis or proceed to alternative methods of restoring arterial patency, for
example PTCA. The addition of PTCA to thrombolytic therapy for certain patient
groups has been shown to be of prognostic benefit and there is increasing evidence
that it should be considered where reperfusion has not occurred. The ability to
identify patients who may benefit from this technique by non-invasive tests such as
ECG changes or serum concentration criteria is of potential clinical benefit.
As was commented upon in the time to diagnosis discussion, the fact that
CK-MB mass is measured quickly and accurately at the bedside makes this
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potentially more useful clinically as it removes the delay of transfer of a serum
sample to the laboratory and analysis remote from the clinical situation. If an
accurate method for the measurement of myoglobin concentration at the bedside
became available, the clinical advantage would be gained by this marker over
CK-MB mass.
In summary, the non-invasive detection of patients who have or have not
achieved successful coronary artery reperfusion can be achieved by a combination
of ECG changes and characteristic patterns of serum biochemical concentrations.
The fact that coronary angiography was not performed in these patients implies that
the "gold standard" diagnostic technique was not performed, and once again the
observations were made retrospectively. However, the prospective application of
these findings to a similar group of patients, with angiographic confirmation of
vessel patency, incorporating appropriate clinical action, especially in those patients
in whom reperfusion is not felt to have occurred, may reveal significant effects upon
prognosis for this particular patient group, the importance of which is recognised




1) Two hours after the administration of thrombolytic therapy, myoglobin is
significantly more accurate than troponin-T in diagnosing coronary artery
reperfusion.
2) Four hours after the administration of thrombolytic therapy, CK-MB mass
is significantly more accurate than CK-MB activity in diagnosing coronary
artery reperfusion.
3) All 4 markers are able, by the time to peak serum concentration, to
differentiate between patients who have or have not achieved successful
reperfusion.
4) For those patients in whom successful reperfusion is deemed to have taken
place, myoglobin has the earliest time to peak serum concentration.
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9 +2.48 + 1.02 59 Y Y
10 +4.32 +2.08 54 Y Y
15 +4.96 +0.96 81 N Y
17 +4.96 +2.40 52 Y Y
26 -3.40 -2.60 24 N N
32 +4.10 + 1.20 71 Y Y
33 +4.96 +2.48 50 Y Y
34 +2.36 + 1.00 58 N Y
36 +4.76 + 1.84 61 N Y
40 +3.40 + 1.20 65 Y Y
42 +4.96 +2.16 56 Y Y
49 +2.56 + 1.80 30 N N
53 +2.80 + 1.32 53 N Y
59 + 1.60 -2.88 280 Y Y
63 -2.04 -0.36 82 N Y
66 + 1.16 +0.84 28 N N
71 +2.4 + 1.84 23 N N
80 + 1.88 +0.96 48 N N
82 +4.96 + 1.52 69 Y Y
83 + 1.60 +0.84 48 Y N
85 +2.16 +0.48 78 N Y
89 +3.08 +0.28 91 N Y
91 + 1.84 +0.48 74 Y Y
92 + 1.62 + 1.58 2 N N
96 +3.5 +2.5 29 N N














108 + 1.52 + 1.16 24 N N
109 +3.08 -1.60 152 Y Y
111 -4.12 -3.28 20 N N
115 +4.96 +0.64 87 Y Y
121 +2.80 +0.04 99 N Y
123 + 1.48 -0.06 141 N Y
127 + 1.68 + 1.00 40 Y N
135 + 1.96 -0.56 129 N Y
136 + 1.68 +0.24 86 Y Y
138 +2.52 +0.24 90 Y Y
141 +2.1 + 1.9 10 Y N
142 +3.40 + 1.20 65 Y Y
147 +2.24 +0.70 69 N Y
149 + 1.44 +0.16 89 Y Y
150 +4.96 +0.00 100 Y Y
154 + 1.80 +0.96 47 N N
155 +2.20 + 1.48 33 N N
157 +2.68 + 1.84 31 N N
159 -4.40 +3.20 27 Y N
161 + 3.12 +0.64 79 N Y
163 + 1.08 +0.84 22 N N
164 + 1.24 +0.68 45 N N
167 +4.96 +4.50 9 N N
169 + 1.80 + 1.40 22 N N
171 +2.3 + 1.8 22 N N
173 + 1.56 + 1.16 26 Y N
187 +4.70 + 1.20 74 Y Y
191 +2.9 +2.7 7 Y N
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Pat ST elev ST elev % ST RHYTHM Reperfusion
no pre 2h post change YES/NO YES/NO
193 +3.10 +3.30 6 N N












= ST segment elevation before thrombolysis (or on admission)
= ST segment elevation 2 hours after thrombolysis (or
= percentage ST segment change from before and after
= presence or absence of reperfusion arrhythmia
= Overall indication as to successful or unsuccessful













9 1 2 28 2 28 12
10 4 14 32 3.5 8 6
15 1 70 180 70 180 6
17 1 70 170 70 170 6
26 38 50 70 1.3 1.8 7
32 27 150 360 5.6 13.3 6
33 1 70 110 70 110 8
34 2 4 9 2 4.5 12
36 1 1 31 1 31 6
40 1 12 60 12 60 6
42 1 3 90 3 90 7
49 8 17 27 2.1 3.3 7
53 18 80 190 4.4 10.6 7
59 1 230 440 230 440 6
63 1 29 39 29 39 4
66 30 60 100 2 3.3 8
71 7 16 30 2.3 4.3 9
80 50 80 110 1.6 2.2 11
82 5 40 70 8 14 10
83 12 30 460 2.5 3.8 9
85 14 30 80 2.1 5.7 6
89 2 5 22 2.5 11 6
91 2 23 42 11.5 21 10
92 1 1 1 1 1 12
96 <2 <2 2 2 2 10
















108 1 1 1 1 1 5
109 1 7 30 7 30 9
111 10 15 49 1.5 4.9 10
115 1 4 42 4 42 4
121 2 17 38 8.5 19 4
123 1 12 32 12 32 4
127 2 18 40 9 20 9
135 2 6 42 3 21 8
136 1 4 49 4 49 7
138 2 6 6 3 3 2
141 <2 6 14 6 14 12
142 2 24 80 12 40 5
147 18 38 50 2.1 2.8 5
149 1 4 48 4 48 10
150 8 80 160 10 20 4
154 18 40 60 2.2 3.3 11
155 28 42 58 1.5 2.1 12
157 2 4 4 2 2. 6
159 6 16 18 2.7 3 7
161 6 21 80 3.5 13.3 9
163 26 42 50 1.6 1.9 12
164 44 70 60 1.6 1.4 12
167 11 15 31 1.4 2.8 12
169 22 30 36 1.4 1.6 8
171 13 15 15 1.2 1.2 9
173 34 80 110 2.4 3.2 8
187 2 90 170 45 85 5
191 <2 2 3 2 3 12
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Pat Cone Cone Cone Ratio Ratio Time to
no pre thr 2 h post 4 h post 2h:pre 4h:pre peak cone
193 1 44 90 44 90 8
197 1 2 8 2 8 7
Abbreviations
Pat no = Patient number
Cone pre thr = Serum concentration before thrombolysis (or admission)
Cone 2h post = Serum concentration 2 hours after thrombolysis (or admission)
Cone 4h post = Serum concentration 4 hours after thrombolysis (or admission)
Ratio 2h:pre = Ratio of serum concentrations at 2 hours after thrombolyis
(or admission), compared to serum concentration before thrombolysis
(or admission)
Ratio 2h:pre = Ratio of serum concentrations at 2 hours after thrombolyis
(or admission), compared to serum concentration before thrombolysis
(or admission)
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9 10 30 30 3.0 3.0 12
10 18 27 27 1.5 1.5 6
15 4 209 209 52.3 52.3 8
17 7.6 237 237 31.2 31.2 7
26 26 113 113 4.4 4.4 11
32 32 440 440 13.8 13.8 6
33 7.0 147 147 21.0 21.0 10
34 15 36 36 2.4 2.4 12
36 2.4 8.3 40 3.5 16.7 8
40 5.2 21 61 4.0 11.7 7
42 11 11.5 120 1.0 10.9 7
49 12 12 21 1.0 1.75 9
53 21 49 92 2.3 4.4 9
59 7.7 101 460 13.1 59.7 6
63 10 46 61 4.6 6.1 9
66 112 149 178 1.3 1.6 11
71 10.6 24 45 2.3 4.2 12
80 134 157 157 1.2 1.2 10
82 10 94 201 9.4 20.1 12
83 55 59 71 1.1 1.3 9
85 45 106 106 2.4 2.4 12
89 5 8 19 1.6 3.8 12
91 6 26 73 4.3 12.2 10
92 5 5 5 1.0 0.9 12
96 11.8 14.9 9.3 1.3 0.8 8
















108 25 22 18 0.9 0.7 9
109 6 11 27 1.8 4.5 9
111 17 20 33 1.2 1.9 12
115 15 14 44 0.9 2.9 12
121 5.5 40 23 7.3 4.2 12
123 6 11 26 1.8 4.3 12
127 9.4 15 39 1.6 4.1 12
135 11 9.5 62 0.9 5.6 8
136 6.5 49 49 7.5 7.5 9
138 10.1 10.5 24 1.0 2.4 7
141 22 28 31 1.3 1.4 10
142 9.6 27 106 2.8 11.0 7
147 15 17 32 1.1 2.1 7
149 7 58 58 8.3 8.3 12
150 20 109 196 5.5 9.8 7
154 14 36 81 2.6 5.8 11
155 102 97 79 1.0 0.8 12
157 6.2 7 13 1.1 2.1 12
159 14 27 52 1.9 3.7 10
161 11 45 110 4.1 10.0 9
163 44 53 69 1.2 1.6 10
164 92 85 78 0.9 0.8 9
167 9 19 31 2.1 3.4 12
169 48 51 51 1.1 1.1 9
171 25 24 23 1.0 0.9 8
173 70 113 149 1.6 2.8 8
187 9 130 212 14.4 23.6 9
191 13 14 14 1.1 1.1 12
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Pat Cone Cone Cone Ratio Ratio Time to
no pre 2h post 4h post 2h:pre 4h:pre peak cone
193 12 51 70 4.3 5.8 8
197 12 14 24 1.2 2.0 9
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9 86.4 508 508 5.9 5.9 8
10 145 1191 1191 8.2 8.2 3
15 25 640 640 25.6 25.6 3
17 70 625 625 8.9 8.9 1
26 356 234 234 0.7 0.7 4
32 289 1040 1040 3.6 3.6 3
33 71 1719 1719 24.2 24.2 4
34 25 305 305 12.2 12.2 12
36 25 149 514 5.9 20.6 5
40 83 389 658 4.7 7.9 4
42 25 207 1608 8.3 64.3 5
49 102 104 86 1.0 0.84 5
53 401 762 906 1.9 2.3 4
59 25 4986 2163 199 86.5 2
63 25 361 327 14.4 13.1 3
66 409 328 205 0.8 0.5 4
71 352 294 197 0.8 0.6 4
80 1062 966 966 0.91 0.91 5
82 152 5391 3255 35.5 21.4 3
83 288 537 468 2.3 1.6 11
85 1188 1920 1920 1.6 1.6 2
89 27 124 94 4.6 3.5 2
91 55 1270 1050 23.1 19.1 3
92 25 25 25 1.0 1.0 12
96 212 208 174 1.0 0.8 4
















108 49 96 100 2.0 2.1 7
109 25 269 469 10.8 18.8 7
111 127 279 570 2.2 4.5 10
115 99 375 1245 3.8 12.6 4
121 35 321 240 9.2 6.9 2
123 51 478 385 9.4 7.5 2
127 203 732 1350 3.6 6.7 8
135 25 391 1440 15.6 57.6 8
136 40 1860 1860 46.5 46.5 3
138 164 294 361 1.8 2.2 7
141 157 294 244 1.9 1.6 6
142 31 1280 672 41.3 21.7 3
147 54 172 489 3.2 9.1 3
149 82 1440 1440 17.6 17.6 3
150 2600 5500 6980 2.1 2.0 4
154 664 1190 2090 1.8 3.1 8
155 146 174 182 1.2 1.2 12
157 67 147 273 2.2 4.1 10
159 269 616 855 2.3 3.2 9
161 262 596 2010 2.3 7.7 6
163 468 347 311 0.7 0.8 5
164 318 291 231 0.9 0.7 6
167 173 737 961 4.3 5.6 10
169 112 92 92 0.8 0.8 5
171 65 65 62 1.0 1.0 6
173 1710 2520 2840 1.5 1.7 8
187 57 2330 1560 40.9 27.4 2
191 130 408 401 3.1 3.1 12
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Pat Cone Cone Cone Ratio Ratio Time to
no pre 2h post 4h post 2h:pre 4h:pre peak cone
193 229 469 323 2.1 1.4 5
197 37 343 221 9.3 6.0 5
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9 0.00 0.12 0.56 12.0 56 12
10 0.31 0.33 0.33 1.0 1.1 6
15 0.00 3.28 3.28 328 328 8
17 0.00 9.86 9.86 986 986 10
26 3.16 14.90 16.40 4.7 4.2 11
32 0.33 15.01 18.20 45.5 55 6
33 0.16 2.40 2.40 15.0 15.0 10
34 0.13 0.21 0.21 1.6 1.6 12
36 0.13 0.16 0.74 1.2 5.7 8
40 0.10 0.25 0.74 2.5 7.4 7
42 0.33 0.27 13.1 0.8 40 12
49 0.14 0.15 0.66 1.0 4.7 11
53 0.30 0.56 0.96 1.9 3.2 9
59 0.09 1.10 21.30 12.2 237 9
63 0.09 2.00 4.93 22.2 55 9
66 0.66 0.87 2.40 1.3 3.6 12
71 0.16 0.49 0.69 3.1 4.3 12
80 1.30 0.82 0.82 0.6 0.6 12
82 0.02 1.40 3.40 70 170 12
83 5.50 1.86 5.40 0.34 1.0 12
85 1.10 5.80 5.80 5.3 5.3 12
89 0.11 0.30 0.10 2.7 1.0 2
91 0.13 0.41 1.33 3.2 10.2 10
92 0.02 0.17 0.30 0.9 1.7 12
96 0.19 0.52 0.73 2.7 3.8 11
















108 0.19 0.19 0.21 1.0 1.1 12
109 0.10 0.17 0.33 1.7 3.3 12
111 0.06 0.04 0.11 0.7 1.8 12
115 0.01 0.05 0.75 5.0 75 12
121 0.05 0.08 0.60 1.6 12 12
123 0.03 0.13 0.32 4.3 10.7 12
127 0.09 0.30 0.19 3.3 2.7 12
135 0.00 0.0 0.35 1.0 35 12
136 0.00 1.5 1.50 15.0 15.0 9
138 0.00 0.00 0.45 1.0 45 7
141 0.45 0.55 0.70 1.2 1.6 10
142 0.00 0.40 2.55 4.0 255 12
147 0.00 0.04 0.16 4.0 16 7
149 0.00 0.60 0.63 60 63 12
150 0.07 0.49 2.40 7.0 34 12
154 0.02 0.18 0.53 9.0 26 11
155 3.80 4.20 4.22 1.1 1.1 12
157 0.02 0.03 0.08 1.5 4.0 12
159 0.03 0.10 0.20 3.3 6.7 9
161 0.06 0.35 1.07 5.8 17.8 9
163 0.71 0.80 0.90 1.1 1.3 9
164 0.84 1.1 1.29 1.3 1.5 10
167 0.15 0.25 0.29 1.7 1.9 12
169 3.20 4.10 4.10 1.3 1.3 11
171 0.57 0.62 0.66 1.1 1.2 10
173 0.30 0.56 0.81 1.9 27 11
187 0.03 3.30 8.26 110 275 7
191 0.11 0.12 0.12 1.1 1.1 12
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Pat Cone Cone Cone Ratio Ratio Time to
no pre 2h post 4h post 2h:pre 4h:pre peak cone
193 0.03 2.60 4.20 86.7 140 10
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